Articles
-
All
-
Scientific Reviews
-
EDM
-
Blog
-
Most Recent
-
Oldest
-
SARS-CoV-2 contains four main structural proteins: spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins. All the proteins and subcellular structures of CoVs are promising targets for SARS-CoV-2 research.
-
The concept of ADC can be traced back to the early 1900s, It is a visionary magic bullet that could deliver a toxic drug to certain malignant cells without affecting other normal tissues. Now, it seems that a golden age of ADC drug development is coming.
-
Tsvetkov et al. published in Science and demonstrated a copper-induced programmed cell death — Cuproptosis. As a novel programmed cell death, excess copper triggers abnormal aggregation of lipoylated proteins in TCA cycle and clearance of Fe-S cluster proteins, ultimately leading to cell death.
-
A comprehensive explanation of ferroptosis
2022-09-15
Ferroptosis is a new type of RCD that depends on iron and characterized by the accumulation of lipid peroxides. In this article, we will pay our attention on ferroptosis and briefly discusses its mechanism. -
It's has been proved that p53, as a tumor suppressor gene and immune guardian, may become a destroyer through its own mutation. Moreover, the mechanism of p53 was found to be related to ferroptosis. This article mainly explores the mechanism between p53 and ferroptosis in detail.
-
Autophagy, derived from the Greek meaning "eating of self", plays an indispensable role in maintaining homeostasis. p27 is an inhibitor of cyclin CDKs, but how p27 regulates autophagy remains unknown. This article will cover the mechanism of autophagy and p27-related cell cycle regulation.
-
CMA (chaperone-mediated autophagy) plays an essential role in maintaining neuronal protein stability and preventing neurodegeneration. In this article, we will comprehensively clarify the role of CMA in the occurrence and development of neurodegenerative diseases.
-
TME (Tumor microenvironment) is considered as a complex integrated system, composed of cellular components such as tumor cells and immune cells, as well as non-cellular components such as ECM and cytokines. According to the spatial distribution of immune cells in TME, "hot" and "cold" TME will be explained in this article.
-
Efferocytosis is the process in which phagocytes remove programmed dead cells. It prevents secondary necrosis of dying cells from releasing harmful cell contents (such as oxides and proteases) that may cause inflammation. Here, we will introduce three stages of efferocytosis: Find, Eat, Digest.
-
Necroptosis, also known as necroptosis, is a form of regulated necrotizing cell death mediated by RIP1 and RIP3 kinases. Necroptosis is a process that prevents the self-destruction of activated cells that are blocked by apoptosis. Necroptosis plays a tumor suppressor role in most cases. It may provide benefits in the researches of a variety of human diseases involving immune inflammation and cell death.
-
Mitophagy:Mechanisms and Detection
2023-05-25
About 60 years ago, Christian de Duve first used the term "autophagy" to describe his observation of the degradation of mitochondria and other intracellular structures in lysosomes of rat liver. Over the years, autophagy has remained a beloved topic of research by the National Natural Science Foundation of China (NSFC).Today, let's talk about mitochondrial autophagy. -
HLA-E, A Novel Immune Checkpoint
2023-06-29
Immune checkpoints have immunosuppressive functions. It can be used in the research of tumor immunotherapy. In this article, we introduce a new paper entitled "Immune checkpoint HLA-E: CD94 - NKG2Amediates evasion of circulating tumor cells from NK cell surveillance "research paper. -
WHO's Q2 drug list has been updated. Let's take you through the list of the most noteworthy small molecule drugs that we should pay attention to.
-
FDA Approved Drug List!
2023-09-14
In the first half of 2023 (as of June 27), the FDA approved 26 new drugs, let's take you learn about it through the article. -
IHC is an indispensable technique for studying tissue morphology and in situ antigen expression, but usually only one or two antigens in tissues can be stained for analysis. It cannot judge the results more intuitively. Today, Little M will introduce you to the upgraded version mlHC.
-
A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening of diseases such as cancer, infectious diseases, and rare diseases.
-
FDA Annual Review | Record-breaking number of new drug approvals in 2023!
-
KRAS, a gene we've heard so much about, has quickly risen to fame after shedding its "undruggable" label. After reading numerous articles, it's easy to feel overwhelmed and wonder: What exactly should we know about this often-discussed but previously "undruggable" target KRAS?
-
Compound Screening Guide!
2024-03-15
How to use compound library? How to design an experiment if you buy a compound library? Want a specific experimental protocol? This article will introduce popular experimental techniques and provide new ideas for publishing high level literature. -
Wnt/β-catenin and tumor EMT
2024-03-18
Epithelial-Mesenchymal Transition (EMT) is closely related to the plasticity of tumor cells and is a necessary process for tumor metastasis. Wnt/β-catenin is one of the main actors involved in the EMT process. Today, we’re here to popularize the tumor EMT and Wnt/β-catenin pathway~ -
The 2024 AACR meeting concluded successfully in California, USA. Which antitumor drugs stole the show at this conference?
-
Katalin Karikó and Drew Weissman were awarded the Nobel Prize in Physiology or Medicine in 2023 for their groundbreaking work in nucleoside modification, which paved the way for the creation of successful mRNA vaccines to fight against COVID-19. Let's now delve into the complete process of mRNA vaccine development.
-
Exosomes, which won the Nobel Prize in 2013, are still a research hotspot in the national natural sciences, and their popularity has only increased over the past decade (in 2022, they still rank 5th in the national natural sciences hotspots!). Why have exosomes become the darling of scientific research? Let's take a look together~
-
How important is the compound library? It connects to drug screening on one end and leads to lead compound modifications on the other, serving as one of the sources of new drug development.
-
Antibodies!
2024-07-26
Today, We introduce antibodies for everyone! -
What Are Popular Anti-tumor Drug Targets?
2024-08-20
The rapid development of targeted anti-cancer drugs has spurred diverse research across various modalities. These include small molecules, monoclonal antibodies (mAbs), cell immunotherapies, antibody-drug conjugates (ADCs), and PROTACs (proteolysis targeting chimeras). -
Cuproptosis, How much do you know?
2024-08-22
Cells die in a variety of ways, including apoptosis, pyroptosis, necrosis, and ferroptosis......And, of course, cuproptosis. So, how much do you know about cuproptosis? -
Virtual Screening and New Uses for Old Drugs
2024-09-17
With the advancement of medical science, drug screening against various disease targets has become the fundamental strategy for drug development. Currently, computer-based virtual screening techniques are emerging in the field of new drug research due to their efficiency and low cost. Let's explore it today! -
Recently, Mol Cell reported the discovery of the first ferroptosis marker, Hyperoxidized PRDX3! Let’s take a look together~
-
Cuproptosis's Knowledge Points!
2024-09-25
With the establishment of the cuproptosis mechanism related research has attracted more and more attention from major journals. Expect to use the sharp sword of cuproptosis to stab the tumor cells. -
2024 Nobel Prize Announcements! Curious about the details? Click to dive into the exciting developments!
-
A New Form of Cell Death: PANoptosis!
-
We are thrilled to share the latest advancements in AI technology as highlighted in this insightful article. From groundbreaking innovations to transformative applications, the future of AI is brighter than ever!
-
When you hear "inflammation" and "DNA damage," you might immediately think of disease or injury. However, in brains, these two processes are key steps in forming long-term memories, particularly related to specialized cells in our brain called hippocampal neurons.
-
Autophagy is a fundamental process that degrades various components within the cell.
-
This article will walk you through the remarkable impacts of anti-payload antibodies, delving into how these molecules are revolutionizing drug development and biological research!
-
Cell Migration vs. Invasion: Differences Revealed by Scratch Assays and Transwell Experiments
2025-05-30
In scientific research, cell migration and invasion are crucial for understanding many important biological processes. This article delves into commonly used detection methods: the scratch assay and Transwell migration/invasion assay. -
How should drug screening experiments be conducted? How can we ensure the accuracy of the lead compounds identified? This article will take you through how MCE's clients conduct drug screening experiments.
-
In this issue, we will conduct an in-depth interpretation from the dimensions of nanoparticle design, mechanism of action, in vivo and in vitro efficacy, and immune regulation, revealing how this research brings new hope for the treatment of invasive tumors through interdisciplinary innovation!
-
IHC, ICC, IF Techniques: A Practical Guide
2025-07-25
Confused About IHC/ICC/IF? Why Does Immunostaining Seem So Complicated? Read This Now! Master Immunostaining with Confidence! -
Chromatin Immunoprecipitation (ChIP) Demystified: A Complete Guide to Epigenetic Analysis
2025-08-05
In this issue, we introduce a powerful technique for detecting interactions between epigenetic regulatory factors and DNA—Chromatin Immunoprecipitation (ChIP)! -
HTS Breakthroughs Powered by MCE Libraries
2025-08-13
Key High-Throughput Screening Breakthroughs of 2024 Featuring MCE -
Encountering challenges with the high costs and long timelines of drug screening? Have a defined target but remain uncertain how to efficiently identify active molecules? Unsure how to validate hits generated from virtual screening? The ‘Winning Combination’ of drug screening offers a powerful solution to address these critical obstacles.
-
This detailed guide outlines the standardized experimental protocols for multiplex immunohistochemistry (mIHC), systematically summarizes common technical issues encountered during sample preparation, staining and imaging processes, and provides practical troubleshooting solutions to ensure reliable and reproducible results in biomedical research and clinical sample analysis.
-
Exosomes—natural nanoscale carriers—are revolutionizing targeted therapy. This article uncovers the science behind their precision in drug delivery.
-
Cracking the PROTAC Permeability Barrier: CD36-Mediated Endocytosis as a Potential Breakthrough
2025-12-03
This article provides an in-depth analysis of cutting-edge literature revealing CD36 as a key mediator of cellular uptake for PROTACs and bRO5 compounds. By structurally optimizing PROTAC molecules to enhance their affinity for CD36, membrane permeability can be markedly improved, leading to significantly enhanced antitumor efficacy. -
A November 2025 Cell study discovers Mitoxyperilysis, a new mTOR-regulated, caspase-independent cell death pathway driven by innate immune and metabolic dysregulation via mitochondrial-plasma membrane contact and oxidative damage, and verifies its potential to induce tumor necrosis for cancer therapy with key regulators including BAX, BAK1 and BID.
-
This paper elaborates on cytokines for culturing major immune cells, their regulatory roles, recombinant cytokines' merits and MCE’s related high-quality products.
-
FISH is a molecular technique using fluorescent probes to detect specific nucleic acids in cells, with high sensitivity and diverse biomedical applications.
-
This article walks you through the experimental design and workflow of flow cytometry, delivering a clear, dynamic, and professional overview to elevate your research.
-
Molecular glue degraders have evolved from a serendipitous observation to one of the most dynamic and transformative fields in biomedical research.
-
Research Solution for Breast Cancer TME
2025-05-21
This review examines the complex interactions within the breast cancer tumor microenvironment, emphasizing how understanding these dynamics is essential for developing effective therapies and overcoming immune resistance. -
This review introduces the major forms of programmed cell death, with a focus on the molecular mechanisms of ferroptosis and the methods used for its detection.
-
This review discusses the fundamentals of lipid biology and lipid metabolism, examines dysregulated lipid metabolism in cancer, and summarizes therapeutic strategies targeting lipid metabolic pathways.
-
This review explores the molecular mechanisms of the DNA damage response, reviews therapeutic strategies targeting DDR pathways in cancer, and examines their roles in cancer drug resistance.
-
This review presents an overview of antibody–drug conjugates from design principles and antitumor mechanisms to structural innovations, clinical progress, and future development prospects.
-
This review explores mechanisms and strategies for modulating the gut microbiota to enhance cancer immunotherapy, providing insights to improve therapeutic efficacy.
-
Combating Immune Evasion in Cancer
2025-10-15
This review summarizes the mechanisms by which tumors evade immune surveillance and discusses therapeutic strategies to restore antitumor immunity. -
This review summarizes the mechanisms of drug resistance in triple-negative breast cancer and highlights emerging therapeutic strategies.
-
Bispecific Antibodies in Cancer Therapy
2025-10-29
This review highlights the mechanisms, technology platforms, and clinical progress of bispecific antibodies, and discusses emerging strategies to guide future development. -
This review provides insights into the pancreatic ductal adenocarcinoma tumor microenvironment, highlighting its cellular composition, stromal heterogeneity, and immune-targeting strategies.
-
This review provides a practical guide to the fundamental mechanisms, regulatory pathways, and detection methods of pyroptosis.
-
Understanding In Vivo CAR-T Cell Therapy
2026-01-22
This review provides a comprehensive overview of in vivo CAR-T therapy, covering technical platforms, clinical translation, and key challenges such as gene delivery and immunogenicity. -
Highlight single-cell metabolomics and stable isotope tracing (SIT) in uncovering metabolic heterogeneity and nutrient flux dynamics in tumors.
-
Explore ADC evolution, immune combination strategies, and clinical advances at the intersection of targeted therapy and immunotherapy.
-
Tumor Organoid-Immune Cell Co-Culture Models: Advances, Applications, and Future Directions
2026-05-07
Summarize technical strategies, application advances, and future directions of tumor organoid–immune co-culture systems. -
Review mechanisms, major challenges, and efficacy-enhancing strategies of TCR-T therapy in solid tumors, with implications for future research and clinical translation.
-
The Dual Role of Cellular Senescence in Cancer: Mechanisms, Microenvironment, and Therapeutics
2026-05-21
Explore the dual role of cellular senescence in cancer, including tumor suppression, SASP-driven tumor promotion, senescence heterogeneity and plasticity, and advances in senescence-targeted therapies. -
Breaking Immune Resistance in Colorectal Cancer: From Molecular Mechanisms to Precision Therapy
2026-06-25
Explore CRC molecular subtypes, immune landscapes, resistance mechanisms, and emerging precision strategies for improving outcomes across distinct subtypes. -
EC0489, a SMDC for Cancer Therapy
2019-03-25
EC0489, a conjugate of folic acid and desacetyl vinblastine hydrazide, is a SMDC under development for the treatment of solid tumours. -
R916562, a dual Axl/VEGF-R2 inhibitor, could be a potential anti-angiogenic and anti-metastatic drug for cancer chemotherapy.
-
Role of PRMT7 Probe SGC3027 in Cancer
2019-03-27
SGC3027 is the first potent, selective and cell active chemical probe for PRMT7. SGC3027 is also a pro-drug, which converts to the active compound SGC8158 -
Alofanib, An Allosteric Inhibitor of FGFR2
2019-03-28
Alofanib is an allosteric inhibitor of FGFR2 and inhibits FGF-mediated proliferation with GI50s of 16-370 nM, showing pronounced antitumor activity. -
AZD5991, a macrocyclic molecule with high selectivity for Mcl-1, reduces Mcl-1 protein in AZD5991-sensitive but not in AZD5991-resistant MM cell lines.
-
A Novel and Efficacious RAF Inhibitor RAF709
2019-03-30
RAF709, a novel and efficacious RAF inhibitor, activates the MAPK pathway and shows antitumor activity in tumor cells harboring BRAF or RAS mutations. -
CF53 is a highly potent, selective and orally active inhibitor of BET protein, with anti-tumor activity in acute leukemia and breast cancer cell lines.
-
CCB02 is an tubulin binder and has potential in the therapy of cancer cells with extra centrosomes. CCB02 also activates spindle assembly checkpoint.
-
H3B-5942 is a selective and irreversible estrogen receptor covalent antagonist, inactivates both ERαWT and ERα mutation.
-
AZD3229 is a Potent Pan-KIT Mutant Inhibitor
2019-04-04
AZD3229 is a potent, pan-KIT mutant inhibitor with potent single digit nM growth inhibition against a diverse panel of mutant KIT driven Ba/F3 cell lines. -
BR351 is a Brain Penetrant MMP Inhibitor
2019-04-05
BR351 is a brain penetrant MMP inhibitor, and a potential tool for the molecular imaging of activated MMPs with PET, with an IC50 in the nanomolar range. -
A Lead PROTAC BRD9 Chemical Degrader
2019-04-06
PROTAC BRD9 Degrader-1 is a lead PROTAC BRD9 chemical degrader and a selective probe useful for the study of BAF complex biology. -
SGC-GAK-1 is a potent, selective, and cell-active GAK inhibitor and shows potent anti-proliferative activity in LNCaP and 22Rv1 cells.
-
COH000 is an allosteric, covalent and irreversible inhibitor of SUMO-activating enzyme, with an IC50 of 0.2 μM for SUMOylation in vitro.
-
HS-1371 is a Small Molecule RIP3 Inhibitor
2019-04-09
HS-1371 is a novel kinase inhibitor of RIP3-mediated necroptosis, showing an inhibitory effect on S227 auto-phosphorylation of RIP3 at the basal level. -
MK-0429 is An Oral Integrin (αvβ3) Inhibitor
2019-04-11
MK-0429, an orally active αvβ3 inhibitor, is a potential therapeutic agent for the prevention of kidney fibrosis, melanoma and osteoporosis. -
PhiKan 083 is a carbazole derivative, which binds to the surface cavity and stabilizes Y220C (a p53 mutant), with a Kd of 167 μM.
-
AZ304, a Dual BRAF Inhibitor Against Cancer
2019-04-12
AZ304 is a potent BRAF inhibitor, blocks both wild type BRAF and V600E mutant BRAF activity, with IC50s in the nanomolar range. -
Novel Greatwall Kinase Inhibitor GKI-1
2019-04-13
GKI-1, a GWL inhibitor, robustly inhibited ROCK1 with an IC50 of ~11 μM, but only weakly affected PKA and had no observable inhibition towards CDK2. -
SSE15206 is a microtubule polymerization inhibitor, with a GI50 of 197 nM in HCT116 cells. Causes aberrant mitosis resulting in G2/M arrest.
-
Erteberel is a Selective ERβ Agonist
2019-04-16
Erteberel (LY500307) is a synthetic, nonsteroidal estrogen which acts as a selective ERβ agonist and under development for the treatment of schizophrenia. -
MBQ-167 is a dual Rac/Cdc42 inhibitor in in metastatic cancer, with IC50s of 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively.
-
PRN1008 is a Reversible Covalent and Oral Active Inhibitor of Bruton’s Tyrosine Kinase (BTK)
2019-04-18
PRN1008 is a selective, reversible covalent and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK), with an IC50 of 1.3 nM. -
Multiple Tyrosine Kinases Inhibitor TAS-115
2019-04-19
TAS-115 is a potent VEGFR and c-Met/HGFR-targeted kinase inhibitor with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively. -
Y06036 is a potent and selective BET inhibitor for potential treatment of castration-resistant prostate cancer. With nanomolar inhibition.
-
JNJ-64619178 is a selective and pseudo-irreversible PRMT5 inhibitor with an IC50 of 0.14 nM. Has potent Activity In Lung Cancer.
-
(E)-AG 99 is an EGFR inhibitor and shows a growth-inhibition on not only serum-starved cells but also normally grown cells. Treatment for Bladder cancer.
-
Cevipabulin is a microtubule-active compound and inhibits the binding of [3H] vinblastine to tubulin, with an IC50 of 18-40 nM for in human tumor cell line.
-
BTR-1 potently inhibits cell growth. It induces S phase arrest, affects DNA replication. Dose-dependently induces cytotoxicity in leukemic cell lines.
-
TAK-828F is a potent, selective and orally active retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonist. TAK-828F inhibits IL-17A cytokine expression and reduces symptoms of autoimmune encephalomyelitis mice.
-
Y06137 is a potent and selective BET inhibitor, which binds to the BRD4(1) bromodomain with a Kd of 81 nM. Antitumor activity.
-
Borussertib is a covalent-allosteric and first-in-class inhibitor of protein kinase Akt, with an IC50 of 0.8 nM and a Ki of 2.2 nM for Akt-wt.
-
NRX-252262 is a β-catenin:β-TrCP interaction enhancer, and its cognate E3 ligase, SCFβ-TrCP, induces mutant β-catenin degradation, with an EC50 of 3.8 nM
-
TAK-981 is a selective inhibitor of the SUMOylation enzymatic cascade, with potential immune-activating and antineoplastic activities
-
TD-428 is a Highly Specific BRD4 Degrader
2019-04-29
TD-428, a immunomodulatory drug analog, is a highly specific BRD4 degrader with a DC50 of 0.32 nM. TD-428 reduces c-Myc levels more efficiently than JQ1. -
SLLN-15 is an oral activ enhancer of autophagy that activates cytostatic macroautophagy/autophagy in triple-negative breast cancer (TNBC).
-
A1874 is a nutlin-based and BRD4-degrading PROTAC with a DC50 of 32 nM. Effective in inhibiting many cancer cell lines proliferation
-
BAY-8002 is a selective and orally active inhibitor of monocarboxylate transporter 1 (MCT1), with an IC50 of 85 nM. Has potential to treat lymphoma.
-
MRTX-1257 is a selective, irreversible, covalent and oral active KRAS G12C inhibitor, with an IC50 of 900 pM for KRAS dependent ERK phosphorylation.
-
STL127705 is a Ku 70/80 heterodimer protein inhibitor, inhibits Ku70/80-DNA interaction (IC50 of 3.5 μM) and Ku-dependent activation of DNA-PKCS kinase.
-
USL311 is a selective CXCR4 antagonist, which prevents the binding of stromal-cell derived factor-1 (SDF-1 or CXCL12) to CXCR4. Anti-tumor activity.
-
TAS-114 is a dual dUTPase/dihydropyrimidine dehydrogenase (DPD) inhibitor, can improving the therapeutic efficacy of fluoropyrimidine.
-
CFI-402257 is a highly selective and oral active TTK/Mps1 inhibitor with an IC50 of 1.7 nM for TTK. CFI-402257 has potential to treat ovary cancer and TNBC.
-
RIPGBM is a selective inducer of apoptosis in glioblastoma multiforme (GBM) cancer stem cells (CSCs) with an EC50 less than 500 nM.
-
TX1-85-1, a ATP-competitive ligand of Her3, covalent modification of Her3 to inhibit Her3 signaling
2019-06-01
TX1-85-1 is a Her3 (ErbB3) inhibitor with an IC50 of 23 nM. TX1-85-1 induces partial degradation of Her3 protein and attenuates Her3-dependent signaling. -
IWP-O1, a Highly Potent Porcupine Inhibitor, Functions by Preventing the Secretion of Wnt Proteins
2019-06-03
IWP-O1 is a Porcupine (Porcn) inhibitor, with an EC50 of 80 pM in L-Wnt-STF cells. IWP-O1 functions by preventing the secretion of Wnt proteins[ -
PF-06465469 is a Covalent Inhibitor of ITK
2019-06-08
PF-06465469 is a potent and covalent inhibitor of ITK with an IC50 of 2 nM. PF-06465469 inhibits MEK1/2 or AKT phosphorylation. -
Riviciclib is a Potent CDKs Inhibitor
2019-06-09
Riviciclib P276-00 free base) is a potent CDK inhibitor, which inhibits CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC50s of 20 nM, 63 nM, and 79 nM, respectively -
JMS-17-2 is a CX3CR1 Antagonist
2019-06-12
JMS-17-2 is a potent and selective CX3CR1 antagonist with an IC50 of 0.32 nM. Has potential to treat cancers such as breast cancer. -
CBS9106, a Reversible Oral CRM1 Inhibitor, Causes Arrest of the Cell Cycle and Induces Apoptosis
2019-06-14
CBS9106 (SL-801) is a reversible oral CRM1 inhibitor antitumor activities. CBS9106 causes arrest of the cell cycle and induces apoptosis. -
NU6140 is a selective CDK2-cyclin A inhibitor (IC50, 0.41 μM). NU6140 also potently inhibits Aurora A and Aurora B, with IC50s of 67 and 35 nM, respectively
-
S18-000003 is a potent, selective and orally active inhibitor of retinoic acid receptor-related orphan receptor-gamma-t (RORγt). S18-000003 ameliorates psoriasis-like lesions in vivo. S18-000003 can be used for the research of skin inflammatory diseases.
-
TH34, an HDAC6/8/10 inhibitor with IC50s of 4.6 μM, 1.9 μM, and 7.7 μM respectively, shows high selectivity over HDAC1/2/3.
-
Alisertib (MLN 8237) is an oral active and selective Aurora A kinase inhibitor with an IC50 of 1.2 nM. To treat hematologic malignancies and solid tumors.
-
PTC299 is a dual and orally active DHODH and VEGF inhibitor, has broad and potent activity against hematological cancer cells.
-
AMG 487 is an orally active and selective antagonist of CXC chemokine receptor 3 (CXCR3). AMG 487 has potential to treat metastatic cancer.
-
S55746 (BLC201) is an orally active and selective BCL-2 inhibitor, with a Ki of 1.3 nM.. S55746 (BLC201) has antitumor activity with low toxicity.
-
WYC-209 is a retinoic acid receptor (RAR) agonist. WYC-209 induces apoptosis primarily via the caspase 3 pathway (IC50 = 0.19 μM for mTRCs).
-
NMS-P515 is a potent, orally active and stereospecific PARP-1 inhibitor, with a Kd of 16 nM and an IC50 of 27 nM (in Hela cells). Anti-tumor activity.
-
FGTI-2734 is a dual farnesyl and geranylgeranyl transferase-1 inhibitor. FGTI-2734 prevents membrane localization of KRAS and mutant KRAS pancreatic tumors.
-
MBM-55 is a potent, selective Nek2 inhibitor with an IC50 of 1 nM. MBM-55 shows antitumor activities and induces cell cycle arrest and apoptosis.
-
ML367 is an ATAD5 Stabilization Inhibitor
2019-08-03
ML367 is a potent inhibitor of ATAD5 stabilization. It blocks DNA repair pathways, and suppresses phosphorylation of RPA32 and CHK1. -
VERU-111 (ABI-231) is a potent and orally bioavailable α and β tubulin inhibitor, which displays strong antiproliferative activity.
-
JH-RE-06, a potent REV1-REV7 interface inhibitor (IC50=0.78 μM; Kd=0.42 μM), targets REV1 that interacts with the REV7 subunit of POLζ.
-
BI-882370 is a potent RAF kinase inhibitor with IC50s of 0.4, 0.8, and 0.6 nM for oncogenic BRAFV600E-mutant, the WT BRAF and CRAF kinases , respectively.
-
MSX-122 is an orally active partial antagonist of CXCR4, inhibiting CXCR4/CXCL12 actions. MSX-122 has both anti-tumor and anti-metastasis activities.
-
MPT0B392 Induces Apoptosis via Inhibiting Tubulin Polymerization and Inducing c-JNK Activation
2019-08-16
MPT0B392 is a novel microtubule depolymerizing agent that triggers induction of the mitotic arrest and induces JNK activation, leading to apoptosis. -
ZT-12-037-01 is a ATP-competitive and specific STK19 inhibitor and inhibits oncogenic NRAS-driven melanocyte malignant transformation.
-
BJE6-106 is a selective PKCδ inhibitor with an IC50 of 0.05 μM and targets selectivity over PKCα. BJE6-106 induces caspase-dependent apoptosis.
-
PT2977 is an orally active and selective HIF-2α inhibitor with an IC50 of 9 nM. PT2977 is a potential treatment for ccRCC and VHL disease.
-
BI-2852 is a potent KRAS inhibitor with nanomolar affinity and reduces pERK and pAKT levels in a dose-dependent manner in a KRAS mutant cell line NCI-H358.
-
AAPK-25 is a potent and selective Aurora kinases and Polo-like Kinases (PLK) dual inhibitor, which shows anti-tumor activity.
-
BAY-293 is a potent inhibitor of Son of Sevenless 1 (SOS1) and blocks RAS activation via disruption of the KRAS-SOS1 interaction with an IC50 of 21 nM.
-
WZ811 is an Orally Active CXCR4 Antagonist
2019-09-07
WZ811 is an orally active, highly potent competitive antagonist of CXCR4, which inhibits chronic lymphocytic leukemia progression and tumorigenesis. -
RU-302 is a pan-TAM inhibitor that blocks the TAM Ig1 ectodomain and the Gas6 Lg domain interaction. RU-302 blocks Gas6-inducible Axl receptor activation.
-
BAY 61-3606 is an orally available, ATP-competitive, reversible and highly selective Syk inhibitor and sensitizes apoptosis by in breast cancer.
-
E3330, an APE1 Redox Inhibitor, Modulates Cell Migration and Invasion in Metastatic Cancer
2019-09-13
E3330 is a direct, orally active AP endonuclease 1 (APE1) inhibitor, which suppresses NF-κB DNA-binding activity. E3330 shows good anticancer properties. -
AOH1160, an Orally Active PCNA Inhibitor, Exhibits Efferctive Anti-cancer Activity with Low Toxicity
2019-09-14
AOH1160 is a potent, first-in-class, orally available PCNA inhibitor and exhibits broad-spectrum anti-cancer activity without causing unacceptable toxicity. -
-
Tasisulam is an anticancer agent and induces apoptosis, which also inhibits mitotic progression and induces vascular normalization.
-
IPR-803 is a potent inhibitor of the uPAR•uPA protein-protein interaction, and binds directly to uPAR with sub-micromolar affinity.
-
Vorolanib is an orally active, multikinase VEGF/PDGF receptor inhibitor with antitumor activity and is expected to disrupt tumor angiogenesis.
-
CCG-222740 is a potent and selective MRTF pathway inhibitor. It effectively reduces fibrosis in the skin and blocks melanoma metastasis.
-
IACS-8803 is a highly potent cyclic dinucleotide stimulator of interferon genes (STING) agonist with robust systemic antitumor efficacy.
-
AC-73 is a first specific, orally active the cluster of differentiation 147 (CD147) inhibitor and specifically disrupts CD147 dimerization.
-
S516 is a potent tubulin polymerization inhibitor with an IC50 of 4.29 μM and has marked antitumor activity against murine and human solid tumors.
-
Niraparib is an Orally Active PARP Inhibitor
2019-12-18
Niraparib is a highly potent and orally bioavailable PARP1 and PARP2 inhibitor. Niraparib has potent anti-cancer activity. -
DRF-1042 is an orally active derivative of Camptothecin and acts to inhibit DNA topoisomerase I with good anticancer activity.
-
CH6953755 is a potent, orally active and selective YES1 kinase inhibitor leading to antitumor activity against YES1 Gene -amplified cancers.
-
CA-4948 is a Selective and Orally Bioavailable IRAK4 Kinase Inhibitor for Lymphoma Treatment
2020-01-05
CA-4948 is a potent, selective and orally bioavailable IRAK4 kinase inhibitor. CA-4948 can be used for the treatment of lymphoma. -
D-I03 is a Selective RAD52 Inhibitor
2020-01-08
D-I03 is a selective RAD52 inhibitor, which specifically inhibits RAD52-dependent single-strand annealing (SSA) and D-loop formation. -
SB-218078, a Chk1 inhibitor, inhibits Chk1 phosphorylation of cdc25C with an IC50 of 15 nM, causeing apoptosis by DNA damage and cell cycle arrest.
-
ADH-503 is an orally active and allosteric CD11b agonist and leads to the repolarization of tumor-associated macrophages.
-
Balixafortide is a potent, selective peptidic CXCR4 antagonist with anti-cancer effects, and blocks β-arrestin recruitment and calcium flux.
-
NU1025 is a potent PARP inhibitor and potentiates the cytotoxicity of ionizing radiation drug. NU1025 has anti-cancer and neuroprotective activity.
-
CCT365623, an Orally Active LOX Inhibitor, Supresses EGFR (pY1068) and AKT Phosphorylation
2020-04-16
CCT365623 is an orally active LOX inhibitor, suppresses EGFR (pY1068) and AKT phosphorylation driven by EGF. CCT365623 has good pharmacokinetic properties. -
TP3011 is a potent DNA topoisomerase I inhibitor. Antitumor activities.Active metabolite of TP3076. TP3011 inhibits cancer cell proliferative activities.
-
PIK-75 is a reversible DNA-PK and p110α selective inhibitor. Impairs cell proliferation, survival, and tumor growth. Induce apoptosis.
-
RBN-2397 is an orally active accross species NAD+ competitive inhibitor of PARP7. RBN-2397 binds to PARP7 and restores interferon (Type I) signaling.
-
DI-82 is a potent deoxycytidine kinase (dCK) inhibitor. DI-82 is potent against hematological malignancies and other cancers.
-
DI-87, an orally active and selective dCK inhibitor, has antitumor activity and is used in combination therapy against tumors expressing dCK.
-
GSK143 is an orally active and highly selective spleen tyrosine kinase (SYK) inhibitor. GSK143 reduces inflammation in the intestinal muscularis in mice.
-
EW-7195 is a potent and selective ALK5 inhibitor, and efficiently inhibits TGF-β1-induced Smad signaling, EMT and breast tumour metastasis to the lung.
-
ZZW-115, a NUPR1 Inhibitor, Possesses Anticancer Activity via Inducing Necroptosis and Apoptosis
2020-08-29
ZZW-115 is a potent NUPR1 inhibitor, with a Kd of 2.1 μM. ZZW-115 induces tumor cell death by necroptosis and apoptosis. ZZW-115 exerts anticancer activity. -
CRT0044876 is a potent and selective APE1 inhibitor. CRT0044876 inhibits the AP endonuclease, 3′-phosphodiesterase and 3′-phosphatase activities of APE1.
-
MSA-2 is an orally available non-nucleotide STING agonist. MSA-2 shows antitumor activity and stimulates interferon-β secretion in tumors.
-
SP-8356, an orally active CD147inhibitor, exerts anti-breast cancer effects by inhibiting NF-κB signaling. Anti-atherosclerotic effects.
-
CB-1158, a potent and orally bioavailable inhibitor of arginase, blocks myeloid cell-mediated immune suppression in the tumor microenvironment.
-
SRX3207 is an orally active and first-in-class dual Syk/PI3K inhibitor. SRX3207 possesses effective anti-tumor activity in vitro and in vivo.
-
Verucopeptin inhibits v-ATPase activity by directly targeting the v-ATPase ATP6V1G subunit but not ATP1V1B2 or ATP6V1D. Also a potent HIF-1 inhibitor.
-
E7820, sulfonamide derivative, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium.
-
Cyclo(-RGDfK) is a selective inhibitor of the αvβ3 integrin. Cyclo(-RGDfK) potently targets cancer cells through binding to the cell surface αvβ3 integrin.
-
Cilengitide is a compound targeting angiogenesis, the cornerstone of tumor growth and metastasis. ανβ3 and ανβ5 are the target of Cilengitide.
-
Tetrac inhibits the cellular actions of thyroid hormone initiated at the hormone receptor on plasma membrane integrin alphavbeta3.
-
SAR-020106 is an ATP-competitive CHK1 inhibitor with an IC50 of 13.3 nM for hCHK1. SAR-020106 can enhance antitumor activity with selected anticancer drugs.
-
AZ9482 is a Triple PARP1/2/6 Inhibitor
2021-01-05
AZ9482 is a triple PARP1, PPAR2 and PPAR6 inhibitor, with IC50 values of 1 nM, 1 nM and 640 nM for PARP1, PARP2 and PARP6, respectively. -
NSC 80467, a potent DNA damaging agent, selectively inhibits survivin, and preferentially inhibits DNA synthesis.
-
G5-7, an orally active and allosteric JAK2 inhibitor. G5-7 induces cell cycle arrest, apoptosis and possesses antiangiogenic effect.
-
NSC-105808, a potent, specific DNA2 nuclease inhibitor, inhibits HR repair, DSB end resection and suppresses proliferation of cancer cells.
-
Senaparib, a selective and orally active PARP1/2 inhibitor, has great potential as a monotherapy as well as in combination with other agents.
-
PF 477736 (PF 00477736) is a Chk1 inhibitor. Breaching the DNA damage checkpoint. PF-00477736 combines with Gemcitabine to abrogates cell cycle arrest.
-
ENMD-1198 is an orally active microtubule-targeting agent with antiproliferative and antiangiogenic activity.
-
TPP-1 is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity (KD=95 nM).
-
Elimusertib is a potent, orally available and selective ATR inhibitor. Elimusertib has potent anti-tumor activity.
-
FAPI-46 is a quinoline-based FAP-targeted radiotracer. FAPI-46 has higher tumor uptake and prolonged tumor accumulation.
-
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction. It induces high levels of IL-2.
-
ML339 is a Selective CXCR6 Antagonist
2021-05-12
ML339 is a small molecule antagonist would block Prostate cancer cell trafficking; hence mediate a metastatic event and disease progression. -
Sitravatinib (MGCD516) is an Orally Bioavailable RTK Inhibitor with PD-1 Blockade Activity
2021-06-03
Sitravatinib, a small molecule RTK inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma. -
Motesanib (AMG 706) is an orally active VEGFR inhibitor. Potently inhibits angiogenesis and induces regression in tumor xenografts.
-
Venadaparib is a selective and orally active PARP1/2 inhibitor with significant in vitro and in vivo activities in multiple cancer models.
-
SG3199, an ADC Cytotoxin, is a Cytotoxic DNA Minor Groove Interstrand Crosslinking PDB Dimer
2021-07-12
SG3199, a PBD dimer, is a warhead in next-generation ADCs with potently cytotoxic and a very short half-life. -
EMD527040 is a highly selective αvβ6 antagonist with antifibrotic activities.
-
DP-C-4 is a CRBN-Based dual PROTAC for EGFR and PARP could provide an effective study for cancer diseases.
-
Inupadenant is an orally active, highly selective A2A receptor antagonist with potent anti-tumor activity.
-
UK122 is a potent and selective urokinase-type plasminogen activator (uPA) inhibitor with anti-cancer activity.
-
SN-38 (NK012) is an active metabolite of the Topoisomerase I inhibitor Irinotecan and inhibits DNA and RNA synthesis.
-
AZD4635 is a potent, selective and orally active antagonist of A2AR that reverses adenosine-mediated immune suppression.
-
Daunorubicin is a topoisomerase II inhibitor with a wide spectrum of anticancer activity and anti-HBV effect.
-
Nintedanib a potent and orally active triple vascular kinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β.
-
PR-104A is a hypoxia-selective DNA cross-linking agent/DNA-damaging agent and cytotoxin. Antitumor Activity. Leukemia (T-ALL).
-
Axitinib is a multi-targeted tyrosine kinase inhibitor and potently inhibitor VEGFR1, VEGFR2, VEGFR3 and PDGFRβ.
-
AZD1390 is a potent, highly selective, orally bioavailable, brain-penetrant ATM inhibitor with an IC50 of 0.78 nM.
-
Rucaparib is a PARP Inhibitor
2022-01-13
Rucaparib is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3). Rucaparib has the potential for CRPC research. -
β-Lapachone, a topoisomerase I inhibitor, induces apoptosis by inhibiting cell cycle progression. β-Lapachone has anti-inflammatory effect.
-
CL097 is a TLR7/8 agonist. CL097 induces pro-nflammatory cytokines. CL097 induces NADPH oxidase priming and efficient diabetogenic cytotoxic T lymphocyte (CTL) function in NOD mice.
-
PFM39 is a potent and selective MRE11 exonuclease inhibitor, and does not inhibit endonuclease, nuclease activity.
-
VAL-083 is an alkylating agent that creates N7 methylation on DNA, VAL-083 exhibits antitumor activity in vitro and in vivo.
-
Lomeguatrib is a highly potent MGMT inactivator, improves the therapeutic effect of alkylating agents in a number of tumour models.
-
Indoximod, an immunometabolic adjuvant, is an orally active IDO pathway inhibitor. Indoximod acts as a Trp mimetic in regulating mTOR.
-
Tanomastat is an orally active, non-peptidic biphenyl MMPs inhibitor, with antiangiogenic, anti-invasive and antimetastatic activities.
-
BM213 is a selective C5aR1 agonist. It’s a useful research tool to study C5aR1 function
-
Mirin is a potent MRN complex inhibitor. Mirin prevents MRN-dependent activation of ATM without affecting ATM protein kinase activity.
-
Pirarubicin, an anthracycline antibiotics, is a topoisomerase II Inhibitor.
-
Telatinib is an orally active inhibitor of VEGFR2, VEGFR3, PDGFα, and c-Kit.
-
Bisantrene is topoisomerase II poisons and DNA intercalators. Bisantrene intercalates with and disrupts the configuration of DNA.
-
Marimastat (BB2516) is a broad spectrum and orally bioavailable inhibitor of MMPs (Matrix metalloproteinases).
-
Gardiquimod is a TLR7/8 agonist and can inhibit HIV-1 infection.
-
Vatalanib is an inhibitor of VEGFR2/KDR. Vatalanib induces inhibition of the angiogenic response to VEGF and PDGF.
-
Actinomycin D (Dactinomycin) is an autophagy activator inhibiting DNA repair with an IC50 of 0.42 μM.
-
Rebeccamycin, an antitumor antibiotic, inhibits DNA topoisomerase I. Rebeccamycin can be used for leukemia research.
-
Toceranib is a selective and orally active inhibitor of RTK and has the potential for the research of canine mast cell tumors.
-
Tiragolumab is an immune checkpoint inhibitor binding to TIGIT. Tiragolumab is effective against multiple solid malignancies.
-
Henatinib is an orally active small-molecule multikinase inhibitor that has demonstrated broad and potent antitumor activities.
-
Rucaparib (AG014699) is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with IC50s <5 nM , possessing anticancer activity.
-
KGP94 is a selective inhibitor of cathepsin L. KGP94 has antitumor activity and improves survival of bone metastases bearing mice.
-
BNS-22 is a potent and selective inhibitor of TOP2α and TOP2β that exhibits anti-proliferative activities.
-
Certepetide is a Tumor-penetrating Enhancer via RGD Motif Interaction with Alphav-integrins
2022-09-01
Certepetide is a tumor-penetrating enhancer and has the potential for the research of metastatic pancreatic ductal adenocarcinoma. -
AZD-9574 is a potent and brain penetrant PARP1 inhibitor and shows >8000-fold selectivity for PARP1 compared to PARP2/3/5a/6.
-
Simmiparib is a highly potent and orally active PARP1 and PARP2 inhibitor with IC50s of 1.75 nM and 0.22 nM, respectively. Antitumor effect.
-
BSP16 is a potent, orally active stimulator of interferon genes (STING) agonist. BSP16 has potent anti-cancer activity.
-
AZ31 is a potent, highly selective, and orally active ATM inhibitor, and is also a potent radiosensitizer in vitro.
-
Parsatuzumab (RG 7414) is a humanized monoclonal antibody, that acts as an immunomodulator, and binds to EGFL7.
-
RP-6685 is a potent, selective and orally active DNA Polθ inhibitor with an IC50 value of 5.8 nM. RP-6685 shows antitumor activity.
-
CAM 833, a potent and selective inhibitor of the BRCA2-RAD51 interaction, and has the potential for the cancer research.
-
LY3177833 is an orally active CDC7 and pMCM2 inhibitor with IC50 values of 3.3 nM and 290 nM, respectively. LY3177833 is a senescence inducer
-
Serplulimab is a humanized monoclonal anti-PD-1 antibody and has the potential for the research of small cell lung cancer.
-
ABT-510, a peptide analog of thrombospondin-1 (TSP-1), can block angiogenesis in vitro and in vivo, and slow tumor growth.
-
Mogamulizumab is an Anti-CCR4 monoclonal antibody. It enhances antibody-dependent cellular cytotoxicity and is effective against leukemia.
-
Mitonafide, a potent cytostatic agent, can inhibit DNA and RNA synthesis. Mitonafide is a potent antitumor agent.
-
OTS193320 is a potent SUV39H2 methyltransferase activity inhibitor. OTS193320 triggers apoptotic cell death.
-
Bapotulimab (BAY-1905254) is an ILDR2 IgG antibody that blocks the immunosuppressive effects of ILDR2 on T-cell activation.
-
Nanrilkefusp alfa is a selective and strong IL-15 agonist. It inhibits tumor metastasis and viability by activating natural killer (NK) cells.
-
Urabrelimab (SRF231) is an anti-CD47 monoclonal antibody, blocking the CD47-SIRPα interaction. It has the potential to research anticancer.
-
Efineptakin alfa (NT-17) is a Long-Acting Recombinant Human IL-7 for Glioblastoma Research
2023-02-07
Efineptakin alfa (NT-17) is a long-acting recombinant human IL-7. Efineptakin alfa can be used for glioblastoma research. -
Pegdinetanib (BMS-844203) is a selective VEGFR-2 inhibitor with antitumor activity.
-
ARN24139 is a potential topoisomerase II (topoII) inhibitor that inhibits cancer cell proliferation and is useful in cancer research.
-
Tifcemalimab, a Humanized anti-BTLA monoclonal antibody, blocks the interaction of HVEM-BTLA by binding to BTLA and activates lymphocytes.
-
Geptanolimab (CBT-501) is a programmed death-1 (PD-1) monoclonal antibody. Geptanolimab can be used in research forsolid tumor research.
-
Dazostinag is a STING Agonist and Can be used for Antibody-Drug Conjugates (ADCs) Synthesis
2023-03-13
Dazostinag is a STING agonist and a playload, to synthesis antibody-drug conjugates (ADCs). It has antitumor activity in vivo.
Products
-
All
-
Inhibitors & Agonists
-
Isotope-Labeled Compounds
-
Fluorescent Dye
-
Peptides
-
Recombinant Proteins
-
Antibodies
-
Screening Libraries
-
Kits
-
Inhibitory Antibodies
-
Reference Standards
-
Induced Disease Models Products
-
GMP Small Molecules
-
Enzyme
-
Biochemical Assay Reagents
-
Natural Products
| Cat. No. | Product Name | Information | Application | Publication |
|---|---|---|---|---|
| HY-10182A | Laduviglusib monohydrochloride |
Laduviglusib (CHIR-99021) monohydrochloride is a potent and selective GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib monohydrochloride shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib monohydrochloride is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib monohydrochloride enhances mouse and human embryonic stem cells self-renewal. Laduviglusib monohydrochloride induces autophagy.
|
Breast Cancer
Pancreatic Cancer
Depression
Glucose Metabolism
Alzheimer's Disease
Obesity
Lung Fibrosis
|
315
|
| HY-10182 | Laduviglusib |
Laduviglusib (CHIR-99021) is a potent, selective and orally active GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib enhances mouse and human embryonic stem cells self-renewal. Laduviglusib induces autophagy.
|
Breast Cancer
Pancreatic Cancer
Depression
Glucose Metabolism
Alzheimer's Disease
Obesity
Lung Fibrosis
|
315
|
| HY-100381 | Nigericin sodium salt |
Nigericin sodium salt is an antibiotic derived from Streptomyces hygroscopicus that act as a K+/H+ ionophore, promoting K+/H+ exchange across mitochondrial membranes. Nigericin sodium salt is a NLRP3 activator. Nigericin sodium salt shows promising anti-cancer activities through decreasing intracellular pH (pHi), and inactivation of Wnt/β-catenin signals. Nigericin sodium salt induces pyroptosis through caspase 1/GSDMD in TNBC.
Source: Streptomyces hygroscopicus |
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Ovarian Cancer
Bacterial Infection
Depression
Hypertension
Lung Fibrosis
Rheumatoid Arthritis
|
249
|
| HY-127019 | Nigericin |
Nigericin is an antibiotic derived from Streptomyces hygroscopicus that act as a K+/H+ ionophore, promoting K+/H+ exchange across mitochondrial membranes. Nigericin is a NLRP3 activator. Nigericin shows promising anti-cancer activities through decreasing intracellular pH (pHi), and inactivation of Wnt/β-catenin signals. Nigericin induces pyroptosis through caspase 1/GSDMD in TNBC.
|
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Ovarian Cancer
Bacterial Infection
Depression
Hypertension
Lung Fibrosis
Rheumatoid Arthritis
|
249
|
| HY-50895 | Gefitinib |
Gefitinib (ZD1839) is a potent, selective and orally active EGFR tyrosine kinase inhibitor with an IC50 of 33 nM. Gefitinib selectively inhibits EGF-stimulated tumor cell growth (IC50 of 54 nM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells. Gefitinib also induces autophagy and cell apoptosis, which can be used for cancer related research, such as Lung cancer and breast cancer .
|
Neurological, Eye or Ear Disease
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Liver Cancer
Pancreatic Cancer
Ovarian Cancer
Digestive System Inflammation
SARS-CoV-2 Infection
Hepatitis C Virus Infection
Obesity
|
217
|
| HY-15772 | Osimertinib |
Lung Cancer
Colorectal Cancer
Prostate Cancer
Liver Cancer
Pancreatic Cancer
Ovarian Cancer
Glucose Metabolism
SARS-CoV-2 Infection
Hepatitis C Virus Infection
Obesity
|
202
|
|
| HY-15147 | XAV-939 |
XAV-939 is a Tankyrase inhibitor. XAV-939 has inhibitory activity for TNKS1 and TNKS2 with IC50 values of 5 nM and 2 nM, respectively. XAV-939 also is an enhancer of osteoblastic differentiation of hMSCs. XAV-939 can be used for the research of conditions associated with activated Wnt signaling, such as cancer, fibrotic diseases and conditions associated with low bone formation.
|
Neurological, Eye or Ear Disease
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Pancreatic Cancer
Ovarian Cancer
Hypertension
Lung Fibrosis
|
201
|
| HY-13027 | DAPT |
DAPT (GSI-IX) is a potent and orally active γ-secretase inhibitor with IC50s of 115 nM and 200 nM for total amyloid-β (Aβ) and Aβ42, respectively. DAPT inhibits the activation of Notch 1 signaling and induces cell differentiation. DAPT also induces autophagy and apoptosis. DAPT has neuroprotection activity and has the potential for autoimmune and lymphoproliferative diseases, degenerative disease and cancers treatment.
|
Breast Cancer
Colorectal Cancer
Liver Cancer
Pancreatic Cancer
Digestive System Inflammation
Alzheimer's Disease
Rheumatoid Arthritis
|
169
|
| HY-50896 | Erlotinib |
Erlotinib (CP-358774) is a selective, orally active EGFR tyrosine kinase inhibitor. Erlotinib also acts as a substrate and inhibitor of OATP2B1, with an IC50 of approximately 0.079 μM for inhibiting OATP2B1-mediated uptake of estrone 3-sulfate. Erlotinib blocks EGFR phosphorylation, downstream signal transduction, as well as the growth and proliferation of cancer cells. Erlotinib inhibits MMP-10-mediated renal injury, fibrotic lesions, the ERK1/2, GSK-3β and β-catenin signaling pathways, fibronectin, α-SMA, collagen deposition, and renal injury markers. Erlotinib is metabolized via CYP3A to produce the active metabolite OSI-420. Erlotinib can be used in research related to non-small cell lung cancer, gastric cancer, papillary renal cell carcinoma, pancreatic cancer, renal fibrosis, and other conditions.
|
|
143
|
| HY-L001P | Bioactive Compound Library Plus |
Bioactive compounds are a general term for a class of substances that can cause certain biological effects in the body, which are the main source of small molecule drugs. These compounds generally penetrate cell membranes, act on specific target proteins in cells, regulate intracellular signaling pathways, and cause some changes in cell phenotype.
MCE owns a unique collection of 32,925 compounds with confirmed biological activities and clear targets. These compounds include natural products, innovative compounds, approved compounds, and clinical compounds. This library is a useful tool for signal pathway research, drug discovery and drug repurposing, etc.
Bioactive Compound Library Plus, with more powerful screening capability, further complements Bioactive Compound Library (HY-L001) by adding some compounds with low solubility or solution stability (Part B) and some novel, rare or exclusive compounds (Part C) to this library. Overall, bioactive compound library plus (HY-L001P) includes tree parts: Part A, Part B and Part C. Compounds in Part A are equal to the products in HY-L001, which can be supplied in solution or solid form. Compounds in Part B and C are only supplied in solid form.
|
|
131
|
| HY-10261 | Afatinib |
Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer.
|
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Neurodegenerative Disease
Depression
Pain
Digestive System Inflammation
Hepatitis C Virus Infection
Obesity
Lung Fibrosis
Rheumatoid Arthritis
|
111
|
| HY-L025 | Anti-Cancer Compound Library |
Cancer is the second leading cause of death globally and seriously threatens human health. A neoplasm and malignant tumor are other common names for cancer. Disruption of the normal regulation of cell-cycle progression and division lies at the heart of the events leading to cancer. Target therapy, which targets proteins that control how cancer cells grow, divide and spread, plays an important role in cancer treatment. Recent studies mainly focus on targeting the key proteins for cancer surviving, cancer stem cells, the tumor microenvironment, tumor immunology, etc.
MCE designs a unique collection of 11,167 anti-cancer compounds that target kinases, cell cycle key components, tumorigenesis related signaling pathways, etc. MCE Anti-cancer compound library is a useful tool for anti-cancer drug screening.
|
|
99
|
| HY-50898 | Lapatinib |
Neurological, Eye or Ear Disease
Lung Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Pancreatic Cancer
Ovarian Cancer
HER-2 Positive Breast Cancer
Metastatic Breast Cancer
SARS-CoV-2 Infection
Hepatitis C Virus Infection
Obesity
|
95
|
|
| HY-A0064 | Verapamil hydrochloride |
Verapamil hydrochloride ((±)-Verapamil hydrochloride) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil hydrochloride also inhibits CYP3A4. Verapamil hydrochloride has the potential for high blood pressure, heart arrhythmias and angina research.
|
|
91
|
| HY-14596 | Genistein |
Neurological, Eye or Ear Disease
Lung Cancer
Colorectal Cancer
Prostate Cancer
Liver Cancer
Pancreatic Cancer
Ovarian Cancer
Digestive System Inflammation
SARS-CoV-2 Infection
Hepatitis C Virus Infection
Obesity
|
91
|
|
| HY-14275 | Verapamil |
Verapamil ((±)-Verapamil) is a calcium channel blocker and a potent and orally active first-generation P-glycoprotein (P-gp) inhibitor. Verapamil also inhibits CYP3A4. Verapamil has the potential for high blood pressure, heart arrhythmias and angina research.
|
Neurological, Eye or Ear Disease
Metabolic or Endocrine Disease
Ovarian Cancer
Viral Infection
Hypertension
|
91
|
| HY-L028 | CNS-Penetrant Compound Library |
The blood-brain barrier (BBB) is the complex network of brain microvessels. It protects the brain from the external bloodstream environment and supplies the brain with the required nutrients for normal function. However, blood-brain barrier is also the obstacle to deliver beneficial drugs to treat CNS (central nervous system) diseases or brain tumors, as it has the least permeable capillaries in the entire body due to physical barriers (tight junctions). Therefore, it is crucial to discover drugs which can cross this barrier for the treatment of brain-based diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and epilepsy.
MCE offers a unique collection of 1,148 compounds with confirmed CNS-Penetrant property. It’s a useful tool for the discovery of drugs used for brain diseases, such as brain tumors, mental disorders, and neurodegenerative diseases.
|
|
91
|
| HY-50878 | Crizotinib |
Crizotinib (PF-02341066) is an orally bioavailable, ATP-competitive ALK and c-Met inhibitor with IC50s of 20 and 8 nM, respectively. Crizotinib inhibits tyrosine phosphorylation of NPM-ALK and tyrosine phosphorylation of c-Met with IC50s of 24 and 11 nM in cell-based assays, respectively. Crizotinib is also a ROS1 inhibitor. Crizotinib has effective tumor growth inhibition.
|
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Non-Small Cell Lung Cancer
Triple-Negative Breast Cancer
|
89
|
| HY-L031 | Small Molecule Immuno-Oncology Compound Library |
Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines.
MCE Small Molecule Immuno-Oncology Compound Library offers 813 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.
|
|
88
|
| HY-L048 | Antifungal Compound Library |
The high rates of morbidity and mortality caused by fungal infections are associated with the current limited antifungal arsenal and the high toxicity of the compounds. Additionally, identifying novel drug targets is challenging because there are many similarities between fungal and human cells. The most common antifungal targets include fungal RNA synthesis and cell wall and membrane components, though new antifungal targets are being investigated. Nonetheless, fungi have developed resistance mechanisms, such as overexpression of efflux pump proteins, overexpression and changes in drug targets and biofilm formation, emphasizing the importance of discovering new antifungal drugs and therapies. Due to the limited antifungal arsenal, researchers have sought to improve treatment via different approaches, such as the combination of antifungal drugs, development of new formulations for antifungal agents and modifications to the chemical structures of traditional antifungals, etc.
MCE offers a unique collection of 577 compounds with validated antifungal activities. MCE antifungal compound library is an effective tool for drug repurposing screening, combination screening and biological investigation.
|
|
87
|
| HY-L017 | Stem Cell Signaling Compound Library |
Adult stem cells are important for tissue homeostasis and regeneration due to their ability to self-renew and generate multiple types of differentiated daughters. Self-renewal is reflected by their capacity to undergo multiple/limitless divisions. Several signaling pathways are involved in self-renewal of stem cells, that is, Notch, Wnt, and Hedgehog pathways or Polycomb family proteins. Recent studies mainly focus on cancer stem cell (CSCs), induced pluripotent stem cell (iPSCs), neural stem cell and maintenance of embryonic stem cell pluripotency. Among them, CSCs have been believed to be responsible for tumor initiation, growth, and recurrence that have implications for cancer therapy.
MCE owns a unique collection of 2,884 compounds that can be used for stem cell regulatory and signaling pathway research.
|
|
86
|
| HY-L020 | Wnt/Hedgehog/Notch Compound Library |
The developmental proteins Hedgehog, Notch and Wnt are key regulators of cell fate, proliferation, migration and differentiation in several tissues. Their related signaling pathways are frequently activated in tumors, and particularly in the rare subpopulation of cancer stem cells.
The Wnt signaling pathway is a conserved pathway in animals. Deregulated Wnt signaling has catastrophic consequences for the developing embryo and it is now well appreciated that defective Wnt signaling is a causative factor for a number of pleiotropic human pathologies, including cancer. Hedgehog signaling pathway is linked to tumorigenesis and is aberrantly activated in a variety of cancers. The Notch signaling pathway is a highly conserved cell signaling system present in most animals. It plays an important role in cell-cell communication, and further regulates embryonic development.
MCE designs a unique collection of 643 Wnt/Hedgehog/Notch signaling pathway-related small molecules. Wnt/Hedgehog/Notch Compound Library serves as a useful tool for stem cell research and anti-cancer drug screening.
|
|
86
|
| HY-L013 | Neuronal Signaling Compound Library |
Neuronal Signaling is involved in the regulation of the mechanisms of the central nervous system (CNS) such as its structure, function, genetics and physiology as well as how this can be applied to understand diseases of the nervous system. Every information processing system in the CNS is composed of neurons and glia, neurons have evolved unique capabilities for intracellular signaling (communication within the cell) and intercellular signaling (communication between cells). G protein-coupled receptors (GPCRs), including 5-HT receptor, histamine receptor, opioid receptor, etc. are the largest class of sensory proteins and are important therapeutic targets in Neuronal Signaling. Besides, Notch signaling, such as β- and γ-secretase, also plays multiple roles in the development of the CNS including regulating neural stem cell (NSC) proliferation, survival, self-renewal and differentiation. GPCR dysfunction caused by receptor mutations and environmental challenges contributes to many neurological diseases. Notch signaling in neurons, glia, and NSCs is also involved in pathological changes that occur in disorders such as stroke, Alzheimer's disease and CNS tumors. Thus, targeting Neuronal Signaling, such as notch signaling and GPCRs, can be used as therapeutic interventions for several different CNS disorders.
MCE designs a unique collection of 3,934 Neuronal Signaling-related compounds that act as a useful tool for the research of neuronal regulation and neuronal diseases.
|
|
84
|
| HY-L101 | Anti-Liver Cancer Compound Library |
Liver cancer is one of the leading malignancies which occupies the second position in cancer deaths worldwide, becoming serious threat to human health. Hepatocellular carcinoma (HCC), also known as hepatoma is the most common type accounting for approximately 90% of all liver cancers.
Current evidence indicates that during hepatocarcinogenesis, two main pathogenic mechanisms prevail: (1) cirrhosis associated with hepatic regeneration after tissue damage caused by hepatitis infection, toxins or metabolic influences, and (2) mutations occurring in single or multiple oncogenes or tumor suppressor genes. Both mechanisms have been linked with alterations in several important cellular signaling pathways. These include the RAF/MEK/ERK pathway, PI3K/AKT/mTOR pathway, WNT/b-catenin pathway, insulin-like growth factor pathway, c-MET/HGFR pathway , etc.
MCE offers a unique collection of 2,960 compounds with identified and potential anti-liver cancer activity. MCE anti-liver cancer compound library is a useful tool for anti-liver cancer drugs screening and other related research.
|
|
84
|
| HY-L151 | PROTAC Library |
PROTACs (Proteolysis-targeting chimeras) is a class of molecules that utilize ubiquitin-proteasome system (UPS) to ubiquitinate and degrade target proteins. The PROTACs molecule consists of two ligands joined by a linker. The one-to-one interaction between PROTACs and target proteins determines the high efficiency of PROTACs, making it a potential molecule for targeted protein degradation (TPD) therapy.
MCE supplies a unique collection of 530 PROTACs that effectively degrade target proteins with more powerful screening capability. MCE PROTAC Library is a useful tool for signal pathway research, protein degradation therapy research, drug discovery and drug repurposing, etc.
|
|
84
|
| HY-L038 | Differentiation Inducing Compound Library |
Stem cells, which are found in all multi-cellular organisms, can divide and differentiate into diverse special cell types and can self-renew to produce more stem cells. To be useful in therapy, stem cells must be converted into desired cell types as necessary which is called induced differentiation or directed differentiation. Understanding and using signaling pathways for differentiation is an important method in successful regenerative medicine. Small molecules or growth factors induce the conversion of stem cells into appropriate progenitor cells, which will later give rise to the desired cell type. There is a variety of signal molecules and molecular families that may affect the establishment of germ layers in vivo, such as fibroblast growth factors (FGFs); the wnt family or superfamily of transforming growth factors β (TGFβ) and bone morphogenetic proteins (BMP). Unfortunately, for now, a high cost of recombinant factors is likely to limit their use on a larger scale in medicine. The more promising technique focuses on the use of small molecules. These small molecules can be used for either activating or deactivating specific signaling pathways. They enhance reprogramming efficiency by creating cells that are compatible with the desired type of tissue. It is a cheaper and non-immunogenic method.
MCE Differentiation Inducing Compound Library contains a unique collection of 2,537 compounds that act on signaling pathways for differentiation. These compounds are potential stimulators for induced differentiation. This library is a useful tool for researching directed differentiation and regenerative medicine.
|
|
83
|
| HY-L039 | Reprogramming Compound Library |
Techniques for reprogramming somatic cells create new opportunities for drug screening, disease modeling, artificial organ development, and cell therapy. The development of reprogramming techniques has grown exponentially since Yamanaka reprogrammed somatic cells to become induced pluripotent stem cells (iPSCs) using four transcription factors, OCT4, SOX2, KLF4, and c-MYC in 2006. Despite the development of efficient reprogramming methods, most methods are inappropriate for clinical applications because they carry the risk of integrating exogenous genetic factors or use oncogenes. Alternative approaches, such as those based on miRNA, non-viral genes, non-integrative vectors, and small molecules, have been studied as possible solutions to the problems. Among these alternatives, small molecules are attractive options for clinical applications. Reprogramming using small molecules is inexpensive and easy to control in a concentration- and time-dependent manner. It offers a high level of cell permeability, ease of synthesis and standardization, and it is appropriate for mass-producing cells.
MCE Reprogramming Compound Library contains a unique collection of 3,197 compounds that act on reprogramming signaling pathways. These compounds are potential stimulators for reprogramming. This library is a useful tool for researching reprogramming and regenerative medicine.
|
|
83
|
| HY-L074 | Anti-Breast Cancer Compound Library |
Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC).
Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer.
MCE supplies a unique collection of 3,365 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.
|
|
83
|
| HY-L079 | Anti-Blood Cancer Compound Library |
Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly.
Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed.
MCE offers a unique collection of 4,276 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.
|
|
83
|
| HY-L097 | Animal Disease Model Inducer Library |
Animal disease models are used in a variety of settings in basic research, such as studies on mechanisms of disease progression and evaluation new drugs. Animal models can be broadly classified into five categories: 1) experimental, 2) spontaneous, 3) negative, 4) orphan, 5) genetically engineered. Experimental models, which are induced artificially in the laboratory, are most common. Some small molecular compounds are usually used as inducers for animal models, such as Ceruletide for inflammatory model, Azoxymethane for tumor model. These inducers are useful tool in building animal models.
MCE offers a unique collection of 52 animal model inducers, involving inflammatory model, tumor model, nervous disease model, etc. MCE Animal Disease Model library is a powerful tool for the establishment of animal disease models.
|
|
83
|
| HY-L103 | Anti-Colorectal Cancer Compound Library |
Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, arises as adenocarcinoma from glandular epithelial cells of the large intestine comprised of the colon and rectum. The majority of cases of CRC are sporadic and result from risk factors, such as a sedentary lifestyle, obesity, processed diets, alcohol consumption and smoking. CRC is also a common preventable cancer.
Studies showed several cellular signaling pathways dysregulated in CRC, leading to the onset of malignant phenotypes. Therefore, it is necessary to analyze the signaling pathways involved in the occurrence and development of colorectal cancer to study the progression and drug treatment of colorectal cancer. Among them, Wnt/β-catenin, p53, TGF-β/SMAD, NF-κB, Notch, VEGF and other target genes and signaling pathways are the focus of research.
MCE offers a unique collection of 2,611 compounds with identified and potential anti-colorectal cancer activity. MCE anti-colorectal cancer compound library is a useful tool for anti-colorectal cancer drugs screening and other related research.
|
|
83
|
| HY-L124 | Anti-Prostate Cancer Compound Library |
Cancer is one of the leading causes of mortality amongst world’s population, in which prostate cancer (PCa) is one of the most encountered malignancies among men. Several molecular mechanisms are involved in prostate cancer development and progression. These include common survival factors in prostate cancer (IGF-1), growth factors (TGF-α, EGF), Wnt, Hedgehog, NF-κB, and mTOR and other signaling pathways. These provide potential therapeutic target in prostate cancer treatment.
MCE offers a unique collection of 3,586 compounds with identified and potential anti-prostate cancer activity. MCE Anti-Prostate Cancer Compound Library is a useful tool for anti-prostate cancer drugs screening and other related research.
|
|
83
|
| HY-L125 | Anti-Pulmonary Fibrosis Compound Library |
Pulmonary fibrosis (PF), also known as diffuse interstitial pulmonary fibrosis, is a very common end-stage manifestation of several diseases, including idiopathic pulmonary fibrosis (IPF), pulmonary hypertension, and scleroderma, characterised by excessive matrix deposition and destruction of the lung architecture, finally leading to respiratory insufficiency. PF has become a global disease with significantly increased incidence rate, and the most common form of pulmonary fibrosis is idiopathic pulmonary fibrosis (IPF).
Lung fibrosis is a complex disease, a multitude of signal factors and signaling pathways is disrupted in this complex disease, such as TGF-β, Wnt, VEGF and PI3K–Akt. MCE offers a unique collection of 2,769 compounds with identified and potential anti-pulmonary fibrosis activity. MCE Anti-Pulmonary Fibrosis Compound Library is a useful tool for anti-pulmonary fibrosis drugs screening and other related research.
|
|
83
|
| HY-L135 | Cancer Stem Cells Compound Library |
With the progress of modern cancer therapy, the life of cancer patients has been extended. However, after initial treatment and recovery, the development of secondary tumors often leads to cancer recurrence. Cancer stem cells are a small number of cells that tumor growth and reproduction depend on.
Cancer stem cells have strong self-renewal ability, which is the direct cause of tumor occurrence. In addition, cancer stem cells also have the ability to differentiate into different cell types, playing a crucial role in tumor metastasis and development. Chemotherapy and radiotherapy induced DNA damage and apoptosis are common cancer treatments. However, cancer stem cells can effectively protect cancer cells from apoptosis by activating DNA repair ability. Cancer stem cells are regarded as the key "seed" of tumor occurrence, development, metastasis and recurrence. Since its first discovery in leukemia in 1994, cancer stem cells have been considered a promising therapeutic target for cancer treatment.
MCE supplies a unique collection of 3,499 compounds targeting key proteins in cancer stem cells. MCE Cancer Stem Cells Compound Library is a useful tool for cancer stem cells related research and anti-cancer drug development.
|
|
83
|
| HY-L161 | Cytokine Inhibitors Library |
Cytokines are a kind of low molecular soluble proteins synthesized and secreted by immunogen, mitogen or other factors. They have functions of regulating innate and adaptive immune responses, promoting hematopoiesis, stimulating cell activation, proliferation and differentiation. The process of releasing a large number of cytokines is also called “Cytokine storm”, which can cause damage to many tissues and organs in the body. Cytokine is involved in the pathogenesis of many human diseases, including cancer, diabetes, chronic inflammatory diseases and so on. Cytokine inhibitors are a class of essential compounds that act by directly inhibiting the synthesis and release of cytokine or blocking the binding of cytokine to their receptors. Cytokine inhibitors are important compounds for the study of tumor and autoimmune diseases.
MCE designs a unique collection of 1,401 cytokine inhibitors, mainly targeting the receptor interleukin (IL), colony-stimulating factor (CSF), interferon (IFN), tumor necrosis factor (TNF), growth factor (GF) and chemokine, which is an effective tool for development and research of anti-cancer, anti-chronic inflammatory diseases and anti-autoimmune diseases compounds.
|
|
83
|
| HY-L174 | Macrophage Related Compound Library |
Macrophages are effector cells of the innate immune system, engulfing bacteria and secreting pro-inflammatory and antibacterial mediators. They are an important component of the first line defense against pathogens and tumor cells. In addition, macrophages play an important role in eliminating damaged cells through programmed cell death. Like all immune cells, macrophages originate from pluripotent hematopoietic stem cells in the bone marrow. Macrophages play key functions in many physiological processes beyond homeostasis and innate immunity, including metabolic function, cell debris clearance, tissue repair, and remodeling. In order to fulfill their different functional roles, macrophages can polarize into a series of phenotypes, including classic (pro inflammatory, M1) and alternative (anti-inflammatory, healing promoting, M2) activation states, as well as a wide range of regulatory phenotypes and subtypes. Macrophages exist in all vertebrate tissues and have a dual function in host protection and tissue damage, maintaining a good balance.
MCE designs a unique collection of 275 macrophage related compounds. It is a good tool to be used for research on Inflammation, cancer and other diseases.
|
|
83
|
| HY-L176 | Multi-Target Compound Library |
The occurrence of diseases is often associated with multiple targets and pathways, and the factors of disease formation are complex and diverse, so the development of more powerful drugs is needed. According to statistics, 21% of the FDA-approved drugs in 2015-2017 were multi-target compounds. Multi-target compounds refer to a drug targeting multiple disease-related targets or multiple subtypes of a target. Multi-target compounds can be applied to drug screening or targeted ligand design. Because the targets of such compounds are diverse and clear, they have the characteristics of saving time and drug cost during the mechanism research of new drug research and development. In addition, due to the diversity of drug targets, multiple strategies can be applied to pharmacological studies.
MCE supplies a unique collection of 7,240 multi-target compounds that targets two or more different targets or different subtypes of the same target. MCE Multi-Target Compound Library can be used for target protein ligand screening or drug development.
|
|
83
|
| HY-L177 | Antibody Inhibitor Library |
Antibody inhibitors are compounds with the same activity as the original therapeutic antibodies, which can be used as positive controls for drug efficacy evaluation and other studies. Antibody inhibitors can also assist in verifying the functional activity of the target protein. These antibody inhibitors are active in vivo and can achieve certain physiological functions by blocking or neutralizing target proteins, such as CD20, HER2, EGFR, VEGFR, TNF-α, etc. In drug screening, antibody inhibitor-based screening can be carried out to identify active compounds targeting target proteins and target diseases.
MCE can provide 1,924 antibody inhibitors that can be used for drug development in cancer, immunity, infection and other hot research areas.
|
|
83
|
| HY-L179 | Radiosensitizer Library |
Radiotherapy is a common treatment for various cancers, and more than 50% of cancer patients require radiotherapy during the disease treatment. With advances in radiation technology and a better understanding of tumor biology, the efficacy of radiation therapy has gradually improved, and more and more patients have benefited from it. However, even with the use of advanced radiotherapy techniques, there are still many malignant tumor cells with low sensitivity to radiation, leading to the radiation effect is not ideal. To solve this problem, radiosensitizers have received more and more attention. Radiosensitizer is a kind of drug that can enhance the radiosensitivity of tumor cells and improve the effect of radiotherapy. Radiation sensitizers act in a variety of ways, such as killing hypoxic cells, enhancing DNA damage, inhibiting DNA damage repair, and blocking cell cycle progression, making tumor cells more susceptible to radiation damage and death than surrounding normal cells.
MCE designs a unique collection of 40 compounds with definite reported radiosensitization. It can be used for drug combination research in anti-cancer treatment.
|
|
83
|
| HY-L204 | Lactic Acid Metabolic Compound Library |
Lactic acid metabolism is one of the key metabolic pathways within living organisms. It plays a crucial role not only in cellular energy conversion but is also closely related to a variety of physiological and pathological processes. The production and clearance of lactic acid are important indicators of cellular metabolic balance, and its abnormal regulation may lead to conditions such as lactic acidosis, muscle fatigue, and hereditary metabolic diseases. Moreover, lactic acid is closely related to the malignancy of tumors and is considered a biomarker for malignant tumors and poor prognosis. Lactic acid can serve as a metabolic substrate to support the metabolic needs of tumor cells under hypoxic conditions, and it can also cause acidification of the tumor microenvironment, suppress immune cell function to promote immune evasion, and induce drug resistance in tumor cells. Currently, targeting lactic acid-lactylation and its related metabolic pathways has become a new research avenue for cancer treatment. In-depth exploration of the molecular mechanisms of lactic acid metabolism can help in screening lead compounds that regulate the lactic acid metabolism.
MCE contains 565 small molecule compounds targeting enzymes involved in lactic acid metabolism. This library is of significant value for researching the role of lactate metabolism in the mechanisms of diseases.
|
|
83
|
| HY-L219 | Antimicrobial Peptides Library |
Antimicrobial Peptides (AMPs), also known as antimicrobial peptides or antibiotic peptides, are a class of polypeptides encoded by specific genes in various biological cells and induced by external stimuli. They exhibit broad-spectrum bioactivity against bacteria, fungi, viruses, protozoa, and even tumor cells. AMPs serve as crucial effector molecules in the host's innate immune system.Due to their wide antimicrobial spectrum, low toxicity to normal cells of higher animals, high safety profile, low tendency to induce resistance, and additional benefits such as immune enhancement and antioxidant effects, antimicrobial peptides hold significant promise in new drug development.
MCE offers 57 types of antimicrobial peptides, which can be applied in high-throughput screening for research in anti-infection therapies, immunotherapy, anticancer drug development, and agricultural disease control.
|
|
83
|
| HY-L228 | Lipid Metabolite Compound Library |
Lipids are important energy storage substances in the human body. They are involved in the regulation of cell structure and function, as well as signaling pathways and gene expression. Abnormal lipid levels in tissues or their dysregulation can lead to various diseases. These include obesity, type 2 diabetes, non-alcoholic fatty liver disease, neurodegenerative diseases, infections, and cancer. Therefore, maintaining normal levels of lipid metabolism is critical to overall health.
One of the key features of cancer is aberrant lipid metabolism. This includes alterations in lipid uptake, lipid desaturation, neolipogenesis, lipid droplets, and fatty acid oxidation in cancer cells. These changes all contribute to cellular survival in an ever-changing microenvironment. They do this by modulating feed-forward oncogenic signals and key oncogenic functions. Additionally, they affect oxidative stress, other types of stress, immune responses, and intercellular communication. Alterations in lipid metabolism have a strong impact on the properties of cancer stem cells. This includes aspects such as self-renewal, differentiation, invasion, metastasis, drug sensitivity, and resistance. Furthermore, these alterations also modulate T cell responses.
MCE can offer 148 metabolites of lipid metabolism pathways, which can be used for drug screening in cancer, immune-based diseases, metabolic diseases, and other diseases.
|
|
83
|
| HY-L260 | KRAS Targeted Compound Library |
KRAS (Kirsten Rat Sarcoma Viral Oncogene Homolog) is one of the most important oncogenic driver genes in oncology, with high mutation frequencies in pancreatic cancer, non‑small cell lung cancer, and colorectal cancer. For a long time, KRAS was considered "undruggable" due to the lack of suitable small‑molecule binding pockets on its protein surface. In recent years, with the discovery of the switch‑II pocket and the successful approval of KRAS G12C inhibitors, KRAS‑targeted research has achieved groundbreaking progress, which has also spurred a wave of development targeting non‑G12C mutants such as G12D and G12V, as well as upstream and downstream regulatory factors including SOS1 and SHP2.
MCE KRAS Targeted Compound Library contains 79 small‑molecule compounds targeting the KRAS, serving as high‑quality research tools for mechanistic studies of KRAS‑mutant tumors, combination therapy development, resistance mechanism exploration, and high‑throughput drug screening, thereby providing robust support for KRAS‑targeted drug discovery.
|
|
83
|
| HY-L919 | MCE CNS BBB Lead-like Library |
With the aging population and increasing competitive pressures, neurodegenerative diseases of the central nervous system (CNS) have become a serious medical challenge in modern society, including Parkinson's disease, Alzheimer's disease, brain tumors, and multiple sclerosis. However, the success rate of CNS drug development remains remarkably low, primarily due to the blood-brain barrier (BBB).
The blood-brain barrier (BBB) is a semipermeable barrier structure that surrounds the microvasculature of the CNS. In capillaries, the wedged endothelial cells are tightly packed and wedge-shaped, lining the interior of the vessels to form extensive tight junctions. Along with a range of receptors, transporters, efflux pumps, and other cellular components, this barrier regulates the entry and exit of molecules between the bloodstream and the brain. The intact BBB blocks the passage of most blood-borne substances into the brain, preventing nearly 100% of large-molecule drugs and over 98% of small-molecule drugs from entering.
Compared to non-CNS drugs, physicochemical properties such as hydrogen bonds, lipophilicity, and molecular weight significantly influence a compound's ability to cross the BBB. Using artificial intelligence (AI) algorithms to predict BBB permeability, a predicted value greater than 0.75 indicates that the compound has strong potential to cross the BBB, providing a promising starting point for CNS drug discovery.
|
|
83
|
| HY-L920 | CNS MPO Lead-like Library |
With the aging population and increasing competitive pressures, neurodegenerative diseases of the central nervous system (CNS) have become a serious medical challenge in modern society, including Parkinson's disease, Alzheimer's disease, brain tumors, and multiple sclerosis.
The CNS MPO (Multi-Parameter Optimization) score is a widely recognized algorithm in medicinal chemistry. Developed by Pfizer, this method is based on an analysis of approved CNS drugs and their interior CNS drug candidates, establishing the CNS MPO rules. It incorporates six key physicochemical properties (ClogP, ClogD, MW, TPSA, HBD, and pKa) to prospectively optimize CNS drug attributes—such as high blood-brain barrier (BBB) permeability, low P-gp efflux liability, low metabolic clearance, and high safety—thereby improving the clinical success rate of CNS drug candidates.
The CNS MPO compound library is a collection of compounds with CNS MPO scores greater than 5, specifically designed for CNS drug discovery.
|
|
83
|
| HY-L941 | Allosteric Modulator Lead‑like Compound Library |
Orthosteric sites are highly conserved, leading to poor subtype selectivity, off-target toxicity and drug resistance in traditional drugs. By contrast, allosteric sites show low conservation, high hydrophobicity, weak polarity, confined geometry and dynamic cryptic properties, granting modulators high selectivity, functional tunability and safety. Thus, allosteric therapy has become a major focus in drug discovery.
MCE curated nearly 1,000 clinical-stage allosteric modulators, analyzed PDB complex structures to identify key pharmacophores and privileged scaffolds, then designed and filtered compounds using rational “scaffold derivation + physicochemical screening” with strict property criteria. The resulting compounds show high rigidity and shape complementarity to shallow, dynamic, hydrophobic allosteric pockets.
This library comprises 4,315 diverse, lead-like compounds ideal for allosteric drug discovery and target screening, covering kinases, GPCRs and more. All are analogs of clinical-stage molecules with similarity > 0.6, combining high druggability and allosteric binding potential to support efficient early-stage R&D.
|
|
83
|
| HY-10585B | Valproic acid sodium (2:1) |
Valproic acid (VPA) sodium (2:1) is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium (2:1) activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium (2:1) is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches.
|
|
69
|
| HY-10585A | Valproic acid sodium |
Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches.
|
|
69
|
| HY-10585 | Valproic acid |
Valproic acid (VPA) is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM. Valproic acid inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid is used in the epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches.
|
Infection
Neurological, Eye or Ear Disease
Metabolic or Endocrine Disease
Respiratory Disease
Small Cell Lung Cancer
|
69
|
| HY-14428 | ICG-001 |
ICG-001 is an inhibitor of β-catenin/TCF mediated transcription. ICG-001 works by specifically binding to cyclic AMP response element-binding protein with an IC50 of 3 μM. ICG-001 selectively blocks the β-catenin/CBP interaction without interfering with the β-catenin/p300 interaction.
|
Neurological, Eye or Ear Disease
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Ovarian Cancer
Digestive System Inflammation
Hypertension
Lung Fibrosis
|
68
|
| HY-12238 | IWR-1 |
IWR-1 (IWR-1-endo) is a tankyrase inhibitor targeting Wnt/β-catenin (IC50 = 180 nM). IWR-1 compromises critical steps of the canonical Wnt signaling, namely translocation of β-catenin to the nucleus and subsequent TCF/LEF activation and expression of Wnt/β-catenin downstream targets. IWR-1 promotes β-catenin phosphorylation by promoting stability of Axin-scaffolded destruction complexes. IWR-1 can be studied in research for anti-tumor purposes, and diseases such as osteosarcoma, colorectal cancer and psoriasis.
|
Neurological, Eye or Ear Disease
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Hypertension
Lung Fibrosis
Rheumatoid Arthritis
|
67
|
| HY-101085 | SKL2001 |
SKL2001 is an agonist of the Wnt/β-catenin pathway, with anti-cancer activity. SKL2001 stabilizes intracellular β-catenin via disruption of the Axin/β-catenin interaction.
|
|
66
|
| HY-P9907 | Trastuzumab |
Trastuzumab is a humanized IgG1 monoclonal antibody that selectively binds to HER2 with high affinity. Trastuzumab can be used for the research of HER2-positive metastatic breast cancer and gastric cancer. (Note: The product specifications below only indicate the effective content of Trastuzumab. The component ratio of this product is Trastuzumab : excipients = 1:0.6-1:0.9.)
Species: Human |
Non-Small Cell Lung Cancer
Luminal Breast Cancer
HER-2 Positive Breast Cancer
Triple-Negative Breast Cancer
Metastatic Breast Cancer
|
66
|
| HY-13016 | Cabozantinib |
Cabozantinib is a potent and orally active inhibitor of VEGFR2 and MET, with IC50 values of 0.035, and 1.3 nM, respectively. Cabozantinib displays strong inhibition of KIT, RET, AXL, TIE2, and FLT3 (IC50=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib shows antiangiogenic activity. Cabozantinib disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis.
|
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Viral Infection
Digestive System Inflammation
Lung Fibrosis
|
58
|
| HY-10550 | Tariquidar |
Tariquidar (XR9576) is a potent and specific inhibitor of P-glycoprotein (P-gp) with the high affinity (Kd=5.1 nM).
|
|
57
|
| HY-120697 | MSAB |
Neurological, Eye or Ear Disease
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Ovarian Cancer
Hypertension
Lung Fibrosis
Rheumatoid Arthritis
|
56
|
|
| HY-17024 | Cyclopamine |
|
56
|
|
| HY-P9905 | Cetuximab |
Non-Small Cell Lung Cancer
Lung Adenocarcinoma
Triple-Negative Breast Cancer
Metastatic Breast Cancer
|
55
|
|
| HY-10440 | Vismodegib |
Vismodegib (GDC-0449) is a BBB-permeable and orally active hedgehog pathway inhibitor with an IC50 of 3 nM. Vismodegib also inhibits P-gp, ABCG2 with IC50 values of 3.0 μM and 1.4 μM, respectively.
|
Neurological, Eye or Ear Disease
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Lung Fibrosis
|
53
|
| HY-N0150 | Monensin sodium |
Monensin (Monensin A) sodium, an orally active antibiotic, is an ionophore that mediates Na+/H+ exchange. Monensin sodium is a potent Wnt signaling inhibitor. Monensin sodium causes a marked enlargement of the multivesicular bodies (MVBs) and regulates exosome secretion. Monensin sodium can be used for bacterial, fungal, and parasitic infections research, and shows anticancer effects.
Source: Streptomyces spp |
Neurological, Eye or Ear Disease
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Bacterial Infection
Fungal Infection
Parasitic Infection
Digestive System Inflammation
Hypertension
Lung Fibrosis
Rheumatoid Arthritis
|
43
|
| HY-15659 | Wnt-C59 |
Wnt-C59 (C59) is a highly potent and oral porcupine (PORCN) inhibitor with an IC50 of 74 pM.
|
Neurological, Eye or Ear Disease
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Hypertension
Lung Fibrosis
Rheumatoid Arthritis
|
37
|
| HY-19989 | MK-571 |
MK-571 (L-660711) is an orally active, potent and selective competitive leukotriene D4 (LTD4) receptor antagonist, with Ki values of 0.22 and 2.1 nM in guinea pig and human lung membranes, respectively. MK-571 is also a MRP4 and ABCC1 (MRP1) inhibitor. MK-571 inhibits constitutive and antigen-stimulated S1P (sphingosine-1-phosphate) release.
|
|
36
|
| HY-13912 | IWP-2 |
IWP-2 is an inhibitor of Wnt processing and secretion with an IC50 of 27 nM. IWP-2 targets the membrane-bound O-acyltransferase porcupine (Porcn) and thus preventing a crucial Wnt ligand palmitoylation. IWP-2 is also an ATP-competitive CK1δ inhibitor with an IC50 of 40 nM for the gatekeeper mutant M82FCK1δ.
|
Neurological, Eye or Ear Disease
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Hypertension
Lung Fibrosis
Rheumatoid Arthritis
|
35
|
| HY-13687 | IKK 16 |
IKK 16 is an orally active IKK inhibitor. IKK 16 shows IC50s of 40 nM, 70 nM, 200 nM, and 50 nM for IKK2, IKK complex, IKK1, and LRRK 2, respectively. IKK 16 is also a pan-PKD inhibitor, inhibiting PKD1, PKD2, and PKD3 with IC50s of 153.9, 115, and 99.7 nM, respectively. IKK 16 is also an ABCB1 inhibitor, interfering with the binding of ABCB1 to its substrates. IKK 16 protects against LPS (HY-D1056)-induced multiple organ dysfunction by reducing the acute inflammatory response induced by endotoxin exposure. IKK 16 can restore renal function and alleviate fibrosis in acute kidney injury. IKK 16 attenuates cardiac dysfunction associated with polymicrobial sepsis in mice with type 2 diabetes mellitus (T2DM) by inhibiting the NF-κB pathway.
|
Breast Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Depression
Pain
Digestive System Inflammation
Cardiovascular Disease
Glucose Metabolism
Parkinson's Disease
Obesity
Lung Fibrosis
Rheumatoid Arthritis
|
31
|
| HY-50879 | Elacridar |
Elacridar is an orally active P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) inhibitor. Elacridar can be used to examine the influence of efflux transporters on agent distribution to brain and the research of cancer.
|
|
31
|
| HY-50752 | LY-411575 |
LY-411575 is a potent γ-secretase inhibitor with IC50 of 0.078 nM/0.082 nM (membrane/cell-based), and also inhibits Notch S3 cleavage with an IC50 of 0.39 nM.
|
Breast Cancer
Colorectal Cancer
Liver Cancer
Pancreatic Cancer
Neurodegenerative Disease
Digestive System Inflammation
Rheumatoid Arthritis
|
29
|
| HY-15206 | Glibenclamide |
Glibenclamide (Glyburide) is an orally active ATP-sensitive K+ channel (KATP) inhibitor and can be used for the research of diabetes and obesity. Glibenclamide inhibits P-glycoprotein. Glibenclamide directly binds and blocks the SUR1 subunits of KATP and inhibits the cystic fibrosis transmembrane conductance regulator protein (CFTR). Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability. Glibenclamide can induce autophagy.
|
Digestive System Disease
Ovarian Cancer
Digestive System Inflammation
Glucose Metabolism
Alzheimer's Disease
|
28
|
| HY-13404 | Capmatinib |
Capmatinib (INC280; INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor (IC50=0.13 nM). Capmatinib can inhibit phosphorylation of c-MET as well as c-MET pathway downstream effectors such as ERK1/2, AKT, FAK, GAB1, and STAT3/5. Capmatinib potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis. Antitumor activity. Capmatinib is largely metabolized by CYP3A4 and aldehyde oxidase.
|
|
27
|
| HY-17514 | Itraconazole |
Itraconazole (R51211) is a triazole antifungal agent and a potent and orally active Hedgehog (Hh) signaling pathway antagonist with an IC50 of ~800 nM. Itraconazole potently inhibits lanosterol 14α-demethylase (cytochrome P450 enzyme), thereby inhibits the oxidative conversion of lanosterol to ergosterol. Itraconazole has anticancer and antiangiogenic effects. Itraconazole is a oxysterol-binding protein (OSBP) inhibitor.
|
Neurological, Eye or Ear Disease
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Pancreatic Cancer
Viral Infection
Bacterial Infection
Fungal Infection
|
24
|
| HY-K6002 | Basement Membrane Matrix |
MCE Basement Membrane Matrix is primarily composed of natural basement membrane matrix extracted from mouse tumors.This product is mainly used for studies of tumor invasion, angiogenesis and organoids culture while avoiding color interference in subsequent experiments. |
|
24
|
| HY-101916 | Heparan Sulfate |
Heparan sulfate, a complex and linear polysaccharide, exists as part of glycoproteins named heparan sulfate proteoglycans, which are expressed abundantly on the cell surface and in the extracellular matrix.
|
|
23
|
| HY-N0020 | Echinacoside |
Echinacoside, one of the phenylethanoids isolated from the stems of Cistanche deserticola, effectively inhibits Wnt/β-catenin signaling. Echinacoside elicits neuroprotection by activating Trk receptors and their downstream signal pathways. Antiosteoporotic activity.
|
Neurological, Eye or Ear Disease
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Hypertension
Lung Fibrosis
Rheumatoid Arthritis
|
21
|
| HY-K6001 | Basement Membrane Matrix (Phenol Red) |
MCE Basement Membrane Matrix (Phenol Red) is primarily composed of a natural basement membrane matrix derived from mouse tumors. This product is mainly for studies of tumor invasion, angiogenesis, and organoid culture. |
|
21
|
| HY-11102 | RO4929097 |
RO4929097 is an orally active γ secretase inhibitor with an IC50 of 4 nM, inhibiting cellular processing of Aβ40 and Notch with EC50 of 14 nM and 5 nM, respectively.
|
Respiratory Disease
Colorectal Cancer
Prostate Cancer
Liver Cancer
Pancreatic Cancer
Viral Infection
Neurodegenerative Disease
Non-Small Cell Lung Cancer
Triple-Negative Breast Cancer
Rheumatoid Arthritis
|
20
|
| HY-N0144 | Piperine |
Piperine is an alkaloid, can be isolated from pepper. Piperine can inhibit the activity of P-glycoprotein and CYP3A4. Piperine inhibits HeLa cells with an IC50 of 61.94±0.054 μg/mL.
|
|
18
|
| HY-P1846A | Jagged-1 (188-204) TFA |
|
18
|
|
| HY-N0133 | Tangeretin |
Tangeretin (Tangeritin), a flavonoid from citrus fruit peels, has been proven to play an important role in anti-inflammatory responses and neuroprotective effects in several disease models, and is a Notch-1 inhibitor.
|
Neurological, Eye or Ear Disease
Breast Cancer
Colorectal Cancer
Liver Cancer
Pancreatic Cancer
Digestive System Inflammation
Rheumatoid Arthritis
|
16
|
| HY-N0527 | Pentagalloylglucose |
Pentagalloylglucose (Penta-O-galloyl-β-D-glucose) is an orally active gallic tannin compound and an inducer of apoptosis and autophagy. Pentagalloglucose induces cell apoptosis and autophagy through the GSK3β/β-catenin pathway. Pentagalloylglucose inhibits UBE2T-mediated p53 ubiquitination, upregulates p53, downregulates RRM1/RRM2 in pancreatic cancer organoids. Pentagalloglucose has antioxidant, anti mutagenic, anti-inflammatory, anticonvulsant, cardioprotective, anti allergic, cholesterol lowering, and anti-tumor activities.
|
Neurological, Eye or Ear Disease
Lung Cancer
Breast Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Digestive System Inflammation
Obesity
Lung Fibrosis
Rheumatoid Arthritis
|
16
|
| HY-123071A | Box5 TFA |
Box5 TFA is a potent Wnt5a antagonist. Box5 TFA inhibits Wnt5a signaling and inhibits Wnt5a-mediated Ca2+ release. Box5 TFA inhibits cell migration. Box5 TFA has the potential for the research of melanoma.
|
|
13
|
| HY-N0889 | Ginkgetin |
Ginkgetin, a biflavone, is isolated from Ginkgo biloba leaves. Ginkgetin exhibit anti-tumor, anti-inflammatory, neuroprotective, anti-fungal activities. Ginkgetin is also a potent inhibitor of Wnt signaling, with an IC50 of 5.92 μΜ.
|
Neurological, Eye or Ear Disease
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Digestive System Inflammation
Hypertension
Lung Fibrosis
Rheumatoid Arthritis
|
13
|
| HY-123071 | Box5 |
Box5 is a potent Wnt5a antagonist. Box5 inhibits Wnt5a signaling and inhibits Wnt5a-mediated Ca2+ release. Box5 inhibits cell migration. Box5 has the potential for the research of melanoma.
|
Neurological, Eye or Ear Disease
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Hypertension
Lung Fibrosis
Rheumatoid Arthritis
|
13
|
| HY-P7155A | DKK-1 Protein, Human (HEK293, His) |
Dkk-1 Protein, Human (HEK293) is involved in embryonic development through its inhibition of the Wnt signaling pathway.
Species: Human; Source: HEK293 |
|
11
|
| HY-N0711 | Carvacrol |
Carvacrol is an orally active and blood-brain barrier-permeable monoterpenic phenol that can be extract from an abundant number of aromatic plants, including thyme and oregano, possessing antioxidant, antibacterial, antifungal, anticancer, anti-inflammatory, hepatoprotective, spasmolytic, and vasorelaxant properties. Carvacrol also causes cell cycle arrest in G0/G1, downregulates Notch-1, and Jagged-1, and induces apoptosis. Carvacrol is used in low concentrations as a food flavoring ingredient and preservative, as well as a fragrance ingredient in cosmetic formulations.
|
Neurological, Eye or Ear Disease
Breast Cancer
Colorectal Cancer
Liver Cancer
Pancreatic Cancer
Bacterial Infection
Fungal Infection
Digestive System Inflammation
Rheumatoid Arthritis
|
10
|
| HY-14721 | Tepotinib |
|
9
|
|
| HY-138298 | Trastuzumab deruxtecan (solution) |
Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer.
|
|
9
|
| HY-138298A | Trastuzumab deruxtecan |
Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer.
|
|
9
|
| HY-13526 | YO-01027 |
YO-01027 (Dibenzazepine;DBZ) is a potent γ-secretase inhibitor with IC50 values of 2.92 and 2.64 nM for Notch and APPL cleavage, respectively.
|
Breast Cancer
Colorectal Cancer
Liver Cancer
Pancreatic Cancer
Neurodegenerative Disease
Rheumatoid Arthritis
|
8
|
| HY-P80914 | TNF alpha Antibody |
TNF alpha Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to TNF alpha.
Host: Rabbit; Reactivity: Human, Mouse, Rat |
|
8
|
| HY-P1416A | Foxy-5 TFA |
Foxy-5 TFA, a WNT5A agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 TFA triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 TFA effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model.
|
|
7
|
| HY-P1416 | Foxy-5 |
Foxy-5, a WNT5A agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model.
|
|
7
|
| HY-111431 | p-Cresyl sulfate |
p-Cresyl sulfate (p-Tolyl sulfate) is a uremic toxin, that can cause renal damage and dysfunction. p-Cresyl sulfate shows antiproliferation activity. p-Cresyl sulfate increases the protein expression of HIF-1α and VHL, decreases the protein expression of HIF-2α. p-Cresyl sulfate induces epithelial-mesenchymal transition (EMT). p-Cresyl sulfate activates the JNK and p38 MAPK signaling pathways.
|
|
6
|
| HY-122632 | Ciliobrevin D |
Ciliobrevin D is a cell-permeable, reversible and specific inhibitor of AAA+ ATPase motor cytoplasmic dynein. Ciliobrevin D inhibits Hedgehog (Hh) signaling and primary cilia formation. Ciliobrevin D inhibits dynein-dependent microtubule gliding and ATPase activity in vitro.
|
Breast Cancer
Colorectal Cancer
Gastric Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
|
6
|
| HY-11018 | Risperidone |
Risperidone is a serotonin 5-HT2 receptor blocker, P-Glycoprotein inhibitor and potent dopamine D2 receptor antagonist, with Kis of 4.8, 5.9 nM for 5-HT2A and dopamine D2 receptor, respectively.
|
|
6
|
| HY-P7154 | DKK-1 Protein, Mouse (CHO) |
Dkk-1 Protein, Mouse (CHO) is shown to be a potent inhibitor of Wnt signaling and member of dickkopf family.
Species: Mouse; Source: CHO |
|
6
|
| HY-N0232 | Psoralidin |
Breast Cancer
Colorectal Cancer
Prostate Cancer
Liver Cancer
Pancreatic Cancer
Bacterial Infection
Depression
Rheumatoid Arthritis
|
5
|
|
| HY-113016 | Elaidic acid |
Elaidic acid is an orally active trans fatty acid. Elaidic acid enhances the stemness of colorectal cancer cells by activating the Wnt/ERK1/2 pathway, thereby promoting cell proliferation, invasion and metastasis, and inhibiting apoptosis. Elaidic acid also inhibits the growth of Lactobacillus and alters the cell surface hydrophobicity of Lactobacillus. Elaidic acid reduces basal 2-deoxyglucose uptake in muscle cells and adipocytes. Elaidic acid can be used in research on colorectal cancer, insulin and other related areas.
|
|
5
|
| HY-121802 | Dynarrestin |
Dynarrestin is a aminothiazole inhibitor of cytoplasmic dyneins 1 and 2. Dynarrestin rapidly and reversibly inhibits dynein 1-driven microtubule gliding in vitro plus a range of dynein 1- and 2-dependent processes in cells without affecting ATP hydrolysis and interfering with ciliogenesis. Dynarrestin suppresses hedgehog (Hh)-dependent proliferation of neuronal precursors and tumor cells.
|
|
5
|
| HY-P99667 | Ipafricept |
Ipafricept (OMP-54F28; FZD8-Fc) is a first class recombinant fusion protein with the extracellular part of the human frizzled-8 receptor fused to a human IgG1 Fc fragment that binds Wnt ligands, which blocks Wnt signaling. Ipafricept reduces tumor growth and results in a decrease in both liver and lung metastases combined with Gemcitabine (HY-17026) in pancreatic cancer mouse models. Ipafricept shows solid tumor inhibition activity with well tolerance, such as desmoid tumor, germ cell cancer, ovarian cancer.
|
|
4
|
| HY-113081 | 1-Methyladenosine |
1-Methyladenosine is an RNA modification that can serve as a tumor marker, with elevated levels in the body associated with cancer development. Following 1-methyladenosine methylation, upregulation of PPARδ expression regulates cholesterol metabolism and activates Hedgehog signaling pathway, driving liver tumorigenesis.
|
|
4
|
| HY-W015309 | Decanoic acid |
Decanoic acid is a key component of the medium-chain triglyceride (MCT) found in coconut oil. Decanoic acid is a brain-penetrant and non-competitive inhibitor of AMPA receptor showing antiseizure activity in rats. Decanoic acid reduces tyrosinase activity and inhibits melanosome maturation. Decanoic acid suppresses the phosphorylation of c-Met and induced apoptosis in hepatocellular carcinoma (HCC) cells by inhibiting the expression of various oncogenic proteins, which is promising for research in the field of mTORC1 signaling, HCC and epilepsy.
|
Metabolic or Endocrine Disease
Lung Cancer
Colorectal Cancer
Gastric Cancer
Liver Cancer
Ovarian Cancer
Parkinson's Disease
|
4
|
| HY-100224 | SANT-1 |
Breast Cancer
Colorectal Cancer
Gastric Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
|
4
|
|
| HY-N1423 | Glycocholic acid |
Glycocholic acid is a bile acid derivative. Glycocholic acid downregulates MDR1, Bcl-2, MRP1, MRP2 and FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5 and S1PR2. Glycocholic acid inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Glycocholic acid modulates related bile acid receptor signaling. Glycocholic acid suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Glycocholic acid can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA).
|
G protein-coupled Bile Acid Receptor 1
FXR
LPL Receptor
Bcl-2 Family
Apoptosis
MDM-2/p53
P-glycoprotein
Bacterial
Caspase
Endogenous Metabolite
Metabolic or Endocrine Disease
Lung Cancer
Experimental Autoimmune Encephalomyelitis
Experimental Autoimmune Encephalomyelitis
|
4
|
| HY-N0836 | Jervine |
Jervine (11-Ketocyclopamine) is an orally active steroidal alkaloid and Hedgehog signaling pathway inhibitor. Jervine can be isolated from Veratrum californicum. Jervine regulates Wnt, inhibits the AKT/mTOR signaling pathway, and activates the AMPK signaling pathway. Jervine induces DNA damage, Apoptosis, Autophagy, ROS production and Mitochondrial damage. Jervine exhibits anti-cancer and anti-inflammatory activities. Jervine reduces tumor growth rate and weight in xenograft models. Jervine can be used in studies related to triple-negative breast cancer, nasopharyngeal carcinoma and non-small cell lung cancer.
|
Hedgehog
Wnt
Akt
mTOR
AMPK
DNA/RNA Synthesis
Apoptosis
Autophagy
Reactive Oxygen Species (ROS)
Mitochondrial Metabolism
Inflammation or Immune System Disease
Non-Small Cell Lung Cancer
Triple-Negative Breast Cancer
Nasopharyngeal Cancer
|
3
|
| HY-100790 | Ciliobrevin A |
Ciliobrevin A (HPI-4) is a hedgehog (Hh) signaling pathway inhibitor with median inhibitory concentration (IC50) less than 10 μM.
|
Breast Cancer
Colorectal Cancer
Gastric Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
|
3
|
| HY-149897 | HA-CD44 interaction inhibitor 2 |
HA-CD44 interaction inhibitor 2 is a CD44 inhibitor that can inhibit the interaction between Hyaluronic acid (HA) (HY-B0633A) and CD44. HA-CD44 interaction inhibitor 2 acts as an antiproliferative agent against CD44+ cancer cells. HA-CD44 interaction inhibitor 2 can disrupt the integrity of cancer spheres and reduce cancer cell viability in a dose-dependent manner. HA-CD44 interaction inhibitor 2 is applicable for tumor research.
|
|
3
|
| HY-P99126 | Anti-Mouse/Human CD44 Antibody (IM7) |
Anti-Mouse/Human CD44 Antibody (IM7) is an anti-huamn and mouse CD44 IgG2b monoclonal antibody that recognizes a conserved epitope outside the HA-binding domain of the CD44 molecule. Anti-Mouse/Human CD44 Antibody (IM7) exerts a potent anti-inflammatory effect by inducing the shedding of cell surface CD44, significantly improving symptoms in mice with rheumatoid arthritis without affecting relevant immune responses. Anti-Mouse/Human CD44 Antibody (IM7) can be used for researches on inflammation conditions and cancer such as arthritis and osteosarcoma.
Species: Human/Mouse |
|
3
|
| HY-P7409 | SHH Protein, Mouse (C25II) |
SHH Protein, Mouse (C25II) is a recombinant mouse sonic hedgehog variant.
Species: Mouse; Source: E. coli |
|
3
|
| HY-P2526A | LyP-1 TFA |
LyP-1 TFA is a cyclic 9 amino acids tumor homing peptide and selectively bind to p32 receptors overexpressed in various tumor-associated cells.
|
|
2
|
| HY-N0247 | Saikosaponin B1 |
Saikosaponin B1 is a bioactive constituent of Radix Bupleuri. Saikosaponin B1 is an agonist of the 5-HT2C receptor with an EC50 of 147.41 μM. Saikosaponin B1 inhibits the Hedgehog (Hh) signaling pathway by targeting the transmembrane protein SMO. Sailosaponin B1 can reduce liver fibrosis. Saikosaponin B1 has anti-cancer activities thus can be studies in research for cancers such as Medulloblastoma (MB).
|
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Depression
Digestive System Inflammation
Lung Fibrosis
Rheumatoid Arthritis
|
2
|
| HY-N10335 | Harringtonolide |
Harringtonolide is a potent RACK1 inhibitor (IC50=39.66 μM in A375 cells). Harringtonolide inhibits the epithelial-mesenchymal transition (EMT) process and cell proliferation by affecting the interaction between FAK and RACK1. Harringtonolide has plant growth inhibitory, antiviral, anti-inflammatory, and antiproliferation activities.
|
|
2
|
| HY-P2526 | LyP-1 |
LyP-1 is a cyclic 9-amino-acids tumor homing peptide and selectively bind to p32 receptors overexpressed in various tumor-associated cells.
|
|
2
|
| HY-B0508 | Ornidazole |
Ornidazole (Ro 7-0207) is a nitroimidazole derivative with anti-trichomonad activity and in vitro activity against a variety of anaerobic bacteria. Ornidazole inhibits Sonic hedgehog (Shh) signaling pathway, exhibits antitumor activity. Ornidazole can be used in research of Crohn’s disease.
Source: Propionibacterium acnes |
Breast Cancer
Colorectal Cancer
Gastric Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Bacterial Infection
Parasitic Infection
|
2
|
| HY-N6954 | Garcinone C |
Garcinone C, a xanthone derivative, is a natural compound extracted from Garcinia oblongifolia that is used as an anti-inflammatory, astringency and granulation-promoting medicine, and has potential cytotoxic effects on certain cancers. Garcinone C stimulates the expression levels of ATR and 4E-BP1, arrests the cell cycle, inhibits cell viability of the human Nasopharyngeal carcinoma (NPC) cell lines CNE1, CNE2, HK1 and HONE1 in a time‑ and dose‑dependent manner through inhibition of Hedgehog signaling pathway. Garcinone C is orally active.
|
Inflammation or Immune System Disease
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Obesity
|
2
|
| HY-N0267 | Hypaconitine |
Hypaconitine inhibits the KCNH2 current with an IC50 of 8.1 nM, and exhibits cardiotoxicity. Hypaconitine inhibits TGF-β1-induced epithelial-mesenchymal transition (EMT) in A549 cell through the inhibition of NF-κB nuclear translocation. Hypaconitine acts as the neuromuscular blocker. Hypaconitine is orally active.
|
Breast Cancer
Prostate Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Depression
Pain
Digestive System Inflammation
Cardiovascular Disease
Alzheimer's Disease
Obesity
|
2
|
| HY-139579 | Pafolacianine |
Pafolacianine (OTL 38) is a fluorescent imaging agent made of near-infrared dye used in detecting tumor lesions during surgical procedures. Pafolacianine excites at 774 to 775 nm and emits at 794 to 796 nm.
|
|
2
|
| HY-P99201 | Zilovertamab |
|
2
|
|
| HY-148810 | Zongertinib |
Zongertinib (BI 1810631) is a potent and selective HER2 and EGFR tyrosine kinase inhibitor with IC50 values of 13 nM and 579 nM, respectively. Zongertinib has antitumor activity and can be used in the study of multiple solid tumors.
|
|
2
|
| HY-141601 | Telisotuzumab vedotin |
Telisotuzumab vedotin (ABBV-399) (Teliso-V) is an anti-c-Met antibody-drug conjugate. Telisotuzumab vedotin consists of an anti-c-Met monoclonal antibody Telisotuzumab (ABT-700) (HY-P99391) and Monomethyl Auristatin E (HY-15162). Telisotuzumab vedotin exerts antitumor activity with acceptable toxicity in vivo. Telisotuzumab vedotin can be used for non-small cell lung cancer (NSCLC) research.
|
|
2
|
| HY-P99575 | Tarlatamab |
Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the KDs of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the KDs of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research.
Species: Human |
|
2
|
| HY-P70467 | SHH Protein, Human |
Sonic Hedgehog (SHH) Protein is a secretory glycoprotein of the Hedgehog family that can self-cleave to form N-SHH. SHH Protein activates Smo by binding to Frizzled and LRP6, inhibits GSK-3β to stabilize β-catenin, and activates FOXM1. SHH Protein also promotes NO release and shortens myocardial APD by phosphorylating eNOS through PI3K/Akt. SHH Protein can promote the maturation of sweat gland cells in three-dimensional culture and play a cardioprotective role in the pig ischemia-reperfusion model. SHH Protein, Human is a recombinant human SHH protein expressed in E. coli with tag-free.
Species: Human; Source: E. coli |
|
2
|
| HY-P80938 | p53 Antibody |
p53 Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to p53.
Host: Rabbit; Reactivity: Human, Mouse, Rat, Monkey |
|
2
|
| HY-K6007 | Basement Membrane Matrix for Organoid Culture |
MCE Basement Membrane Matrix for Organoid Culture is primarily composed of natural basement membrane matrix extracted from mouse tumors. This product is mainly used for organoid culture. |
|
2
|
| HY-K6008 | Basement Membrane Matrix HC |
MCE High-Concentration Basement Membrane Matrix (Phenol Red-Free) is primarily composed of natural basement membrane matrix extracted from mouse tumors. It is rich in extracellular matrix components and various naturally occurring growth factors, and is mainly used for the establishment of animal models and 3D tumor models. |
|
2
|
| HY-K6011 | Tumor Tissue Dissociation Solution |
MCE Tumor Tissue Dissociation Solution is able to gently and efficiently dissociate tumor tissue samples into cell suspensions or cell aggregates, which can then be used for the subsequent construction of tumor organoids. |
|
2
|
| HY-E70182 | Hyaluronidase 2 |
Hyaluronidase 2 (EC:3.2.1.35; HYAL2) is a hyaluronidase. Hyaluronidase 2 cleaves high-molecular-weight hyaluronan into intermediate, ~20 kDa, and tetrasaccharide fragments. Hyaluronidase 2 directly interacts with CD44 and ERM proteins, reduces CD44 hyaluronan binding capacity and ERM activation. Hyaluronidase 2 can be used for the research of gliomas, inflammatory bowel disease, congenital heart defects, heart failure.
|
|
1
|
| HY-D1905 | ICG acid |
ICG acid is a fluorescent dye used in medical diagnostics. ICG acid has absorption peaking at 800 nm and can absorb the near IR laser energy and release heat in the dyed tissue. ICG acid has been used in fluorescence-guided surgery to identify critical structures, including intra-abdominal tumors.
|
|
1
|
| HY-10585S3 | Valproic acid-d4 sodium |
Valproic acid-d4 (sodium) is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.
|
|
1
|
| HY-D1464A | CH1055 triethylamine |
CH1055 triethylamine is a near-infrared II (NIR-II) fluorescent dye that can be used as a fluorescent probe for in vivo imaging. CH1055 triethylamine can be conjugated with antibodies or ligands for specific imaging (for example the tumor imaging).
|
|
1
|
| HY-123298 | Chrysotoxine |
Chrysotoxine is a dual inhibitor of Src/Akt. Chrysotoxine suppresses cancer stem cells (CSCs) phenotypes by down-regulating Src/Akt signaling. Chrysotoxine reduces cell viability and increases apoptosis level in H460 and H23 cells instead of non-tumor cell lines. Chrysotoxine shows rapid excretion and low bioavailability in rats. Chrysotoxine is used in cancer research.
|
|
1
|
| HY-N1854 | Pinobanksin 3-acetate |
Pinobanksin 3-acetate is a flavanone and flavonoid ester with antioxidant activity. Pinobanksin 3-acetate is naturally present in Sonoran propolis, honey, medicinal plants, and forestry coproducts of Pinus caribaea. Pinobanksin 3-acetate exerts anti-colorectal cancer activity by modulating proliferation, apoptosis, cell cycle, and Wnt signaling pathways. Pinobanksin 3-acetate can be used for the research of colon cancer.
Source: Sonoran propolis |
|
1
|
| HY-10585S | Valproic acid-d4 |
Valproic acid-d4 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.
|
|
1
|
| HY-N6896 | Isoviolanthin |
Isoviolanthin is a flavonoid glycoside. Isoviolanthin can be extracted from Dendrobium officinale. Isoviolanthin has a strong affinity for binding to KDM6B, CHAC2, ESCO2, and IPO4. Isoviolanthin decreases MMP-2 and MMP-9. Isoviolanthin inhibits TGF-β/Smad and PI3K/Akt/mTOR signaling pathways. Isoviolanthin increases Fhl3 expression. Isoviolanthin has cytoprotective effects. Isoviolanthin has anticancer activity against hepatocellular carcinoma.
|
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Pain
Digestive System Inflammation
Obesity
Lung Fibrosis
Rheumatoid Arthritis
|
1
|
| HY-P1682 | Balixafortide |
Balixafortide (POL6326) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC50 < 10 nM. Balixafortide shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide blocks β-arrestin recruitment and calcium flux with IC50s < 10 nM. Balixafortide is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects.
|
|
1
|
| HY-121118 | Coronaridine |
|
1
|
|
| HY-12710 | Rauwolscine |
Rauwolscine is a selective α2-adrenoceptor antagonist that inhibits tumor growth and induces apoptosis.
|
|
1
|
| HY-D1464 | CH1055 |
CH1055 is a near-infrared II (NIR-II) fluorescent dye that can be used as a fluorescent probe for in vivo imaging. CH1055 can be conjugated with antibodies or ligands for specific imaging (for example the tumor imaging).
|
|
1
|
| HY-P991451 | Anti-ALPP Antibody |
Anti-ALPP Antibody (SGN-ALPV antibody) is a human monoclonal antibody (mAb) targeting ALPP. Anti-ALPP Antibody can be used in solid tumors research.
Species: Human |
|
1
|
| HY-N0554 | Escin IA |
Escin IA is an oral LOXL2 inhibitor and EMT inhibitor, with selectivity for LOXL2-expressing cells. Escin IA suppresses invasion, migration, and metastasis of breast cancer cells, and acts as the primary anti-TNBC metastasis constituent of Aesculus chinensis Bunge fruit saponin fraction. Escin IA can be used for the research of triple-negative breast cancer, acute inflammation, and ethanol-induced gastric mucosal lesions.
|
|
1
|
| HY-N8572 | 3',4'-Dimethoxyflavone |
3',4'-Dimethoxyflavone is a lipophilic flavone, can be isolated from the leaves of Primula veris. 3',4'-Dimethoxyflavone can reduce the synthesis and accumulation of PARP and protect cortical neurones against cell death induced by Parthanatos. 3',4'-Dimethoxyflavone is also an aryl hydrocarbon receptor antagonist in human breast cancer cells. 3',4'-Dimethoxyflavone can promote the proliferation of human hematopoietic stem cells. 3',4'-Dimethoxyflavone has various biological activities, including antioxidant, anti-cancer, anti-inflammatory, anti-atherogenic, hypolipidaemic, and neuroprotective or neurotrophic effects.
|
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Breast Cancer
Pancreatic Cancer
Ovarian Cancer
Cardiovascular Disease
|
1
|
| HY-129139 | Cyanidin-3-O-arabinoside |
Cyanidin-3-O-arabinoside is a p38 MAPK phosphorylation inhibitor. Cyanidin-3-O-arabinoside reduces the expression of VDAC1, inhibits mtROS accumulation, reverses cellular senescence, blocks excessive mitochondrial calcium influx, reduces the formation of mitochondria-associated endoplasmic reticulum membranes, and suppresses the VDAC1-IP3R1 interaction. Cyanidin-3-O-arabinoside activates hair follicle stem cell proliferation and improves the condition of slowed hair growth. Cyanidin-3-O-arabinoside is applicable to research related to colon cancer and androgenetic alopecia.
|
|
1
|
| HY-P1682A | Balixafortide TFA |
Balixafortide TFA (POL6326 TFA) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC50 < 10 nM. Balixafortide TFA shows 1000-fold selective for CXCR4 than a large panel of receptors including CXCR7. Balixafortide TFA blocks β-arrestin recruitment and calcium flux with IC50s < 10 nM. Balixafortide TFA is also a potent hematopoietic stem and progenitor cell (HSPC) mobilizing agent. Anti-cancer effects.
|
|
1
|
| HY-W591424 | m-PEG2000-NHS ester |
m-PEG2000-NHS ester (mPEG2000-SC) is a reagent with both cell adhesion inhibition and peptide conjugation functions. The NHS ester group of m-PEG2000-NHS ester forms stable amide bonds with primary amine-containing molecules (e.g., the N-terminus of MMP-2-cleavable octapeptide) to generate mPEG-peptide intermediates for liposome surface modification. When m-PEG2000-NHS ester is immobilized on a cystamine-modified gold surface, it can construct an in vitro model for cell adhesion kinetic studies, and higher PEG density and thicker layers correlate with lower cell adhesion rates. m-PEG2000-NHS ester can synthesize MMP-2-responsive PEGylated lipid conjugates to achieve MMP-triggered dePEGylation in the tumor microenvironment. m-PEG2000-NHS ester can be used in studies related to colon cancer and other conditions.
|
|
1
|
| HY-P9974 | Vantictumab |
Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab can be studied against cancers through direct actions on tumor cells, including CSCs, and effects on the stroma, such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma.
Species: Human |
|
1
|
| HY-121608 | Lumiflavin |
Lumiflavin (Lumiflavine), a riboflavine analog, causes significant inhibition of riboflavine uptake. Lumiflavin can effectively reduce the riboflavin enrichment in cancer stem-like cells (CSCs) and sensitize the effect of cisplatin Diamminedichloroplatinum (DDP) on CSCs. Lumiflavin is promising for research of ovarian cancer.
|
|
1
|
| HY-154812 | Gintemetostat |
Gintemetostat (KTX-1001) is an orally active, highly specific NSD2/MMSET histone methyltransferase inhibitor with human NSD2 IC50 values ranging 0.460-2.17 nM and NSD2 SET domain IC50 of 2.32 nM and Kd values ranging 6.3-70.4 nM.Gintemetostat reduces H3K36me2 levels, impairs multiple myeloma cell adhesion and colony formation, enhances cytotoxicity, boosts T-cell activation, and sensitizes resistant multiple myeloma cells to other agents.Gintemetostat can be used for the research of multiple myeloma and relapsed and refractory multiple myeloma.
|
|
1
|
| HY-P72257 | Cellular tumor antigen P53/TP53, Human (His-SUMO) |
The cellular tumor antigen P53/TP53 is a tumor suppressor that can induce growth arrest or apoptosis in a variety of tumor types. It regulates the cell cycle by negatively controlling genes critical for division. Cellular tumor antigen P53/TP53, Human (His-SUMO) is the recombinant human-derived Cellular tumor antigen P53/TP53, expressed by E. coli , with N-SUMO, N-6*His labeled tag.
Species: Human; Source: E. coli |
|
1
|
| HY-P70513 | DKK-1 Protein, Human (HEK293, N-His) |
DKK-1 Proteinas are potent antagonists of canonical Wnt signaling, inhibiting LRP5/6-Wnt interactions and forming a ternary complex with KREMEN to promote LRP5/6 internalization.In addition to its proapoptotic function by antagonizing KREMEN1 independently of Wnt, DKK-1 also exhibits antiapoptotic activity. DKK-1 Protein, Human (HEK293, N-His) is the recombinant human-derived DKK-1 protein, expressed by HEK293 , with N-8*His labeled tag.
Species: Human; Source: HEK293 |
|
1
|
| HY-P80257 | p53 Antibody (YA250) |
p53 Antibody (YA250) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to p53.
Host: Rabbit; Reactivity: Human |
|
1
|
| HY-N0565AS | Doxycycline-d3 (hydrochloride) |
Doxycycline-d3 hydrochloride is deuterium labeled Doxycycline hydrochloride (HY-N0565A). Doxycycline hydrochloride is an orally active highly lipophilic, tissue-permeable MMP inhibitor with broad-spectrum antibacterial activity. Doxycycline hydrochloride is also a semi-synthetic antibiotic with chelating properties, which blocks bacterial protein synthesis and inhibits extracellular matrix degradation through interactions with zinc and calcium atoms. Doxycycline hydrochloride also inhibits mitochondrial biogenesis, translation, and the expression of respiratory chain proteins. Doxycycline hydrochloride induces apoptosis, inhibits autophagy and EMT, downregulates stem cell markers, and activates the PI3K-AKT pathway, thereby effectively inhibiting the viability and proliferation of cancer cells such as breast cancer cells. Doxycycline hydrochloride also promotes the survival and self-renewal of embryonic stem cells and neural stem cells, and reduces the frequency of medium changes in culture. Doxycycline hydrochloride has been applied in studies related to breast cancer, prostate cancer, bladder cancer, and other cancers.
|
|
/
|
| HY-N0565S3 | Doxycycline-13C,d3 |
Doxycycline-13C,d3 is 13C and deuterium labeled Doxycycline (HY-N0565). Doxycycline is an orally active highly lipophilic, tissue-permeable MMP inhibitor with broad-spectrum antibacterial activity. Doxycycline is also a semi-synthetic antibiotic with chelating properties, which blocks bacterial protein synthesis and inhibits extracellular matrix degradation through interactions with zinc and calcium atoms. Doxycycline also inhibits mitochondrial biogenesis, translation, and the expression of respiratory chain proteins. Doxycycline induces apoptosis, inhibits autophagy and EMT, downregulates stem cell markers, and activates the PI3K-AKT pathway, thereby effectively inhibiting the viability and proliferation of cancer cells such as breast cancer cells. Doxycycline also promotes the survival and self-renewal of embryonic stem cells and neural stem cells, and reduces the frequency of medium changes in culture. Doxycycline has been applied in studies related to breast cancer, prostate cancer, bladder cancer, and other cancers.
|
|
/
|
| HY-D0992 | PerCP |
PerCP is a peridinin-chlorophyll protein complex derived from the dinoflagellate *Glenodinium*, suitable for immunofluorescence staining of formalin-fixed, paraffin-embedded human tumor sections. As a red fluorescent dye, PerCP enables clear differentiation between antibody-bound tumor regions and yellow-green autofluorescence of tissues. PerCP allows simultaneous observation of tissue morphology without counterstaining. PerCP can be used in cancer research (Ex/Em = 482/677 nm).
|
|
/
|
| HY-10585AS | Valproic acid-d7 sodium |
Valproic acid-d7 (sodium) is the deuterium labeled Valproic acid (sodium salt). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.
|
|
/
|
| HY-D2281 | FAP Ligand 2 |
|
/
|
|
| HY-N10673 | 10α-Hydroxyepigambogic acid |
10α-Hydroxyepigambogic acid can be extracted from Garcinia hanburyi. 10α-Hydroxyepigambogic acid can be used in the research of tumors.
|
|
/
|
| HY-N1302 | Shizukaol D |
|
/
|
|
| HY-16397AS | Phenformin-d5 hydrochloride |
Phenformin-d5 (Phenethylbiguanide-d5) hydrochloride is the deuterium labeled Phenformin hydrochloride. Phenformin hydrochloride is an orally active biguanide hypoglycemic agent. Phenformin hydrochloride inhibits mitochondrial respiratory chain complex I, leading to an increased AMP/ATP ratio, activation of AMPK, and subsequent inhibition of the mTOR pathway, thereby suppressing cell proliferation, inducing apoptosis and autophagy. Phenformin hydrochloride inhibits cancer stem cells (CSCs) and possesses potent antitumor potential.
|
|
/
|
| HY-B0508S | Ornidazole-d5 |
Ornidazole-d5 is deuterium labeled Ornidazole. Ornidazole (Ro 7-0207) is a nitroimidazole derivative with anti-trichomonad activity and in vitro activity against a variety of anaerobic bacteria. Ornidazole inhibits Sonic hedgehog (Shh) signaling pathway, exhibits antitumor activity. Ornidazole can be used in research of Crohn’s disease.
|
|
/
|
| HY-12292G | IM-12 (GMP) |
IM-12 GMP is IM-12 (HY-12292) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. IM-12 is an orally active anti-inflammatory agent that targets and inhibits the NF-κB and STAT3 signaling pathways. IM-12 activates the Wnt signaling pathway and promotes the nuclear translocation of β-catenin by inhibiting GSK3β, while also blocking the tyrosine kinase activity of p210BCR/ABL. IM-12 reduces the levels of IL-6, IL-17, NO, prostaglandin E2, iNOS and COX-2, and induces ER stress, Ca2+ release, autophagy and apoptosis. IM-12 is heat-sensitive and does not induce autophagy in IM-resistant p210BCR/ABLT315I mutant cells. IM-12 is also a component of the 5iLA medium used for naive pluripotent stem cell research. IM-12 has been applied in studies related to carrageenan (HY-125474)-induced hind paw edema, TNBS-induced colitis, and acute and chronic myeloid leukemia.
|
|
/
|
| HY-P11660 | β-catenin-IN-10 |
β-catenin-IN-10 is a β-catenin:TCF4 interaction inhibitor with an IC50 of 5.44 μM. β-catenin-IN-10 inhibits the Wnt and AR signaling pathways with IC50 values of 0.105 μM and 1.02 μM, respectively. β-catenin-IN-10 suppresses the proliferation of castration-resistant prostate cancer cells. β-catenin-IN-10 is applicable to research related to prostate cancer.
|
|
/
|
| HY-P990206 | Anti-Mouse Jagged 2 Antibody (HMJ2-1) |
Anti-Mouse Jagged 2 Antibody (HMJ2-1) is an anti-mouse Jagged 2 IgG monoclonal antibody. Anti-Mouse Jagged 2 Antibody (HMJ2-1) regulates Treg/Th17 balance through IL-9. Anti-Mouse Jagged 2 Antibody (HMJ2-1) increases Jagged2-Notch signaling through activation of RBP-Jk. Anti-Mouse Jagged 2 Antibody (HMJ2-1) can be used for researches on inflammation conditions and xenotransplantation such as experimental autoimmune encephalomyelitis (EAE).
Species: Mouse |
|
/
|
| HY-12879G | IWP-4 (GMP) |
IWP-4 (GMP) is the GMP-grade form of IWP-4 (HY-12879). IWP-4 is a Wnt inhibitor with an IC50 of 25 nM. IWP-4 specifically inhibits casein kinase 1δ/ε (CK1δ/ε), with an IC50 of 1.06 μM against wild-type CK1δ, 1.02 μM against the CK1δ kinase domain, and 7.07 μM against CK1ε; it shows enhanced inhibitory activity against the M82F CK1δ mutant (IC50 = 0.14 μM). IWP-4 is applicable to research related to cancer, Alzheimer's disease (AD), and heart failure.
|
|
/
|
| HY-W414581 | 7-Keto-27-hydroxycholesterol |
|
/
|
|
| HY-N0889R | Ginkgetin (Standard) |
Ginkgetin (Standard) is the analytical standard of Ginkgetin. This product is intended for research and analytical applications. Ginkgetin, a biflavone, is isolated from Ginkgo biloba leaves. Ginkgetin exhibit anti-tumor, anti-inflammatory, neuroprotective, anti-fungal activities. Ginkgetin is also a potent inhibitor of Wnt signaling, with an IC50 of 5.92 μΜ.
|
|
/
|
| HY-P992200 | Anti-CD146 Antibody (AA98) |
Anti-CD146 Antibody (AA98) is an antibody targeting CD146 and an angiogenesis inhibitor. Anti-CD146 Antibody (AA98) blocks the dimerization of CD146 as well as its downstream PI3K/AKT, p38 MAPK and NF-κB signaling pathways; it inhibits the expression of MMP9 and ICAM1, epithelial-mesenchymal transition (EMT), and the proliferation, migration and tube formation of endothelial cells. Anti-CD146 Antibody (AA98) enhances radiation-induced cancer cell apoptosis and survival inhibition, reduces tumor microvessel density, and suppresses tumor growth, invasion and vasculogenic mimicry. Anti-CD146 Antibody (AA98) can be used in research related to cervical cancer, liver cancer, malignant phyllodes tumor of the breast, uveal melanoma, leiomyosarcoma, pancreatic cancer, other tumors and angiogenesis.
Species: Human |
|
/
|
| HY-P10392 | aStAx-35R |
|
/
|
|
| HY-133800 | Volvaltrate B |
Volvaltrate B is an anticancer agent, iridoid, can be obtained from the root of valerian (Valeriana officinalis). Volvaltrate B is effective against ovarian tumors in female mice. Volvaltrate B has the potential to study cancer.
|
|
/
|
| HY-P11413 | PAI-1 |
PAI-1 is a serine protease inhibitor (SERPIN). PAI-1 binds to and irreversibly inhibits uPA, tPA and furin; it also interacts with vitronectin, α1-acid glycoprotein, CRT, TLR4, proteasome α-3 subunit, uPAR, LRP1, Integrin αvβ3 and thrombin. PAI-1 regulates fibrinolysis, extracellular matrix turnover, cell migration, angiogenesis, inflammatory response and tissue remodeling; it mediates epithelial-mesenchymal transition (EMT)/endothelial-mesenchymal transition (EndMT), apoptosis and thrombus stabilization. PAI-1 can be used in research related to sepsis, acute lung injury, cardiovascular diseases, tissue fibrosis, diabetic nephropathy, obstructive nephropathy and non-insulin-dependent diabetes mellitus.
|
|
/
|
| HY-B0520AS1 | Benztropine-d3 mesylate |
Benztropine-d3 (mesylate) is the deuterium labeled Benztropine mesylate. Benztropine mesylate (Benzatropine mesylate) is an orally active centrally acting anticholinergic agent that can be used for Parkinson's disease research. Benztropine mesylate is an anti-histamine agent and a dopamine re-uptake inhibitor. Benztropine mesylate is also a human D2 dopamine receptor allosteric antagonist. Benztropine mesylate also has anti-CSCs (cancer stem cells) effects.
|
|
/
|
| HY-14930S | Mirodenafil-d7 |
Mirodenafil-d7 (SK3530-d7) is the deuterium labeled Mirodenafil (HY-14930). Mirodenafil (SK3530) is an orally active, potent, reversible, and selective?phosphodiesterase?5 (PDE5)?inhibitor. Mirodenafil is a?glucocorticoid receptor?(GR)?modulator Mirodenafil activates the?Wnt/β-catenin?signaling pathway by downregulating Dkk1 expression. Mirodenafil can be used for the research of erectile dysfunction (ED), Alzheimer’s disease (AD) and systemic sclerosis (SSc).
|
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Metabolic or Endocrine Disease
|
/
|
| HY-D3432 | WazaGaY-1 |
WazaGaY-1 is an aza-BODIPY derivative, functions as a NIR-I/NIR-II fluorescent contrast agent. WazaGaY-1 undergoes internalization into tumor cells predominantly via clathrin-coated pits. WazaGaY-1 can be used for the research of glioblastoma, ovarian carcinoma and melanoma (Ex/Em = 685/820 nm).
|
|
/
|
| HY-129694 | Lenoremycin |
Lenoremycin (Ro 21-6150) is a microbial metabolite. Lenoremycin decreases β-catenin and cyclin D1 proteins levels. Lenoremycin decreases cancer stem cells (CSCs) populations via inducing reactive oxygen species production.
Source: Streptomyces hygroscopicus |
|
/
|
| HY-P11198 | AC-P19M |
AC-P19M is an anticancer peptide. AC-P19M induces apoptosis by disrupting the cell membrane of cancer cells. AC-P19M reverses epithelial-mesenchymal transition (EMT). AC-P19M shows anti-angiogenic activity through the inhibition of VEGF-VEGFR2/ERK/Akt signaling. AC-P19M can be used for lung cancer research.
|
|
/
|
| HY-D3182 | AldRed 588-A |
AldeRed 588-A is a fluorescent labeling reagent and a substrate for aldehyde dehydrogenase (ALDH). AldeRed 588-A is metabolized by functionally active ALDH enzymes, thereby specifically labeling viable ALDHbright cell populations with red-shifted fluorescence. AldeRed 588-A supports one-step isolation and sorting of ALDH-expressing cells (including normal stem cells and cancer stem cells), and can be used in combination with green fluorophores for multicolor experimental applications. AldeRed 588-A is widely applicable to research related to various cancers such as bladder cancer, breast cancer, and head and neck cancer.
|
|
/
|
| HY-D3185 | AlDeSense AM |
AlDeSense AM is a cell-permeable ALDH1A1-selective fluorescent reporter. AlDeSense AM is oxidized by ALDH1A1, which eliminates photoinduced electron transfer quenching and enhances the fluorescent signal. AlDeSense AM can be used to detect cells with cancer stem cell properties, as well as to monitor the plasticity of cancer stem cells in cell culture systems and animal models. AlDeSense AM is applicable to the study of cancers associated with cancer stem cells, including chronic myeloid leukemia, melanoma, and breast cancer.
|
|
/
|
| HY-135146G | GSK-3484862 (GMP) |
GSK-3484862 GMP is GSK-3484862 (HY-135146) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. GSK-3484862 is a highly potent non-covalent inhibitor and demethylating agent of DNMT1. GSK-3484862 induces genome-wide DNA demethylation, including the regulatory elements of DNMT3B and the promoter region of TERT, and significantly inhibits cell viability, growth, proliferation and self-renewal. GSK-3484862 blocks the transformation of young AT2 cells, induces apoptosis, and generates transcriptomic features similar to those of senescent cells. GSK-3484862 is widely used in studies related to lung cancer, oral squamous cell carcinoma and lung adenocarcinoma.
|
|
/
|
| HY-107614G | 1-Oleoyl lysophosphatidic acid sodium (GMP) |
1-Oleoyl lysophosphatidic acid sodium (GMP) is the GMP-grade form of 1-Oleoyl lysophosphatidic acid sodium (HY-107614). GMP-grade small molecules serve as auxiliary reagents in cell therapy. 1-Oleoyl lysophosphatidic acid sodium is a bioactive lipid signaling molecule. 1-Oleoyl lysophosphatidic acid sodium inhibits lysoPLD-catalyzed hydrolysis of lysophosphatidylcholine and FS-3. 1-Oleoyl lysophosphatidic acid sodium activates LPA1 and LPA2, thereby triggering calcium mobilization, NFATc1 translocation, Rho/ROCK activation, Smad2/3 phosphorylation and c-Fos expression. 1-Oleoyl lysophosphatidic acid sodium induces anxiety-like, depression-like and hypoactivity phenotypes, regulates osteoclast cytoskeleton and viability, reduces osteoclast bone resorptive activity, and drives mesenchymal stem cell differentiation into myofibroblast-like cells. 1-Oleoyl lysophosphatidic acid sodium stimulates the secretion of transforming growth factor-β1 and stromal cell-derived factor-1. 1-Oleoyl lysophosphatidic acid sodium is applicable to research related to anxiety, depression and ovarian cancer.
|
|
/
|
| HY-N16399 | Black tea extract |
Black tea extract is the extract of Black tea. Black tea extract prevents inorganic arsenic (iAs) induced ROS generation, inhibiting uncontrolled proliferation, epithelial to mesenchymal transition (EMT) and metastasis in HaCaT cells. Black tea extract has an anti-fibrotic activity. Black tea extract can be used for skin cancers research.
|
|
/
|
| HY-155887 | DSPE-PEG-Amine, MW 3400 ammonium |
DSPE-PEG-Amine (DSPE-PEG-NH2), MW 3400 ammonium is an amino-functionalized PEGylated phospholipid. It serves not only as a key component for preparing σ receptor-targeted liposomes (such as anisamide-modified lipids) but also as a starting material for synthesizing click chemistry- and tumor-targeted lipids including DSPE-PEG-DBCO (HY-155788) and DSPE-PEG2000-TCO (HY-170704). DSPE-PEG-Amine, MW 3400 ammonium effectively modulates the ζ potential of nanoparticles, enables complexation with nucleic acids or proteins to protect DNA from nuclease degradation, and supports ligand conjugation on the nanoparticle surface. It is used in studies related to DU-145 tumors, breast cancer, and other relevant research.
|
|
/
|
| HY-P2158 | Hemoregulatory peptide 5b |
Hemoregulatory peptide 5b is an acidic pentapeptide and also a selective inhibitor of myeloid hematopoiesis. Hemoregulatory peptide 5b inhibits myeloid hematopoietic colony formation, as well as the proliferation of committed myeloid hematopoietic stem cells and differentiating myeloid cells. Hemoregulatory peptide 5b exerts anticancer effects against mouse breast cancer and rat glioma. Hemoregulatory peptide 5b exhibits dose-dependent complex hematopoietic regulatory effects in vivo. Hemoregulatory peptide 5b can be used in research related to breast cancer, glioma, and lymphoma.
|
|
/
|
| HY-W008449S2 | 1-Methylxanthine-d3 |
1-Methylxanthine-d3 is deuterated labeled 1-Methylxanthine (HY-W008449). 1-Methylxanthine, a caffeine derivative, is an essential human urinary metabolite of caffeine and theophylline (1,3-dimethylxanthine, TP). 1-Methylxanthine enhances the radiosensitivity of tumor cells.
|
|
/
|
| HY-N0488S2 | Vincristine-d6 sulfate |
Vincristine-d6 (sulfate) is the deuterium labeled Vincristine sulfate. Vincristine sulfate (Leurocristine; NSC-67574; 22-Oxovincaleukoblastine) is a microtubule inhibitor that disrupts microtubule polymerization by binding to β-tubulin (with a Ki of 85 nM in bovine), arrests the cell cycle and induces apoptosis. Vincristine sulfate inhibits cell replication, tumor blood flow and the proliferation of various cancer cells, while triggering effects such as oxidative stress, inflammation, calcium overload, epithelial-mesenchymal transition and peripheral neuropathic pain. Vincristine sulfate upregulates the expression of various transporters and nuclear receptors, and enriches gastric cancer stem-like cells. Vincristine sulfate is used in research related to various tumors including acute lymphoblastic leukemia, lymphoma, melanoma, gastric cancer, solid tumors and sarcomas.
|
|
/
|
| HY-B0150G | Nicotinamide (GMP) |
Nicotinamide (GMP) (Niacinamide (GMP)) is the GMP level of Nicotinamide (HY-B0150). GMP guidelines are used to produce Nicotinamide (GMP). GMP small molecules works appropriately as an auxiliary reagent for cell research manufacture. Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC50: 2 μM). Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD+, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity.
|
|
/
|
| HY-W665456 | Fmoc-PNA-U-OH |
Fmoc‑PNA‑U‑OH is a peptide nucleic acid monomer that can be used for the synthesis of peptide nucleic acids (PNAs). Fmoc‑PNA‑U‑OH exhibits specific binding to adenine, resistance to enzymatic degradation, and strong hybridization properties. Fmoc‑PNA‑U‑OH can be applied in research fields such as gene diagnosis, molecular biology, and antisense therapy.
|
|
/
|
| HY-P3052 | RGDV |
RGDV is a platelet aggregation inhibitor. RGDV inhibits platelet-dependent thrombus formation. RGDV is used for tumor recognition via the targeting effect.
|
|
/
|
| HY-P991730 | Kiatomab |
|
/
|
|
| HY-B0520AS | Benztropine-13C,d3 mesylate |
Benztropine-13C,d3 (mesylate) is the 13C- and deuterium labeled Benztropine (mesylate). Benztropine mesylate (Benzatropine mesylate) is an orally active centrally acting anticholinergic agent that can be used for Parkinson's disease research. Benztropine mesylate is an anti-histamine agent and a dopamine re-uptake inhibitor. Benztropine mesylate is also a human D2 dopamine receptor allosteric antagonist. Benztropine mesylate also has anti-CSCs (cancer stem cells) effects.
|
|
/
|
| HY-181781 | LSD1-IN-48 |
LSD1-IN-48 is a tranylcypromine-pyrimidine derivative and selective LSD1 inhibitor with a human IC50 of 7.87 nM. LSD1-IN-48 increases H3K4me1/2 histone methylation levels. LSD1-IN-48 induces apoptosis, upregulates CD86, downregulates SOX2 and CD44, inhibits proliferation in cancer cells. LSD1-IN-48 can be used for the research of acute myeloid leukemia.
|
|
/
|
| HY-N15588 | Smyrindiol |
Smyrindiol is a compound found in Dorstenia turbinate. Smyrindiol exerts anti-inflammatory and antimicrobial activities by inhibiting the secretion of tumor-associated proteases (MMP-2). Smyrindiol can be used in the study of brain tumors such as glioblastoma.
|
|
/
|
| HY-10585AG | Valproic acid sodium (GMP) |
Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches.
|
|
/
|
| HY-P11824 | CoA-C2-SGRGK-cCPP |
CoA-C2-SGRGK-cCPP is a NatD (NAA40) bisubstrate inhibitor with an IC50 of 78 nM and a Ki of 39 nM. CoA-C2-SGRGK-cCPP competitively targets the peptide substrate binding site and noncompetitively targets the CoA binding site of NatD to block acetyltransferase activity. CoA-C2-SGRGK-cCPP reduces cellular Nα-acetylation on histone H4, modulates EMT marker expression. CoA-C2-SGRGK-cCPP can be used for the research of non-small cell lung cancer.
|
|
/
|
| HY-P4089 | REA |
REA is a homing peptide that targets pre-cancerous tumor lymphatic vessels. REA homes to lymphatic vessels at the pre-cancerous tumor stage, but does not recognize tumor lymphatic vessels. REA can be used in pre-cancerous tumor research.
|
|
/
|
| HY-W142432S | Perfluoroundecanoic acid-13C7 |
Perfluoroundecanoic acid-13C7 is the 13C-labeled Perfluoroundecanoic acid (HY-W142432). Perfluoroundecanoic acid is a perfluoroalkyl substance (PFAS). Perfluoroundecanoic acid is an orally active oxidative stress inducer. Perfluoroundecanoic acid promotes macrophage M2 polarization, activates Wnt/β-catenin signaling and enhances β-catenin nuclear accumulation. Perfluoroundecanoic acid -induced M2 phenotype macrophage accelerates tumor progression in vitro and in vivo. Perfluoroundecanoic acid induces DNA damage, reproductive and pathophysiological dysfunctions via oxidative stress in male Swiss mice. Perfluoroundecanoic acid inhibits Leydig cell development in pubertal male rats via inducing oxidative stress and autophagy. Perfluoroundecanoic acid accelerates insulitis development in a mouse model of type 1 diabetes. Perfluoroundecanoic acid can be used for the study of ovarian cancer, type 1 diabetes and inflammation.
|
|
/
|
| HY-P1755 | p53 (17-26) |
p53 (17-26) is a peptide derived from the P53 MDM2 binding domain, with a Kd of 50 nM for MDM2. p53 (17-26) causes cell lysis by damaging cancer cells and nuclear membranes, and induces cancer cell necrosis. p53 (17-26) exhibits antitumor activity and is applicable to research related to pancreatic cancer.
|
|
/
|
| HY-W707640 | Salbutamol-d4 |
Salbutamol-d4 (Albuterol-d4; AH-3365-d4) is the deuterium labeled Salbutamol (HY-B1037). Salbutamol (Albuterol) is a short-acting beta-2 adrenergic receptor agonist with oral activity. Salbutamol promotes tumorigenesis of gastric cancer cells through the β2-AR/ERK/EMT pathway. Salbutamol is used to study bronchospasms caused by asthma and chronic obstructive pulmonary disease (COPD).
|
|
/
|
| HY-E70178 | Protein O-Glucosyltransferase 1 |
|
/
|
|
| HY-P10295 | p53 (232-240) |
p53 (232-240) is a peptide segment of the 232-240 amino acid sequence of the human tumor suppressor protein p53. p53 (232-240) enhances its binding affinity to the Major histocompatibility complex (MHC), thereby enhancing the immunogenicity of this peptide to enhance the immune system's response to tumor antigens. p53 (232-240) can be used in the development of cancer vaccines and in the study of tumor cell recognition and clearance by the immune system.
|
|
/
|
| HY-12238G | IWR-1 (GMP) |
IWR-1 (IWR-1-endo) (GMP) is the IWR-1 (HY-12238) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. IWR-1 (IWR-1-endo) is a tankyrase inhibitor targeting Wnt/β-catenin (IC50 = 180 nM). IWR-1 compromises critical steps of the canonical Wnt signaling, namely translocation of β-catenin to the nucleus and subsequent TCF/LEF activation and expression of Wnt/β-catenin downstream targets. IWR-1 promotes β-catenin phosphorylation by promoting stability of Axin-scaffolded destruction complexes. IWR-1 can be studied in research for anti-tumor purposes, and diseases such as osteosarcoma, colorectal cancer and psoriasis.
|
|
/
|
| HY-N7215 | Jatrophone |
Jatrophone is a diterpenoid with anticancer activity isolated from Jatropha isabelli. Jatrophone interferes with the Wnt/β-catenin pathway to inhibit the proliferation and epithelial-mesenchymal transition (EMT) of triple-negative breast cancer cells.
Source: Jatropha gossypiifolia |
|
/
|
| HY-105529 | Indicine N-oxide |
Indicine N-oxide (NSC 132319), a pyrrolizidine alkaloid, is an antitumor agent for pediatric cancer and solid tumors research.
|
|
/
|
| HY-P11680 | Boc-PNA-thioU(PMB)-OH |
BOC-PNA-thioU(PMB)-OH is a peptide nucleic acid (PNA) monomer characterized by a PMB protecting group on its thiouracil, which enhances its binding affinity to adenine. BOC-PNA-thioU(PMB)-OH exhibits excellent resistance to enzymatic degradation and strong hybridization properties, making it valuable for applications in gene diagnosis, antisense therapy, and other molecular biology fields requiring higher binding strength and greater functionalization.
|
|
/
|
| HY-15772GL | Osimertinib (GMP Like) |
Osimertinib (AZD-9291; Mereletinib) GMP Like is the GMP Like level of Osimertinib (HY-15772). GMP Like small molecules works appropriately as an auxiliary reagent for cell research manufacture. Osimertinib GMP Like is an inhibitor that selectively targets EGFRT790M and activated EGFR mutants. Osimertinib GMP Like exerts multiple anti-tumor mechanisms, including radiosensitization, induction of apoptosis and ferroptosis, as well as inhibition of cancer stemness. Osimertinib GMP Like suppresses EGFR nuclear translocation and downstream survival signaling pathways, significantly reduces cell viability and lipid droplet content, and also exerts synergistic effects with radiotherapy or specific targeted agents to effectively overcome drug resistance and radioresistance. Formulations of Osimertinib GMP Like modified with liposomes or iRGD enable sustained release, tumor-specific accumulation, and breakthrough of the blood-brain barrier limitation. Osimertinib GMP Like can be used in research related to radioresistant glioblastoma and non-small cell lung cancer.
|
|
/
|
| HY-D2285 | MOR-CES2 |
MOR-CES2 is a near-infrared fluorescent probe (Ex= 630 nm, Em=735 nm) capable of identifying cancer cells and tissues, as well as exhibiting a sensitive response to inflammation. MOR-CES2 holds potential as an efficient imaging tool in assisting surgical resection of CES2-related tumors.
|
|
/
|
| HY-15772G | Osimertinib (GMP) |
Osimertinib (AZD-9291; Mereletinib) GMP is the GMP level of Osimertinib (HY-15772). GMP small molecules works appropriately as an auxiliary reagent for cell research manufacture. Osimertinib GMP is an inhibitor that selectively targets EGFRT790M and activated EGFR mutants. Osimertinib GMP exerts multiple anti-tumor mechanisms, including radiosensitization, induction of apoptosis and ferroptosis, as well as inhibition of cancer stemness. Osimertinib GMP suppresses EGFR nuclear translocation and downstream survival signaling pathways, significantly reduces cell viability and lipid droplet content, and also exerts synergistic effects with radiotherapy or specific targeted agents to effectively overcome drug resistance and radioresistance. Formulations of Osimertinib GMP modified with liposomes or iRGD enable sustained release, tumor-specific accumulation, and breakthrough of the blood-brain barrier limitation. Osimertinib GMP can be used in research related to radioresistant glioblastoma and non-small cell lung cancer.
|
|
/
|
| HY-P991744 | Anti-Mouse CXCR4 Antibody (Cx4Mab-1) |
Anti-Mouse CXCR4 Antibody is a monoclonal antibody that specifically recognizes murine CXCR4 (C-X-C chemokine receptor 4), also known as fusin or CD184. CXCR4 is a seven-transmembrane G protein–coupled receptor whose principal endogenous ligand is CXCL12 (stromal cell–derived factor-1α, SDF-1α) and is widely expressed in hematopoietic cells, endothelial cells, neurons, as well as embryonic and adult stem cells. The CXCR4–CXCL12 signaling axis activates multiple downstream pathways, including ERK1/2, Ras, p38 MAPK, PLC/MAPK, and SAPK/JNK, thereby regulating cell survival, proliferation, migration, and stemness maintenance. Aberrant overexpression of CXCR4 is closely associated with poor prognosis and metastasis in various cancers, with CXCR4-positive tumor cells preferentially home to CXCL12-rich tissues such as the liver, bone marrow, lung, and lymph nodes. Accordingly, CXCR4 and its CXCL12-related antagonists emerge as attractive targets for experimental anticancer therapy. Anti-Mouse CXCR4 Antibody is generated using a cell-based immunization and screening strategy and exhibits high affinity for both endogenous and exogenous murine CXCR4. Anti-Mouse CXCR4 Antibody can be used for thestudy of chronic lymphocytic leukemia and multiple myeloma.
|
|
/
|
| HY-W714048 | Laduviglusib-d4 |
Laduviglusib-d4 (CHIR-99021-d4) is the deuterium labeled Laduviglusib (HY-10182). Laduviglusib (CHIR-99021) is a potent, selective and orally active GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib enhances mouse and human embryonic stem cells self-renewal. Laduviglusib induces autophagy.
|
|
/
|
| HY-P991569 | PF-04840082 |
PF-04840082 is a humanized IgG2 monoclonal antibody inhibitor targeting Dkk-1. PF-04840082 binds the physiological antagonist (Dkk-1) of the Wnt/LRP5 signal pathway and increases bone mass and bone mass density by activating osteoblasts. PF-04840082 can be used for osteoporosis research.
Species: Human |
|
/
|
| HY-105129AS | Pimonidazole-d10 |
Pimonidazole-d10 is the deuterium labeled Pimonidazole. Pimonidazole is a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in tumor. Pimonidazole accumulates in hypoxic cells via covalent binding with macromolecules or by forming reductive metabolites after reduction of its nitro group, it can be used for qualitative and quantitative assessment of tumor hypoxia .
|
|
/
|
| HY-P5208 | CBLB 612 |
CBLB 612 is an anti-radiation agent. CBLB 612 can be used in the propagation of mouse and monkey moderate stimulation hematopoietic stem cell (HSC), and lure that they are passed to peripheral blood from bone marrow into. CBLB 612 is an important auxiliary agent for cancer.
|
|
/
|
| HY-N4175 | Cucurbitacin A |
Cucurbitacin A, a triterpenoid that could be isolated from the Stems of Cucumis melo, shows anti-cancer activity.
|
|
/
|
| HY-B0508S1 | Ornidazole-13C2,15N2 |
Ornidazole-13C2,15N2 is the 13C, 15N labeled Ornidazole. Ornidazole (Ro 7-0207) is a nitroimidazole derivative with anti-trichomonad activity and in vitro activity against a variety of anaerobic bacteria. Ornidazole inhibits Sonic hedgehog (Shh) signaling pathway, exhibits antitumor activity. Ornidazole can be used in research of Crohn’s disease.
|
|
/
|
| HY-75954S | 2-Hydroxyhexanoic acid-d3 |
2-Hydroxyhexanoic acid-d3 is the d3 labeled 2-Hydroxyhexanoic acid (HY-75954). 2-Hydroxyhexanoic acid is a metabolite. 2-Hydroxyhexanoic acid is elevated in metastatic pancreatic neuroendocrine tumors. 2-Hydroxyhexanoic acid does not promote the proliferation, migration or invasion of pancreatic neuroendocrine tumor cells. 2-Hydroxyhexanoic acid can be used in the research of metastatic pancreatic neuroendocrine tumors.
|
|
/
|
| HY-N7589 | Demethylcarolignan E |
Demethylcarolignan E is a phenylpropanoid ester that can be isolated from the stems of Hibiscus taiwanensi. Demethylcarolignan E has cytotoxicity against human cancer lines A549 and MCF-7 (IC50: <10 μg/mL).
|
|
/
|
| HY-P3707 | Tumor targeted pro-apoptotic peptide |
Tumor targeted pro-apoptotic peptide (CNGRC-GG-D(KLAKLAK)2) is an anti-tumor peptide. Tumor targeted pro-apoptotic peptide disrupts mitochondrial membranes and promotes apoptosis, showing anticancer activity in mice.
|
|
/
|
| HY-E70172 | Heparan Sulfate 3-O-Sulfotransferase 4 |
Heparan Sulfate 3-O-Sulfotransferase 4 is a sulfotransferase. Heparan Sulfate 3-O-Sulfotransferase 4 regulates Notch signaling.
|
|
/
|
| HY-151580S | CDK2-IN-14-d3 |
CDK2-IN-14-d3 is a potent and selective CDK2 inhibitor. CDK2-IN-14-d3 can be used in research of cancer.
|
|
/
|
| HY-13689G | Go 6983 (GMP) |
Go 6983 GMP is Go 6983 (HY-13689) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Go 6983 is a dual inhibitor targeting Suv39h1/2 (KMT1A/KMT1B) and PKC, as well as a transcriptional activator capable of inducing DNA hypomethylation. Go 6983 stimulates the transcription of Prdm14 by reducing Suv39h1/2 protein levels, decreasing histone modifications in the Prdm14 promoter region, and increasing the recruitment of RNA polymerase II. Go 6983 induces genome-wide DNA hypomethylation by inhibiting de novo methyltransferase expression and increasing Tet1/Tet2 levels, thereby promoting self-renewal and pluripotency maintenance of stem cells. Meanwhile, Go 6983 can block PKC-mediated signaling pathways to reduce the expression of EMT-related genes and eliminate the upregulation of antioxidant genes downstream of NRF2. Go 6983 is mainly used in mechanism studies related to myocardial ischemia/reperfusion injury.
|
|
/
|
| HY-B0194AS | Tizanidine-d4 hydrochloride |
Tizanidine-d4 hydrochloride is deuterium labeled Tizanidine hydrochloride (HY-B0194A). Tizanidine hydrochloride, a skeletal muscle relaxant, is an orally effective central α2-adrenoceptor agonist (IC50 = 6.9 nmol). Tizanidine hydrochloride primarily exerts muscle relaxation effects by inhibiting the release of excitatory amino acids (glutamate and aspartate) from the presynaptic terminals of spinal cord interneurons. Tizanidine hydrochloride has anti-injury activity and can inhibit gastrointestinal (GI) transport. Tizanidine hydrochloride can inhibit the proliferation, migration, and invasion of lung cancer cells and induce cell apoptosis by upregulating Nischarin and inhibiting the AKT and Wnt3a/β-catenin signaling pathways. Tizanidine hydrochloride can be used to treat spasticity caused by diseases such as multiple sclerosis (MS), stroke, and spinal cord injury (SCI).
|
|
/
|
| HY-15244G | Alpelisib (GMP) |
Alpelisib GMP is Alpelisib (HY-15244) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Alpelisib (BYL-719) is an orally active PI3Kα-selective inhibitor that blocks the conversion of PIP2 to PIP3, thereby inhibiting pathways including PI3K/AKT/mTOR, MAPK/ERK, Notch and JAK-STAT. Alpelisib also induces apoptosis, G0/G1 phase arrest and senescence; it significantly inhibits the proliferation, self-renewal, stemness and epithelial-mesenchymal transition (EMT) of tumor cells, reduces cancer stem cell populations and decreases the expression of stem cell markers. Alpelisib not only enhances the sensitivity to Eribulin (HY-13442) and exerts a synergistic effect with Paclitaxel (HY-B0015), but may also induce drug resistance by upregulating the SGK3/GSK3β/β-catenin signaling pathway. Alpelisib can be applied to research related to breast cancer, gastric cancer and lipomas associated with PTEN hamartoma tumor syndrome.
|
|
/
|
| HY-12299G | WH-4-023 (GMP) |
WH-4-023 GMP is WH-4-023 (HY-12299) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. WH-4-023 (Dual LCK/SRC inhibitor) is a Lck/Src dual target inhibitor with functions in stem cell maintenance and differentiation regulation. WH-4-023 blocks epithelial-mesenchymal transition, supports the self-renewal of porcine embryonic stem cells, and inhibits their differentiation into mesoderm and endoderm. WH-4-023 is a key component of 3i/LAF medium, and enables the stable establishment and long-term maintenance of porcine pre-gastrulation epiblast stem cell lines. Removal of WH-4-023 reduces the expression of pluripotency factors in porcine and human extended pluripotent stem cells. WH-4-023 can be applied to relevant studies such as non-small cell lung cancer resistant to EGFR-TKIs.
|
|
/
|
| HY-N0565AG | Doxycycline (hydrochloride) (GMP) |
Doxycycline hydrochloride GMP is Doxycycline (hydrochloride) (HY-N0565A) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Doxycycline hydrochloride is an orally active highly lipophilic, tissue-permeable MMP inhibitor with broad-spectrum antibacterial activity. Doxycycline hydrochloride is also a semi-synthetic antibiotic with chelating properties, which blocks bacterial protein synthesis and inhibits extracellular matrix degradation through interactions with zinc and calcium atoms. Doxycycline hydrochloride also inhibits mitochondrial biogenesis, translation, and the expression of respiratory chain proteins. Doxycycline hydrochloride induces apoptosis, inhibits autophagy and EMT, downregulates stem cell markers, and activates the PI3K-AKT pathway, thereby effectively inhibiting the viability and proliferation of cancer cells such as breast cancer cells. Doxycycline hydrochloride also promotes the survival and self-renewal of embryonic stem cells and neural stem cells, and reduces the frequency of medium changes in culture. Doxycycline hydrochloride has been applied in studies related to breast cancer, prostate cancer, bladder cancer, and other cancers.
|
Infection
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Breast Cancer
Prostate Cancer
Bladder Cancer
|
/
|
| HY-N2584AR | Isoxanthohumol (Standard) |
Isoxanthohumol (Standard) is the analytical standard of Isoxanthohumol (HY-N2584A). This product is intended for research and analytical applications. Isoxanthohumol is an orally active flavonoid compound. Isoxanthohumol has biological activities such as anti-tumor, anti-inflammatory, antioxidant, antiviral, antifungal, and inhibition of adipogenesis. Isoxanthohumol can induce apoptosis, autophagy, and migration of tumor cells. Isoxanthohumol is active against viruses such as HSV, BVDV, CMV, and Rhino. Isoxanthohumol can be used for the research of tumors, metabolic, and inflammatory diseases.
|
Reference Standards
HSV
Apoptosis
Reactive Oxygen Species (ROS)
Autophagy
CMV
Fungal
Integrin
S100 Protein
|
/
|
| HY-N9149 | Cryptanoside A |
|
/
|
|
| HY-B0965S | Thioridazine 2-Sulfone-d3 |
Thioridazine-d3 2-Sulfone is the deuterium labeled Thioridazine hydrochloride. Thioridazine hydrochloride, an orally active antagonist of the dopamine receptor D2 family proteins, exhibits potent anti-psychotic and anti-anxiety activities. Thioridazine hydrochloride is also a potent inhibitor of PI3K-Akt-mTOR signaling pathways with anti-angiogenic effect. Thioridazine hydrochloride shows antiproliferative and apoptosis induction effects in various types of cancer cells, with specificity on targeting cancer stem cells (CSCs).
|
|
/
|
| HY-12848G | SAG (GMP) |
|
/
|
|
| HY-P991309 | ZM-008 |
ZM-008 is an anti-LLT1 monoclonal antibody. ZM-008 blocks the interaction between LLT1 and CD161 on the surface of NK cells and T cells. ZM-008 restores anti-tumor immune activity, shifts the tumor microenvironment to an immune-responsive state, and recovers NK cell-mediated cytotoxicity against tumor cells, thereby reversing immunosuppression in immune-resistant "cold" tumors. ZM-008 is applicable to the research of immune-resistant solid tumors.
Species: Human |
|
/
|
| HY-P10488 | cycFWRPW |
cycFWRPW is a peptide inhibitor of TLE1. TLE1 is an oncogenic transcriptional co‐repressor that exerts its repressive effects through binding of transcription factors, and inhibits Wnt signaling.
|
|
/
|
| HY-149413 | FHND5071 |
|
/
|
|
| HY-P990851 | Anti-c-Kit/CD117 Antibody (SR-1) |
Anti-c-Kit/CD117 Antibody (SR-1) is a kind of mouse IgG2a κ chimeric antibody inhibitor, targeting to human c-Kit/CD117. Anti-c-Kit/CD117 Antibody (SR-1) binds to the extracellular domain of human c-Kit (also known as CD117) and blocks stem cell factor (SCF) binding to CD117. Anti-c-Kit/CD117 Antibody (SR-1) can be used for the researches of cancer and immunology, such as gastrointestinal stromal tumor (GIST) and xenograft.
Species: Human |
|
/
|
| HY-P990252 | Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) |
Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) is an anti-mouse Delta-like protein 4/DLL4 IgG monoclonal antibody. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can reduce angiogenesis and density by blocking the DLL4-Notch signaling pathway. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) reduces inflammatory response by decreasing NF-κB activity and pro-inflammatory factors (IL-1β, iNOS, IL-6) levels. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can inhibit Th17 cell differentiation and IL-17A production. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can reduce macrophage infiltration and alleviate insulin resistance. Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) can be used for researches on inflammation, metabolic conditions and cancer such as atherosclerosis, pancreatic cancer and asthma.
Species: Mouse |
|
/
|
| HY-P3448S | Certepetide-13C6,15N2 |
Certepetide-13C6,15N2 (CEND-1-13C6,15N2) is the 13C- and 15N-labeled Certepetide (HY-P3448). Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating NRP-1, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors.
|
|
/
|
| HY-N15176 | Bisucaberin |
Bisucaberin is a natural siderophore, is a DNA synthesis inhibitor. Bisucaberin shows cytostasis for tumor cells. Bisucaberin sensitizes tumor cells to macrophage-mediated cytolysis.
Source: Alteromonas haloplanktis Strain SB-1123 |
|
/
|
| HY-N0976 | 1,11b-Dihydro-11b-hydroxymedicarpin |
1,11b-Dihydro-11b-hydroxymedicarpin (11b-Hydroxy-11b,1-dihydromedicarpin) is a pterocarpan from Ononis viscosa subsp. breviflora is a Medicarpin derivative. Medicarpin, a natural pterocarpan, heals cortical bone defect by activation of Notch and Wnt canonical signaling pathways. Medicarpin prevents arthritis in post-menopausal conditions by arresting the expansion of TH17 cells and pro-inflammatory cytokines. Medicarpin down-regulates pro-inflammatory cytokines like TNF-α, IL-6 and IL-17A, while up-regulates anti-inflammatory cytokine IL-10 in arthritis (CIA) model of mice.
|
|
/
|
| HY-W440913 | DSPE-PEG5000-Cy5 |
DSPE-PEG5000-Cy5 is a fluorescently labeled PEGylated phospholipid. After intravenous injection, DSPE-PEG5000-Cy5 shows only extremely low fluorescence accumulation at tumor sites in orthotopic tumor-bearing mice, and can be used as a negative control for evaluating tumor accumulation of nanoparticles. DSPE-PEG5000-Cy5 can serve as a fluorescent marker to prepare Cy5-labeled NPs-DPPA and NPs-DPPA (C3F8) for pharmacokinetic and biodistribution studies in mice. DSPE-PEG5000-Cy5 is widely applicable to research in fields related to triple-negative breast cancer, hepatocellular carcinoma and so on.
|
|
/
|
| HY-N8572R | 3',4'-Dimethoxyflavone (Standard) |
3',4'-Dimethoxyflavone is a lipophilic flavone, can be isolated from the leaves of Primula veris. 3',4'-Dimethoxyflavone can reduce the synthesis and accumulation of PARP and protect cortical neurones against cell death induced by Parthanatos. 3',4'-Dimethoxyflavone is also an aryl hydrocarbon receptor antagonist in human breast cancer cells. 3',4'-Dimethoxyflavone can promote the proliferation of human hematopoietic stem cells. 3',4'-Dimethoxyflavone has various biological activities, including antioxidant, anti-cancer, anti-inflammatory, anti-atherogenic, hypolipidaemic, and neuroprotective or neurotrophic effects.
|
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Blood or Cardio-cerebrovascular Disease
Breast Cancer
|
/
|
| HY-N7000R | Perillyl alcohol (Standard) |
Perillyl alcohol (Standard) is the analytical standard of Perillyl alcohol (HY-N7000). Perillyl alcohol is an orally active monoterpene. Perillyl alcohol exhibits multiple activities such as analgesic, anti-inflammatory, anti-tumor, anti-angiogenic, and anti-nociceptive effects. Perillyl alcohol can induce apoptosis and cell cycle arrest in tumor cells.
|
Cancer
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Blood or Cardio-cerebrovascular Disease
|
/
|
| HY-B0109AS | Dorzolamide-d3 hydrochloride |
Dorzolamide-d3 hydrochloride is deuterated labeled Dorzolamide hydrochloride (HY-B0109A). Dorzolamide (L671152) hydrochloride is a potent carbonic anhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity.
|
|
/
|
| HY-P3448S1 | Certepetide-13C2,15N |
Certepetide-13C2,15N (CEND-1-13C2,15N) is the 13C- and 15N-labeled Certepetide (HY-P3448). Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating NRP-1, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors.
|
|
/
|
| HY-122552 | Chrysotobibenzyl |
Chrysotobibenzyl can be isolated from stem of Dendrobium pulchellum. Chrysotobibenzyl inhibits lung cancer cell (H460 and H292) migration, invasion, filopodia formation via Cav-1, integrins β1, β3, and αν, and EMT suppressions. Chrysotobibenzyl also sensitizes lung cancer cell death mediated by Cisplatin (HY-17394).
|
|
/
|
| HY-10585AS1 | Valproic acid-d14 sodium |
Valproic acid-d14 (sodium) is deuterium labeled Valproic acid (sodium). Valproic acid sodium salt (Sodium Valproate) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium salt activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.
|
|
/
|
| HY-P11379 | ELTLGEFLKL |
ELTLGEFLKL is a survivin peptide. ELTLGEFLKL shows significant stabilization of HLA-A*0201. ELTLGEFLKL can be used in the research of tumor immunotherapy.
|
|
/
|
| HY-100224G | SANT-1 (GMP) |
|
/
|
|
| HY-Y0070 | Cyanamide |
Cyanamide is a cell division and plant growth inhibitor, as well as an allelochemical derived from Vicia villosa. Cyanamide inhibits root growth and biomass accumulation in a dose-dependent manner by disrupting the formation of mitotic spindles and phragmoplast complexes, reducing the number of mitotic cells and blocking the cell cycle. The effects of Cyanamide are partially reversible after removal from low-concentration environments. Cyanamide is also a specific inhibitor of aldehyde dehydrogenase (ALDH). Although Cyanamide has no direct effect on tumor growth, it can significantly enhance the anti-tumor efficacy of Cyclophosphamide (HY-17420) at non-toxic doses by inhibiting the inactivation of Cyclophosphamide. Cyanamide enables Cyclophosphamide to exert equivalent therapeutic effects at lower doses, effectively inhibiting the growth of primary and metastatic tumors and prolonging the lifespan of tumor-bearing mice. Cyanamide is commonly used in studies related to ha-1 hepatoma and rls lymphosarcoma.
|
|
/
|
| HY-P5352 | Hyaluronan-IN-1 |
Hyaluronan-IN-1 (Pep-1) is a Hyaluronan inhibitor with a Kd value of 1.65 μM. Hyaluronan-IN-1 blocks CD44-dependent cell adhesion. Hyaluronan-IN-1 inhibits cell adhesion to hyaluronan substrates. Hyaluronan-IN-1 suppresses the development of contact hypersensitivity in mice by blocking the homing process of inflammatory cells to the skin. Hyaluronan-IN-1 also inhibits responses during the sensitization phase. Hyaluronan-IN-1 reduces lung metastasis of melanoma and prolongs the survival of mice. Hyaluronan-IN-1 can be used in research related to contact hypersensitivity, chronic skin inflammation, and melanoma.
|
|
/
|
| HY-B1037S3 | Salbutamol-d9 acetate |
Salbutamol-d9 (Albuterol-d9) acetate is the deuterium labeled Salbutamol (HY-B1037). Salbutamol (Albuterol) is an orally active short-acting β2-adrenergic receptor agonist. Salbutamol promotes tumorigenesis in gastric cancer cells through the β2-AR/ERK/EMT pathway. Salbutamol can relax bronchial smooth muscle and is used to study bronchospasm induced by asthma and chronic obstructive pulmonary disease.
|
|
/
|
| HY-N13247 | Ajuga Turkestanica Extract |
|
/
|
|
| HY-119846 | Afromosin |
Afromosin is an isoflavone, that can be isolated from Millettia dielsiana Harms. Afromosin exhibits remarkable tumor inhibitory effects.
|
|
/
|
| HY-P10971 | Nef-M1 |
Nef-M1 (Nef-Motif-1) is an antagonist peptide targeting CXCR4 and an apoptosis inducer derived from a myristoylated protein encoded by the nef gene in HIV. Nef-M1 inhibits tumor angiogenesis and epithelial-mesenchymal transition (EMT). Nef-M1 activates the apoptosis pathway by increasing the level of caspase-3 in cancer cells. Nef-M1 simultaneously inhibits VEGF-A, p-GSK-3β and vimentin, and enhances E-cadherin, thereby inhibiting angiogenesis and EMT processes. Nef-M1 can be used in the study of colorectal cancer and breast cancer.
|
|
/
|
| HY-P4091 | LSD |
LSD is a peptide. LSD can specifically recognize the lymphatics of C8161 melanoma, but it does not bind to the lymphatics of normal tissues or tumor blood vessels. When conjugated with a proapoptotic peptide, LSD can reduce the number of tumor lymphatics. LSD can be used in the research of targeted therapy and diagnosis of tumor lymphatics.
|
|
/
|
| HY-17514S2 | Itraconazole-d9 |
Itraconazole-d9 is the deuterium labeled Itraconazole. Itraconazole (R51211) is a triazole antifungal agent and a potent and orally active Hedgehog (Hh) signaling pathway antagonist with an IC50 of ~800 nM. Itraconazole potently inhibits lanosterol 14α-demethylase (cytochrome P450 enzyme), thereby inhibits the oxidative conversion of lanosterol to ergosterol. Itraconazole has anticancer and antiangiogenic effects. Itraconazole is a oxysterol-binding protein (OSBP) inhibitor.
|
|
/
|
| HY-N7972 | 19-Oxocinobufotalin |
19-Oxocinobufotalin is capable of suppressing EMT (Epithelial-mesenchymal transition) and weakening the migratory and invasive potential of PC3 cells.
Source: toad |
|
/
|
| HY-W015860 | 3-Methylbenzene-1,2-diamine |
3-Methylbenzene-1,2-diamine (Tolylene-2,3-diamine) is a CD44 hyaluronic acid-binding domain ligand, with a Kd of 8.5 mM for hCD44 HABD and a Kd of 6.4 mM for mCD44 HABD. 3-Methylbenzene-1,2-diamine acts as a non-inhibitor that does not interfere with the binding of CD44 HABD to polymeric hyaluronic acid in vitro.
|
|
/
|
| HY-B1037S2 | Salbutamol-d9 |
Salbutamol-d9 (Albuterol-d9) is the deuterium labeled Salbutamol (HY-B1037). Salbutamol (Albuterol) is an orally active short-acting β2-adrenergic receptor agonist. Salbutamol promotes tumorigenesis in gastric cancer cells through the β2-AR/ERK/EMT pathway. Salbutamol can relax bronchial smooth muscle and is used to study bronchospasm induced by asthma and chronic obstructive pulmonary disease.
|
|
/
|
| HY-W106860 | 9H-Carbazole-3-carbaldehyde |
9H-Carbazole-3-carbaldehyde (3-Formylcarbazole) is a carbazole compound and an anticancer agent. 9H-Carbazole-3-carbaldehyde is present in the stems of Clausena lansium (Lour.) Skeels. 9H-Carbazole-3-carbaldehyde can be used in the research of cervical cancer, leukemia, non-small cell lung cancer and liver cancer.
|
|
/
|
| HY-N0488S | Vincristine-d3 sulfate |
Vincristine-d3 sulfate is the deuterium labeled Vincristine sulfate. Vincristine sulfate (Leurocristine; NSC-67574; 22-Oxovincaleukoblastine) is a microtubule inhibitor that disrupts microtubule polymerization by binding to β-tubulin (with a Ki of 85 nM in bovine), arrests the cell cycle and induces apoptosis. Vincristine sulfate inhibits cell replication, tumor blood flow and the proliferation of various cancer cells, while triggering effects such as oxidative stress, inflammation, calcium overload, epithelial-mesenchymal transition and peripheral neuropathic pain. Vincristine sulfate upregulates the expression of various transporters and nuclear receptors, and enriches gastric cancer stem-like cells. Vincristine sulfate is used in research related to various tumors including acute lymphoblastic leukemia, lymphoma, melanoma, gastric cancer, solid tumors and sarcomas.
|
|
/
|
| HY-17514S1 | Itraconazole-d3 |
Itraconazole-d3 (R51211-d3) is the deuterium labeled Itraconazole (HY-17514). Itraconazole (R51211) is a triazole antifungal agent and a potent and orally active Hedgehog (Hh) signaling pathway antagonist with an IC50 of ~800 nM. Itraconazole potently inhibits lanosterol 14α-demethylase (cytochrome P450 enzyme), thereby inhibits the oxidative conversion of lanosterol to ergosterol. Itraconazole has anticancer and antiangiogenic effects. Itraconazole is a oxysterol-binding protein (OSBP) inhibitor.
|
|
/
|
| HY-P991004 | Itanistomig |
Itanistomig (LB-101) is a tetravalent bispecific antibody targeting PD-L1 and CD47. Itanistomig blocks PD-L1 and achieves tumor enrichment through binding to PD-L1, and also exerts conditional CD47 blocking activity via cleavage of the hinge linker in the PD-L1-positive tumor microenvironment. Itanistomig induces antibody-dependent cellular phagocytosis in human CD14+ cells and drives tumor regression. Itanistomig can be used in research related to solid tumors.
Species: Human |
|
/
|
| HY-P99887 | Pimivalimab |
Pimivalimab (JTX-4014) is a PD-1 inhibitor. Pimivalimab can be used for the research of solid tumor.
Species: Human |
|
/
|
| HY-P99035 | Naptumomab |
Naptumomab is a fusion protein of a tumor-targeting superantigen (TTS). Naptumomab stimulates the immune system to recognize and kill tumor cells and can be used in the study of refractory solid tumors such as renal cell carcinoma.
Species: Human |
Inflammation or Immune System Disease
Non-Small Cell Lung Cancer
Luminal Breast Cancer
Triple-Negative Breast Cancer
|
/
|
| HY-B0965AS | Thioridazine-d3 hydrochloride |
Thioridazine-d3 (hydrochloride) is the deuterium labeled Thioridazine. Thioridazine, an antagonist of the dopamine receptor D2 family proteins, exhibits potent anti-psychotic and anti-anxiety activities. Thioridazine is also a potent inhibitor of PI3K-Akt-mTOR signaling pathways with anti-angiogenic effect. Thioridazine shows antiproliferative and apoptosis induction effects in various types of cancer cells, with specificity on targeting cancer stem cells (CSCs).
|
|
/
|
| HY-10585S4 | Valproic acid-d4-1 |
Valproic acid-d4-1 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.
|
|
/
|
| HY-P10679 | GPLGLAGGWGERDGS |
GPLGLAGGWGERDGS is a peptide with MMP enzyme responsiveness and tumor targeting function, which can be used to monitor enzyme-guided nanoparticle assembly in tumors.
|
|
/
|
| HY-17514S | Itraconazole-d5 |
Itraconazole-d5 is the deuterium labeled Itraconazole. Itraconazole (R51211) is a triazole antifungal agent and a potent and orally active Hedgehog (Hh) signaling pathway antagonist with an IC50 of ~800 nM. Itraconazole potently inhibits lanosterol 14α-demethylase (cytochrome P450 enzyme), thereby inhibits the oxidative conversion of lanosterol to ergosterol. Itraconazole has anticancer and antiangiogenic effects.
|
|
/
|
| HY-B0633E | Hyaluronic acid, low endotoxin |
Hyaluronic acid, low endotoxin (Hyaluronan, low endotoxin) is a biopolymer composed of repeating disaccharide units containing low levels of endotoxin. Hyaluronic acid is a major component of the extracellular matrix (ECM). It is synthesized on the plasma membrane. Hyaluronic acid exerts its effects by binding to receptors CD44 and RHAMM. Hyaluronic acid activates PI3K-Akt signaling. Hyaluronic acid also enhances cell invasion and angiogenesis by promoting or stimulating the binding of proteolytic MMP-9 to the cell surface. Elevated hyaluronic acid levels are associated with tumor cell growth, adhesion, migration, invasion, and angiogenesis in digestive system cancers. Hyaluronic acid is involved in tissue remodeling and rapid cell proliferation in several physiological processes, including embryonic morphogenesis and wound healing. Hyaluronic acid can be used as a regulator of cancer-associated lymphangiogenesis. Hyaluronic acid can be used as a drug delivery carrier for sodium butyrate, enhancing its anti-proliferative activity against breast cancer cell lines. Hyaluronic acid can lubricate the corneal endothelium. Hyaluronic acid can improve tissue hydration and enhance the resistance of cells to mechanical damage. Hyaluronic acid has been conjugated with antibodies to ensure that the active compound continues to exert its effects at the site of inflammation. Hyaluronic acid can be used in research in the fields of osteoarthritis, ophthalmology, cosmetic dermatology, oncology, and liver diseases.
|
|
/
|
| HY-P992126 | Remigromig |
Remigromig (EYE-103; MK-3000) is a humanized dual-target monoclonal antibody that targets LRP5 and FZD4. Remigromig activates the Wnt/β-catenin signaling pathway by mimicking the natural ligand Norrin, induces tight junction formation and restores blood-retinal barrier function. Administered via intravitreal injection, Remigromig reduces retinal vascular leakage, and demonstrates improvements in best-corrected visual acuity and reductions in retinal thickness in studies of diabetic macular edema. Remigromig can be used for research related to macular degeneration.
Species: Human |
|
/
|
| HY-N0565S1 | Doxycycline-d3 (hyclate) (major) |
Doxycycline-d3 hyclate (major) is the deuterium labeled Doxycycline hyclate (HY-N0565B). Doxycycline hyclate is an orally active highly lipophilic, tissue-permeable MMP inhibitor with broad-spectrum antibacterial activity. Doxycycline hyclate is also a semi-synthetic antibiotic with chelating properties, which blocks bacterial protein synthesis and inhibits extracellular matrix degradation through interactions with zinc and calcium atoms. Doxycycline hyclate also inhibits mitochondrial biogenesis, translation, and the expression of respiratory chain proteins. Doxycycline hyclate induces apoptosis, inhibits autophagy and EMT, downregulates stem cell markers, and activates the PI3K-AKT pathway, thereby effectively inhibiting the viability and proliferation of cancer cells such as breast cancer cells. Doxycycline hyclate also promotes the survival and self-renewal of embryonic stem cells and neural stem cells, and reduces the frequency of medium changes in culture. Doxycycline hyclate has been applied in studies related to breast cancer, prostate cancer, bladder cancer, and other cancers.
|
|
/
|
| HY-113081S | 1-Methyladenosine-d3 |
1-Methyl Adenosine-d3 is the deuterium labeled 1-Methyladenosine. 1-Methyladenosine is an RNA modification that can serve as a tumor marker, with elevated levels in the body associated with cancer development. Following 1-methyladenosine methylation, upregulation of PPARδ expression regulates cholesterol metabolism and activates Hedgehog signaling pathway, driving liver tumorigenesis.
|
|
/
|
| HY-P10875 | HL2-m5 |
|
/
|
|
| HY-10585AR | Valproic acid sodium (Standard) |
Valproic acid (sodium) (Standard) is the analytical standard of Valproic acid (sodium). This product is intended for research and analytical applications. Valproic acid (Sodium Valproate) sodium is an orally active HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid sodium activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium is used in the treatment of epilepsy, bipolar disorder, metabolic disease, HIV infection and prevention of migraine headaches.
|
Infection
Neurological, Eye or Ear Disease
Metabolic or Endocrine Disease
Respiratory Disease
Small Cell Lung Cancer
|
/
|
| HY-176785S | MCB-294 |
MCB-294 is a dual-state pan-KRAS inhibitor that selectively inhibits KRAS over NRAS and HRAS. MCB-294 capable of binding both the active (GTP-bound) and inactive (GDP-bound) forms of KRAS with Kds of approximately 1 pM and 10 nM, respectively. MCB-294 broadly impairs the growth of hTERT-HPNE cells expressing G12D, G12C, G12V, G12S, G13D, and wild-type KRAS, with IC50s of approximately 700 nM. MCB-294 induces irreversible apoptosis in KRAS-mutated tumors. MCB-294 effectively suppress KRASG12C inhibitor-resistant cancer cells and remodel the tumor immune microenvironment. MCB-294 can be used for the study of pancreatic cancer, colorectal cancer and lung cancer.
|
|
/
|
| HY-P99489 | Budigalimab |
Budigalimab (ABBV 181; PR 1648817) is a humanized, recombinant IgG1 monoclonal antibody targeting programmed cell death 1 (PD-1) receptor. Budigalimab has an Fc mutation that reduces the inhibition of Fc receptor interactions and effector factors. Budigalimab can block the binding of PD-1 and PD-L1, which has anti-tumor activity. Budigalimab can be used in the study of solid tumors.
Species: Human |
|
/
|
| HY-P99589 | Sotevtamab |
|
/
|
|
| HY-B1037S | Salbutamol-d3 |
Salbutamol-d3 (Albuterol-d3) is the deuterium labeled Salbutamol (HY-B1037). Salbutamol (Albuterol) is an orally active short-acting β2-adrenergic receptor agonist. Salbutamol promotes tumorigenesis in gastric cancer cells through the β2-AR/ERK/EMT pathway. Salbutamol can relax bronchial smooth muscle and is used to study bronchospasm induced by asthma and chronic obstructive pulmonary disease.
|
|
/
|
| HY-N2896 | Arjunolic acid |
Arjunolic acid is an orally active, multifunctional bioactive compound. Arjunolic acid exhibits free radical scavenging activity, as well as fungal and bacterial activities. Arjunolic acid induces apoptosis (Apoptosis) in various cancer cells. Arjunolic acid protects hepatocytes against induced oxidative stress and apoptosis by reducing reactive oxygen species and inhibiting NF-κB activation. Arjunolic acid regulates pancreatic dysfunction in type 2 diabetic rats by blocking the activation of the TLR-4/MyD88 and canonical Wnt pathways. Arjunolic acid inhibits neuroinflammation and ameliorates depressive behaviors via the SIRT1/AMPK/Notch1 signaling pathway in microglia. Arjunolic acid improves Crohn's disease-like colitis by restoring gut microbiota composition and inhibiting TLR4 signaling. Arjunolic acid suppresses osteosarcoma progression by inhibiting Wnt3a-mediated M2 polarization of macrophages. Arjunolic acid ameliorates diabetic retinopathy via the autophagy pathway regulated by AMPK/mTOR/HO-1. Arjunolic acid is applicable to research related to type 2 diabetes, organ toxicity, depression, Crohn's disease, osteosarcoma, diabetic retinopathy, and testicular dysfunction.
|
Free Radical Scavengers
Reactive Oxygen Species (ROS)
Apoptosis
Fungal
Bacterial
NF-κB
SOD
AMPK
mTOR
Notch
Toll-like Receptor (TLR)
Wnt
MyD88
Sirtuin
Digestive System Disease
Leukemia/Lymphoma/Myeloma
Bacterial Infection
Fungal Infection
Depression
Digestive System Inflammation
Crohn's Disease
|
/
|
| HY-W134005 | Mg(Ⅱ)-EDTA disodium tetrahydrate |
Mg(Ⅱ)-EDTA (Ethylenediaminetetraacetic acid magnesium) disodium tetrahydrate is a divalent metal chelator and ferroptosis inducer. Mg (Ⅱ)-EDTA disodium tetrahydrate reduces E-cadherin expression by chelating Ca2+ on the surface of tumor cells, thereby triggering cell dissociation and inducing epithelial-mesenchymal transition (EMT). Mg (Ⅱ)-EDTA disodium tetrahydrate further chelates lysosomal iron to form EDTA-Fe, induces ferroptosis through the Fenton reaction, and synergistically enhances immune responses to inhibit tumor metastasis. Mg (Ⅱ)-EDTA (disodium tetrahydrate) can be used in tumor-related research.
|
|
/
|
| HY-113081AS | 1-Methyladenosine-d3 hydrochloride |
1-Methyladenosine-d3 hydrochloride is the hydrochloride salt form of deuterium labeled 1-Methyladenosine (HY-113081). 1-Methyladenosine is an RNA modification that can serve as a tumor marker, with elevated levels in the body associated with cancer development. Following 1-methyladenosine methylation, upregulation of PPARδ expression regulates cholesterol metabolism and activates Hedgehog signaling pathway, driving liver tumorigenesis.
|
|
/
|
| HY-113081R | 1-Methyladenosine (Standard) |
1-Methyladenosine (Standard) is the analytical standard of 1-Methyladenosine. This product is intended for research and analytical applications. 1-Methyladenosine is an RNA modification that can serve as a tumor marker, with elevated levels in the body associated with cancer development. Following 1-methyladenosine methylation, upregulation of PPARδ expression regulates cholesterol metabolism and activates Hedgehog signaling pathway, driving liver tumorigenesis.
In Vitro:Compared to surrounding tumor tissues, 1-methyladenosine methylation in RNA is aberrantly elevated in hepatocellular carcinoma (HCC) cell lines and liver cancer stem cells (CSCs). Methylated 1-methyladenosine can promote cholesterol synthesis and activate the Hedgehog signaling pathway by enhancing the translation of PPARδ in liver CSCs, ultimately driving the self-renewal and tumorigenesis of liver cancer stem cells.
|
|
/
|
| HY-N2732 | 6-Prenylapigenin |
6-Prenylapigenin (6-Prenyl-4',5,7-trihydroxyflavone; 6-C-Prenylapigenin) is a prenylated flavonoid that exists in the stems and leaves of Maclura pomifera. 6-Prenylapigenin exhibits cytotoxicity against cancer cells such as leukemia cells and solid tumor cells.
|
|
/
|
| HY-P99179 | CTX-2026 |
CTX-2026 is a fully human antibody that binds to CD277. CTX-2026 shows an anti-tumor effect on ovarian tumor models. CTX-2026 can be used for the research of cancer.
Species: Human |
|
/
|
| HY-10585S1 | Valproic acid-d6 |
Valproic acid-d6 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.
|
|
/
|
| HY-P10164 | Pen-N3 |
Pen-N3 is a PDZ peptide. Pen-N3 inhibits Wnt/b-catenin signaling by recognizing dishevelled protein.
|
|
/
|
| HY-122965 | Batatasin III |
Batatasin III, a stilbenoid, inhibits cancer migration and invasion by suppressing epithelial to mesenchymal transition (EMT) and FAK-AKT signals. Batatasin III has anti-cancer activities.
|
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Gastric Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Pain
Digestive System Inflammation
Obesity
Lung Fibrosis
|
/
|
| HY-12678S1 | Entrectinib-d8 |
Entrectinib-d8 (NMS-E628-d8; RXDX-101-d8) is a deuterated version of Entrectinib (HY-12678). Entrectinib (NMS-E628) is an orally available, blood-brain barrier permeable, central nervous system active TrkA/B/C, ROS1 and ALK inhibitor with IC50 values of 1, 3, 5, 12 and 12, respectively. 7 nM. Entrectinib induces apoptosis and cycle arrest in cancer cells, has anti-tumor activity, and also alleviates bleomycin-induced pulmonary fibrosis in mice.
|
|
/
|
| HY-N7695 | Physalin B |
Physalin B is an orally active anti-inflammatory and anticancer agent. Physalin B can be isolated from Physalis alkekengi L. var. Franchetii. Physalin B inhibits the activation of the NF-κB, NLRP3 inflammasome, STAT3, PI3K/Akt and Hedgehog signaling pathways, regulates the phosphorylation levels of GSK-3β, p38 MAPK, ERK1/2 and JNK, and promotes the nuclear translocation of NRF2. Physalin B reduces the levels of pro-inflammatory cytokines and factors, induces mitochondrial reactive oxygen species (mito-ROS) production, Apoptosis, G2/M cell cycle arrest and incomplete Autophagy, alters cytoskeleton structure and alleviates oxidative stress. Physalin B reduces cancer cell viability, ameliorates liver and lung tissue damage and alleviates liver fibrosis. Physalin B can be used in research related to ulcerative colitis, breast cancer, acute lung injury, colon cancer, non-alcoholic steatohepatitis, liver fibrosis, lung cancer, pancreatic cancer, lymphoma, ovarian cancer, sarcoma and leukemia.
|
Apoptosis
NF-κB
NOD-like Receptor (NLR)
STAT
PI3K
Akt
Hedgehog
GSK-3
p38 MAPK
ERK
JNK
Keap1-Nrf2
Reactive Oxygen Species (ROS)
Autophagy
Lung Cancer
Breast Cancer
Colorectal Cancer
Leukemia/Lymphoma/Myeloma
Pancreatic Cancer
Ovarian Cancer
Digestive System Inflammation
Acute Lung Injury
Ulcerative Colitis
Hepatic Fibrosis
|
/
|
| HY-P991319 | TAB-004 |
TAB-004 is a murine IgG1 monoclonal antibody that specifically binds to the tumor-associated hypoglycosylated mucin 1 (tMUC1), with high selectivity for human tMUC1. TAB-004 can be conjugated with Indocyanine green (ICG) (HY-D0711) for in vivo targeted imaging. TAB-004 can be used for the research of early detection, tumor progression monitoring and cancer stem cell targeting in breast cancer and pancreatic cancer.
Species: Human |
|
/
|
| HY-B0194S | Tizanidine-d4 |
Tizanidine-d4 is the deuterium labeled Tizanidine (HY-B0194). Tizanidine, a skeletal muscle relaxant, is an orally effective central α2-adrenoceptor agonist (IC50 = 6.9 nmol). Tizanidine primarily exerts muscle relaxation effects by inhibiting the release of excitatory amino acids (glutamate and aspartate) from the presynaptic terminals of spinal cord interneurons. Tizanidine has anti-injury activity and can inhibit gastrointestinal (GI) transport. Tizanidine can inhibit the proliferation, migration, and invasion of lung cancer cells and induce cell apoptosis by upregulating Nischarin and inhibiting the AKT and Wnt3a/β-catenin signaling pathways. Tizanidine can be used to treat spasticity caused by diseases such as multiple sclerosis (MS), stroke, and spinal cord injury (SCI).
|
|
/
|
| HY-P99925 | Enoticumab |
Enoticumab (REGN421, SAR153192) is an IgG1κ antibody targeting human Dll4. DLL4 is a ligand of the Notch signaling pathway and regulates fatty acid uptake through non-transcriptional regulation of macropinocytosis-dependent long-chain fatty acid uptake. Specific in vivo activity of Enoticumab in an ovarian xenograft model. EGN421 (2.5 mg/kg once weekly) resulted in 86% and 83% tumor growth inhibition in mouse subcutaneous TOV-112D or intraperitoneal A2780 human tumor xenograft models, respectively.
Species: Human |
|
/
|
| HY-P990841 | Anti-pan-Glypican Antibody (HS20) |
Anti-pan-Glypican Antibody (HS20) is a kind of human IgG1 κ human antibody, targeting to human pan-Glypican. Anti-pan-Glypican Antibody (HS20) can neutralize the heparan sulfate (HS) chains on GPC3 thereby disrupting the Wnt3a-GPC3 interactions leading to blockade of the Wnt3a/β-catenin signaling. Anti-pan-Glypican Antibody (HS20) can be used for the research of cancer, such as hepatocellular carcinoma (HCC).
Species: Human |
|
/
|
| HY-17514R | Itraconazole (Standard) |
Itraconazole (Standard) is the analytical standard of Itraconazole. This product is intended for research and analytical applications. Itraconazole (R51211) is a triazole antifungal agent and a potent and orally active Hedgehog (Hh) signaling pathway antagonist with an IC50 of ~800 nM. Itraconazole potently inhibits lanosterol 14α-demethylase (cytochrome P450 enzyme), thereby inhibits the oxidative conversion of lanosterol to ergosterol. Itraconazole has anticancer and antiangiogenic effects. Itraconazole is a oxysterol-binding protein (OSBP) inhibitor.
|
|
/
|
| HY-113081S1 | 1-Methyladenosine-d3 hydriodide |
1-Methyladenosine-d3 hydriodide is the deuterium labeled 1-Methyladenosine (HY-113081). 1-Methyladenosine is an RNA modification that can serve as a tumor marker, with elevated levels in the body associated with cancer development. Following 1-methyladenosine methylation, upregulation of PPARδ expression regulates cholesterol metabolism and activates Hedgehog signaling pathway, driving liver tumorigenesis.
|
|
/
|
| HY-N1510 | Kaempferol 3-O-gentiobioside |
Kaempferol 3-O-gentiobioside is an orally active flavonoid, with a Ka value of 57 µM against human NOTCH1 and an IC50 value of 50 μM against α-glucosidase. Kaempferol 3-O-gentiobioside inhibits the NOTCH signaling pathway. It downregulates the expression of TLR4 and NLRP3, and suppresses the activation and nuclear translocation of NF-κB. Kaempferol 3-O-gentiobioside inhibits the expression of MUC5AC, reduces nitrite and ROS levels, and attenuates excessive mucus secretion. It exhibits antibacterial activity, reducing the formation and growth of MRSA biofilms. Kaempferol 3-O-gentiobioside blocks the TGF-β/ALK5/Smad signaling pathway and inhibits epithelial-mesenchymal transition. It suppresses the proliferation, migration, invasion and metastatic growth of tumor cells. Kaempferol 3-O-gentiobioside alleviates airway inflammation and mucus hypersecretion in mice with allergic asthma. It reduces the volume of ovarian cancer xenografts in mice. Kaempferol 3-O-gentiobioside can be used in research related to allergic asthma, diabetes, MRSA infection, breast cancer, gastric cancer and ovarian cancer.
|
Glycosidase
Notch
Toll-like Receptor (TLR)
NF-κB
Mucin
Reactive Oxygen Species (ROS)
Bacterial
TGF-beta/Smad
Anaplastic lymphoma kinase (ALK)
Breast Cancer
Gastric Cancer
Ovarian Cancer
Autoimmune Disease
Staphylococcus Aureus Infection
Allergic Asthma
|
/
|
| HY-N2785 | Desmethylicaritin |
Desmethylicaritin is a phytoestrogenic molecule, has inducible effect on directional differentiation of embryonic stem cells into cardiomyocytes. Desmethylicaritin also suppresses adipogenesis via Wnt/β-catenin signaling pathway.
|
|
/
|
| HY-W011338S | Benzyl butyl phthalate-d4 |
Benzyl butyl phthalate-d4 is the deuterium labeled Benzyl butyl phthalate. Benzyl butyl phthalate, a member of phthalic acid esters (PAEs), can trigger the migration and invasion of hemangioma (HA) cells via upregulation of Zeb1. Benzyl butyl phthalate activates aryl hydrocarbon receptor (AhR) in breast cancer cells to stimulate SPHK1/S1P/S1PR3 signaling and enhances formation of metastasis-initiating breast cancer stem cells (BCSCs).
|
|
/
|
| HY-10585S2 | Valproic acid-d15 |
Valproic acid-d15 is the deuterium labeled Valproic acid. Valproic acid (VPA; 2-Propylpentanoic Acid) is an HDAC inhibitor, with IC50 in the range of 0.5 and 2 mM, also inhibits HDAC1 (IC50, 400 μM), and induces proteasomal degradation of HDAC2. Valproic acid activates Notch1 signaling and inhibits proliferation in small cell lung cancer (SCLC) cells. Valproic acid sodium salt is used in the treatment of epilepsy, bipolar disorder and prevention of migraine headaches.
|
|
/
|
| HY-N2103 | Tenacissoside G |
Tenacissoside G is a C21 steroid from the stems of Marsdenia tenacissima. Tenacissoside G reverses multidrug resistance in P-glycoprotein (Pgp)-overexpressing multidrug-resistant cancer cells.
|
|
/
|
| HY-Y0395 | 3-Carboxyphenylboronic acid |
3-Carboxyphenylboronic acid is a biochemical reagent with multiple functions including nanoparticle enhancement, perovskite passivation, fluorescence quenching, and adhesion. 3-Carboxyphenylboronic acid improves tumor penetration and pulmonary retention of nanoparticles, and serves as a tumor-targeting ligand for carboxymethyl chitosan nanoparticles. 3-Carboxyphenylboronic acid optimizes film crystallization via coordinate chelation of free lead/iodide ions in perovskites. 3-Carboxyphenylboronic acid acts as an additive for n-i-p perovskite solar cells. Conjugation of 3-Carboxyphenylboronic acid with PPEG8 quenches the near-infrared fluorescence of single-walled carbon nanotubes, enabling aqueous dispersion of carbon nanotubes through binding to the diol structure of saccharides.
|
|
/
|
| HY-D0226 | Quinizarin |
Quinizarin (1,4-Dihydroxyanthraquinone), a part of the anticancer agents such as Doxorubicin, Daunorubicin, and Adriamycin, interacts with DNA by intercalating mode (Kd=86.1 μM). Quinizarin is used as a fungicide and pesticide chemical and has shown the ability to inhibit tumor cell growth.
|
|
/
|
| HY-P4998 | Chemotactic Domain of Elastin |
Chemotactic Domain of Elastin is an elastin-derived peptide with chemotactic effects on certain tumor cells, such as M27 tumor cells. Chemotactic Domain of Elastin can be used in cancer research.
|
|
/
|
| HY-N10790 | RA-V |
|
/
|
|
| HY-N2108 | 7-Ethylcamptothecin |
7-Ethylcamptothecin is a derivative of Camptothecin (HY-16560) and a DNA topoisomerase I inhibitor that exhibits significant antitumor activity against tumor cells. 7-Ethylcamptothecin serves as a key precursor for the synthesis of 20 (S)-O-substituted benzoyl-7-ethylcamptothecin compounds. 7-Ethylcamptothecin is widely used in various tumor-related scientific studies.
|
|
/
|
| HY-P990650 | PY159 |
PY159 is a humanized antibody targeting TREM1/CD354. PY159 reprograms immunosuppressive intratumoral myeloid cells towards an inflammatory, anti-tumor phenotype, promotes anti-tumor immune responses, upregulates monocyte activation markers, and induces proinflammatory cytokines. PY159 can be used for the research of platinum-resistant ovarian cancer, advanced solid tumors, and advanced refractory solid tumors.
Species: Human |
|
/
|
| HY-P99906 | Sirexatamab |
Sirexatamab (DKN-01; LY-2812176) is a humanized IgG4 monoclonal antibody targeting DKK1, with Kd values of 3.3 pM and 20 pM for human and murine (mDKN-01) forms, respectively. Sirexatamab binds to DKK1 to neutralize its activity and reverse the inhibition of the canonical Wnt/β-catenin signaling pathway. Sirexatamab can be used in research related to cancers such as non-small cell lung cancer, endometrial cancer, and ovarian cancer.
Species: Human |
|
/
|
| HY-B0633D | Hyaluronic acid sodium (MW 200-1560) |
Hyaluronic acid sodium (MW 200-1560) is a biopolymer composed of repeating disaccharide units, with a molecular weight of 200-1560. Hyaluronic acid sodium is a major component of the extracellular matrix (ECM). It is synthesized on the plasma membrane. Hyaluronic acid sodium exerts its effects by binding to receptors CD44 and RHAMM. Hyaluronic acid sodium activates PI3K-Akt signaling. Hyaluronic acid sodium also enhances cell invasion and angiogenesis by promoting or stimulating the binding of proteolytic MMP-9 to the cell surface. Elevated hyaluronic acid levels are associated with tumor cell growth, adhesion, migration, invasion, and angiogenesis in digestive system cancers. Hyaluronic acid sodium is involved in tissue remodeling and rapid cell proliferation in several physiological processes, including embryonic morphogenesis and wound healing. Hyaluronic acid sodium can be used as a regulator of cancer-associated lymphangiogenesis. Hyaluronic acid sodium can be used as a drug delivery carrier for sodium butyrate, enhancing its anti-proliferative activity against breast cancer cell lines. Hyaluronic acid sodium can lubricate the corneal endothelium. Hyaluronic acid sodium can improve tissue hydration and enhance the resistance of cells to mechanical damage. Hyaluronic acid sodium has been conjugated with antibodies to ensure that the active compound continues to exert its effects at the site of inflammation. Hyaluronic acid sodium can be used in research in the fields of osteoarthritis, ophthalmology, cosmetic dermatology, oncology, and liver diseases.
|
|
/
|
| HY-P99286 | Drozitumab |
Drozitumab (PRO 95780) is a human agonistic monoclonal antibody which binds the death receptor DR5. Drozitumab has potent antitumor activity against rhabdomyosarcoma.
Species: Human |
Leukemia/Lymphoma/Myeloma
Non-Small Cell Lung Cancer
Triple-Negative Breast Cancer
Metastatic Colorectal Cancer
|
/
|
| HY-P10392B | aStAx-35R TFA |
|
/
|
|
| HY-P99258 | Brontictuzumab |
Brontictuzumab (OMP 52M51) is a monoclonal antibody (MAb) that inhibits Notch1 signal. Brontictuzumab selectively binds the negative regulatory region of the Notch1. Brontictuzumab inhibits tumor cell proliferation. Brontictuzumab can be used in the research of leukemia and lymphoma.
Species: Human |
|
/
|
| HY-P10810 | QPH-FR |
QPH-FR is a LGR5 inhibitor. QPH-FR competitively binds to LGR5 and prevents the formation of the LGR5/RSPO1 complex. QPH-FR promotes RNF43/ZNRF3-mediated ubiquitination of FZD receptors, inhibits the Wnt β-catenin signaling pathway, and reduces the stemness of colorectal cancer cells. QPH-FR is applicable to relevant research on colorectal cancer.
|
|
/
|
| HY-NP0194A | C1q Protein (mouse) |
C1q Protein (mouse) is a complement protein and is a recognition molecule of the classical pathway, performs a diverse range of complement and non-complement functions. C1q Protein (mouse) binds various ligands derived from self, non-self, and altered self and modulate the functions of immune
and non-immune cells. C1q Protein (mouse) can be used for the research of mutiple disease. |
Infection
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Blood or Cardio-cerebrovascular Disease
Metabolic or Endocrine Disease
|
/
|
| HY-N0432 | Astragaloside I |
Astragaloside I, one of the main active ingredients in Astragalus membranaceus, has osteogenic properties. Astragaloside I stimulates osteoblast differentiation through activating the Wnt/β-catenin signaling pathway.
|
|
/
|
| HY-P99708 | Livmoniplimab |
|
/
|
|
| HY-113286 | 4-Guanidinobutanoic acid |
4-Guanidinobutanoic acid is a metabolite of arginine and an orally active SLC36A1/Hedgehog signaling pathway activator. 4-Guanidinobutanoic acid drives epithelial reprogramming, enhances intestinal stem cell function and goblet cell differentiation. 4-Guanidinobutanoic acid promotes the enrichment of Akkermansia muciniphila via mucus-dependent niche expansion, regulates intestinal homeostasis, and establishes a microbiota-host feedback loop. 4-Guanidinobutanoic acid exhibits anti-aging and healthspan-regulating properties. 4-Guanidinobutanoic acid can be used in research related to ulcerative colitis, amyotrophic lateral sclerosis, and Duchenne muscular dystrophy.
|
|
/
|
| HY-137042 | Cyanine5 alkyne |
Cyanine5 alkyne (Alkyne-Cy5) is a fluorescent dye used to label azide proteins and can be used to analyse post-translational modifications of proteins, glycosylation etc. Cyanine5 alkyne can also be used as a mitochondrial OXPHOS inhibitor to inhibit the growth of cancer stem cells (CSC). Cyanine5 alkyne is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
|
/
|
| HY-P99320 | Tarextumab |
|
/
|
|
| HY-171821 | PF-08046054 |
PF-08046054 (SGN-PDL1V) is a PD-L1-directed Antibody-drug conjugate (ADC), which is comprised of an anti-PD-L1 antibody conjugated to VcMMAE (HY-15575). PF-08046054 is direct cytotoxicity to PD-L1-expressing tumor cells via the intracellular delivery of MMAE. PF-08046054 can be used for the study of solid tumors
|
|
/
|
| HY-W460407 | N,N'-Dimethylhydrazine dihydrochloride |
N,N'-Dimethylhydrazine (1,2-Dimethylhydrazine) dihydrochloride is a tumor inducer that induces colon tumors in rodents.
|
|
/
|
| HY-P9969 | Matuzumab |
|
/
|
|
| HY-149898 | HA-CD44 interaction inhibitor 1 |
HA-CD44 interaction inhibitor 1 is a CD44 inhibitor that can inhibit the interaction between Hyaluronic acid (HA) (HY-B0633A) and CD44. HA-CD44 interaction inhibitor 1 exerts an antiproliferative effect on CD44+ cancer cell lines. HA-CD44 interaction inhibitor 1 can be used for the research of cancer.
|
|
/
|
| HY-W250111 | Carboxymethyl chitosan |
Carboxymethyl chitosan is a derivative of chitosan. Carboxymethyl chitosan inhibits Apoptosis and ROS. Carboxymethyl chitosan increases the expression of Bcl-2 and reduces the expression of Bax, cytochrome c and caspase-3. Carboxymethyl chitosan inhibits the migration of various cells. Carboxymethyl chitosan exerts antitumor effects on Lewis tumors and hepatocarcinoma.
|
|
/
|
| HY-171945 | Telisotuzumab Adizutecan |
Telisotuzumab Adizutecan (ABBV-400) is an anti-c-Met antibody-drug conjugate (ADC). Telisotuzumab Adizutecan is composed of the humanized anti-c-Met antibody Telisotuzumab (HY-P99391) and the topoisomerase 1 inhibitor (7-MAD-MDCPT) (HY-132162). Telisotuzumab Adizutecan exhibits significant anti-tumor activity against advanced solid tumors such as colorectal cancer, gastric cancer, and non-small cell lung cancer.
|
|
/
|
| HY-Y1365 | Gelatins |
Gelatins is a non-toxic, non carcinogenic, biodegradable, and non irritating natural polymer derived from partial hydrolysis of collagen. Due to its strong liquid absorption and swelling ability, Gelatins has excellent hemostatic properties and can be used as a matrix material for the reduction, growth, and stability of metal nanoparticles. Gelatins can also be used for tumor cell culture and tumor therapy.
|
|
/
|
| HY-P99391 | Telisotuzumab |
Telisotuzumab (ABT-700) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab induces apoptosis. Telisotuzumab can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers.
Species: Human |
|
/
|
| HY-P7155B | DKK-1 Protein, Human (HEK293) |
DKK-1 Proteinas are potent antagonists of canonical Wnt signaling, inhibiting LRP5/6-Wnt interactions and forming a ternary complex with KREMEN to promote LRP5/6 internalization.In addition to its proapoptotic function by antagonizing KREMEN1 independently of Wnt, DKK-1 also exhibits antiapoptotic activity. DKK-1 Protein, Human (HEK293) is the recombinant human-derived DKK-1 protein, expressed by HEK293 , with tag free.
Species: Human; Source: HEK293 |
|
/
|
| HY-P76124 | VHL Protein, Human (His) |
VHL protein is an important component of the von Hippel-Lindau ubiquitination complex and plays a key role in ubiquitination and proteasomal degradation. As a target recruitment subunit in the E3 ubiquitin ligase complex, VHL specifically recruits hydroxylated hypoxia-inducible factor (HIF) under normoxic conditions and regulates cellular responses to oxygen levels. VHL Protein, Human (His) is the recombinant human-derived VHL protein, expressed by E. coli , with N-6*His labeled tag.
Species: Human; Source: E. coli |
|
/
|
| HY-P7812 | DKK-3 Protein, Human (HEK293, His) |
DKK-3 protein antagonizes canonical Wnt signaling by blocking LRP5/6-Wnt interactions and forming a ternary complex with KREMEN, thereby promoting LRP5/6 internalization.In vertebrate development, DKK-3, together with other DKKs, critically inhibits Wnt-regulated processes such as axial patterning, limb development, somitogenesis, and eye formation.DKK-3 Protein, Human (HEK293, His) is the recombinant human-derived DKK-3 protein, expressed by HEK293 , with C-6*His labeled tag.
Species: Human; Source: HEK293 |
|
/
|
| HY-P7290 | SHH Protein, Mouse |
SHH Protein, Mouse is a morphogenic factor that actively orchestrates many aspects of cerebellar development and maturation.
Species: Mouse; Source: E. coli |
|
/
|
| HY-P7204 | IHH Protein, Human |
IHH Protein, Human is involved in chondrocyte differentiation, proliferation and maturation especially during endochondral ossification.
Species: Human; Source: E. coli |
|
/
|
| HY-P75287 | DKK-3 Protein, Mouse (HEK293, His) |
DKK-3 protein antagonizes canonical Wnt signaling by inhibiting LRP5/6-Wnt interaction. It forms a ternary complex with KREMEN and promotes LRP5/6 internalization. DKK-3 Protein, Mouse (HEK293, His) is the recombinant mouse-derived DKK-3 protein, expressed by HEK293 , with C-His labeled tag.
Species: Mouse; Source: HEK293 |
|
/
|
| HY-P70801 | TNF RI/TNFRSF1A Protein, Human (His) |
TNFRSF1A (TNF RI) protein has a high ability to
bind with tumor necrosis factor-alpha (TNF-α). TNFRSF1A is a STAT3 target gene
that regulates the NF-κB pathway. TNFRSF1A activate NF-κB, mediate apoptosis,
and function as a regulator of inflammation. TNF RI/TNFRSF1A Protein, Human (His) is
expressed by E. coli with a 6*His tag at the N-terminus.
Species: Human; Source: E. coli |
|
/
|
| HY-P70885 | FAM3C Protein, Human (HEK293, His) |
The FAM3C protein emerged as a potential contributor to different cellular processes with a role in retinal lamination formation, emphasizing its involvement in retinal development. In addition, FAM3C is also involved in promoting epithelial-mesenchymal transition (EMT), indicating its potential impact on cell differentiation and tissue remodeling. FAM3C Protein, Human (HEK293, His) is the recombinant human-derived FAM3C protein, expressed by HEK293 , with C-6*His labeled tag.
Species: Human; Source: HEK293 |
|
/
|
| HY-P71703 | p53 Protein, Rat (His) |
The p53 protein acts as a tumor suppressor, regulates the cell cycle and induces growth arrest or apoptosis.It activates genes that inhibit cell division and trigger apoptosis by controlling the expression of various proteins.p53 Protein, Rat (His) is the recombinant rat-derived p53 protein, expressed by E.coli , with N-6*His labeled tag.
Species: Rat; Source: E. coli |
|
/
|
| HY-P7339 | DHH Protein, Mouse |
|
/
|
|
| HY-P73417 | SHH Protein, Human (HEK293, His) |
Sonic Hedgehog (SHH) Protein is a secretory glycoprotein of the Hedgehog family that can self-cleave to form N-SHH. SHH Protein activates Smo by binding to Frizzled and LRP6, inhibits GSK-3β to stabilize β-catenin, and activates FOXM1. SHH Protein also promotes NO release and shortens myocardial APD by phosphorylating eNOS through PI3K/Akt. SHH Protein can promote the maturation of sweat gland cells in three-dimensional culture and play a cardioprotective role in the pig ischemia-reperfusion model. SHH Protein, Human (HEK293, His) is a recombinant human SHH protein expressed in HEK293 cells with C-terminal His-tag.
Species: Human; Source: HEK293 |
|
/
|
| HY-P702556 | TSG-6 Protein, Human (His) |
The TSG-6 protein is a major extracellular matrix regulator that catalyzes the transfer of heavy chains to hyaluronic acid to form hyaluronic acid-HC oligomers that are critical for tissue remodeling and oocyte fertilization. It assembles hyaluronic acid in the pericellular matrix, which acts as a platform for receptor aggregation. TSG-6 Protein, Human (His) is the recombinant human-derived TSG-6 protein, expressed by E. coli , with N-6*His labeled tag.
Species: Human; Source: E. coli |
|
/
|
| HY-P704517 | CCN5 Protein, Human (His) |
CCN5 Protein, Human (His) is the recombinant human-derived CCN5 protein, expressed by E. coli, with C-10*His tag.
Species: Human; Source: E. coli |
|
/
|
| HY-P700605 | DHH Protein, Human |
The DHH protein is cleaved into N- and C-product fragments through autoproteolysis and cholesterol transferase activity, where the N-product acquires the cholesterol moiety. In the endoplasmic reticulum, DHH is critical for juxtocrine signaling, endothelial integrity, and Schwann cell-mediated nerve sheath development. DHH Protein, Human (Tag Free) is the recombinant human-derived DHH protein, expressed by E. coli , with tag free.
Species: Human; Source: E. coli |
|
/
|
| HY-P7288 | SHH Protein, Mouse (CHO) |
SHH Protein, Mouse (CHO) is a morphogenic factor that actively orchestrates many aspects of cerebellar development and maturation.
Species: Mouse; Source: CHO |
|
/
|
| HY-P7338 | DHH Protein, Human (C23II) |
|
/
|
|
| HY-P705518 | Cellular tumor antigen P53/TP53 Protein, Human (His) |
The cellular tumor antigen P53/TP53 is a tumor suppressor that can induce growth arrest or apoptosis in a variety of tumor types. It regulates the cell cycle by negatively controlling genes critical for division. Cellular tumor antigen P53/TP53, Human (His) is the recombinant human-derived Cellular tumor antigen P53/TP53 protein, expressed by E. coli, with N-6*His labeled tag.
Species: Human; Source: E. coli |
|
/
|
| HY-P7305 | TNF RI/TNFRSF1A Protein, Human (CHO) |
TNFRSF1A (TNF RI) protein has a high
ability to bind with tumor necrosis factor-alpha (TNF-α). TNFRSF1A is a STAT3
target gene that regulates the NF-κB pathway. TNFRSF1A activate NF-κB, mediate
apoptosis, and function as a regulator of inflammation. TNFRSF1A Protein, Human
(CHO) is expressed by CHO and has a transmembrane region (D41-N201) .
Species: Human; Source: CHO |
|
/
|
| HY-P700253 | DHH Protein, Human (His-GST, Myc) |
|
/
|
|
| HY-P705930 | ITK Protein, Human (Active, 269a.a, sf9, His, GST) |
ITK protein is an important tyrosine kinase that regulates adaptive immune responses by affecting the development and function of T cells and NKT cells. Upon T cell receptor (TCR) activation, ITK undergoes LCK-mediated phosphorylation, leading to its activation. ITK Protein, Human (Active, 269a.a, sf9, His, GST) is the recombinant human-derived ITK, expressed by Sf9 insect cells, with His and GST labeled tag.
Species: Human; Source: Sf9 insect cells |
|
/
|
| HY-P72261 | Wilms tumor protein/WT1 Protein, Human (His-SUMO) |
Wilms tumor protein (WT1) is a key transcription factor that critically regulates cell development and survival by binding to 5'-GCG(T/G)GGGCG-3'. It oversees target genes such as erythropoietin (EPO) and is critical for the development of the genitourinary system. Wilms tumor protein/WT1 Protein, Human (His-SUMO) is the recombinant human-derived Wilms tumor protein/WT1 protein, expressed by E. coli , with N-SUMO, N-6*His labeled tag.
Species: Human; Source: E. coli |
|
/
|
| HY-P74795 | ITK Protein, Mouse (sf9, His-GST) |
ITK protein is a tyrosine kinase that plays a crucial role in directing adaptive immune responses by controlling the development, function, and differentiation of conventional T cells and unconventional NKT cells.After T cell receptor (TCR) activation by antigen-presenting cells (APC), ITK is recruited to the cell membrane and phosphorylated by LCK, thereby making it fully activated.ITK Protein, Mouse (sf9, His-GST) is the recombinant mouse-derived ITK protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.
Species: Mouse; Source: Sf9 insect cells |
|
/
|
| HY-P77640 | DKK-3 Protein, Human (Biotinylated, HEK293, His-Avi) |
DKK-3 protein antagonizes canonical Wnt signaling by blocking LRP5/6-Wnt interactions and forming a ternary complex with KREMEN, thereby promoting LRP5/6 internalization.In vertebrate development, DKK-3, together with other DKKs, critically inhibits Wnt-regulated processes such as axial patterning, limb development, somitogenesis, and eye formation.DKK-3 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived DKK-3 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.
Species: Human; Source: HEK293 |
|
/
|
| HY-P78681 | DKK-3 Protein, Human (R335G, HEK293, His) |
DKK-3 protein antagonizes canonical Wnt signaling by blocking LRP5/6-Wnt interactions and forming a ternary complex with KREMEN, thereby promoting LRP5/6 internalization.In vertebrate development, DKK-3, together with other DKKs, critically inhibits Wnt-regulated processes such as axial patterning, limb development, somitogenesis, and eye formation.DKK-3 Protein, Human (R335G, HEK293, His) is the recombinant human-derived DKK-3 protein, expressed by HEK293 , with C-6*His labeled tag and R335G, , , , mutation.
Species: Human; Source: HEK293 |
|
/
|
| HY-P72443 | TNF RI/TNFRSF1A Protein, Mouse |
TNFRSF1A (TNF RI) protein has a high
ability to bind with tumor necrosis factor-alpha (TNF-α). TNFRSF1A is a STAT3
target gene that regulates the NF-κB pathway. TNFRSF1A activate NF-κB, mediate
apoptosis, and function as a regulator of inflammation. TNF RI/TNFRSF1A
Protein, Mouse is expressed by E. coli and has a
transmembrane region (I22-A212).
Species: Mouse; Source: E. coli |
|
/
|
| HY-P74657 | p53 Protein, Rhesus Macaque |
p53 protein, a tumor suppressor, induces growth arrest or apoptosis in various tumors, regulating cell division through gene control, including cyclin-dependent kinase inhibitors. It stimulates BAX and FAS antigen expression or represses Bcl-2 to induce apoptosis. p53's multifaceted role underscores its importance in orchestrating cellular responses, maintaining genomic integrity, and countering aberrant cell proliferation. p53 Protein, Rhesus Macaque is the recombinant Rhesus Macaque-derived p53 protein, expressed by E. coli , with tag free.
Species: Rhesus Macaque; Source: E. coli |
|
/
|
| HY-P701853 | APC Protein, Human (His) |
The APC protein is a multifaceted tumor suppressor that rapidly degrades CTNNB1 and acts as a negative regulator in the Wnt pathway. Its phosphorylation status intricately affects activity. APC Protein, Human (His) is the recombinant human-derived APC protein, expressed by E. coli , with N-6*His labeled tag.
Species: Human; Source: E. coli |
|
/
|
| HY-P85931 | Wilms Tumor Protein Antibody (YA5623) |
Wilms Tumor Protein Antibody (YA5623) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to Wilms Tumor Protein.
Host: Mouse; Reactivity: Human, Mouse, Rat, Pig |
|
/
|
| HY-P82532 | Wilms Tumor Protein Antibody (YA2277) |
Wilms Tumor Protein Antibody (YA2277) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Wilms Tumor Protein.
Host: Rabbit; Reactivity: Human, Mouse |
|
/
|
| HY-P83601A | ITK Antibody (YA3346)(PBS only) |
|
/
|
|
| HY-P85135A | ITK Antibody (YA4827)(PBS only) |
|
/
|
|
| HY-P83948 | p53 Antibody (YA3645) |
p53 Antibody (YA3645) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to p53.
Host: Mouse; Reactivity: Human |
|
/
|
| HY-P82532A | Wilms Tumor Protein Antibody (YA2277)(PBS only) |
Wilms Tumor Protein Antibody (YA2277) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Wilms Tumor Protein.
Host: Rabbit; Reactivity: Human, Mouse |
|
/
|
| HY-P83085 | SLC22A3 Antibody (YA2830) |
SLC22A3 Antibody (YA2830) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to SLC22A3.
Host: Rabbit; Reactivity: Human |
|
/
|
| HY-P83601 | ITK Antibody (YA3346) |
|
/
|
|
| HY-P85135 | ITK Antibody (YA4827) |
|
/
|
|
| HY-P86440 | Wilms Tumor Protein Antibody (YA6132) |
Wilms Tumor Protein Antibody (YA6132) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Wilms Tumor Protein.
Host: Rabbit; Reactivity: Human, Mouse, Rat |
|
/
|
| HY-P86923 | Wilms Tumor Protein Antibody(YA6616) |
Wilms Tumor Protein Antibody(YA6616) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Wilms Tumor Protein.
Host: Rabbit; Reactivity: Mouse |
|
/
|
| HY-P811181 | TPD52L2 Antibody |
TPD52L2 Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to TPD52L2.
Host: Rabbit; Reactivity: Human, Mouse, Rat |
|
/
|
| HY-K0603 | Alcian Blue Staining Solution (pH 1.0) |
MCE Alcian Blue Staining Solution (pH 1.0) is commonly used for selective detection of sulfated mucins in histological research, including cartilage staining, mucin type differentiation, and aiding in the identification of mucinous epithelial tumors. |
|
/
|
| HY-K0611 | Modified Van Gieson Staining Kit |
MCE Modified Van Gieson Staining Kit employs Celestine Blue and Mayer’s hematoxylin for nuclear staining, providing clearer and more stable nuclear visualization while facilitating longer preservation of stained sections. Ponceau S is used for collagen fiber staining, offering stable coloration and strong resistance to fading. This method enables effective differentiation between collagen fibers and muscle fibers, and can assist in distinguishing collagen fiber–derived tumors from myogenic tumors to a certain extent. It is also suitable for observing tissue or organ injury, repair processes, and the degree of fibrosis. |
|
/
|
| HY-K1067 | Exosome Isolation and Purification Kit (From Tissue) |
MCE Exosome Isolation and Purification Kit (From Tissue) provides a simple and effective method to isolate and purify intact exosomes from a variety of tissues (such as brain, heart, lung, liver, muscle, lymph nodes, thymus, embryo, tumor, etc.). |
|
/
|
| HY-K6006 | Basement Membrane Matrix IPSC-qualified |
MCE Basement Membrane Matrix IPSC-qualified is primarily composed of natural basement membrane matrix extracted from mouse tumors. This product is mainly used for stem cells culture. |
|
/
|
| HY-K6012 | Tissue Dissociation Solution |
MCE Tissue Dissociation Solution is able to gently and efficiently dissociate tissue samples into cell suspensions or cell aggregates, which can then be used for the subsequent construction of tumor organoids. |
|
/
|
| HY-K6119P | Mouse Intestinal Organoid Plus Kit |
MCE Mouse Intestinal Organoid Plus Kit is an upgraded serum-free culture system developed based on the Mouse Small Intestinal Organoid Culture Kit (HY-K6119), designed for the establishment, expansion, and long-term maintenance of mouse small intestinal organoids. The kit contains basal culture medium and multiple essential supplements, and an optional Wnt ligand supplement is provided to enable modulation of Wnt signaling activity in the culture system. |
|
/
|
| HY-K6301 | Human iPSC/ESC Cortical Brain Organoid Induction Differentiation Kit |
MCE Human iPSC/ESC Cortical Brain Organoid Induction Differentiation Kit is a standardized culture system specifically designed to recapitulate the developmental processes and functional features of the human cerebral cortex through forebrain ventralization-based signaling regulation. By sequentially activating the Wnt/β-catenin pathway and gradually inhibiting BMP/Smad signaling, this system efficiently drives human pluripotent stem cells (PSC) to differentiate into high-purity glutamatergic neurons (VGLUT1/2+ > 85%), while simultaneously promoting the formation of Pax6+/BLBP+ radial glial cells that establish a biomimetic ventricular-zone–like structure. |
|
/
|
| HY-K6303 | Human iPSC/ESC Cardiomyocyte Induction Differentiation Kit |
MCE Human iPSC/ESC Cardiomyocyte Induction Differentiation Kit is based on the classical GiWi system. By precisely modulating the Wnt/β-catenin signaling pathway in a temporally controlled manner (sequential activation and inhibition), the kit enables highly efficient directed differentiation of human pluripotent stem cells into cardiomyocytes. It is suitable for cardiac disease modeling, drug cardiotoxicity assessment, and mechanistic studies. |
|
/
|
Targets/Pathways
































































































































































































































































